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Abstract 
 
The ability to assess the distribution and extent of tau pathology and 
neuroinflammation in Progressive Supranuclear Palsy (PSP) and Alzheimer’s 
disease (AD) ‘in vivo’ and to validate it using post mortem data is critical to 
develop reliable biomarkers for these disorders, and for tracking the effects of 
clinical trials using disease-modifying therapies. The main aim of my PhD was 
therefore to assess the utility of the PET radiotracers [18F]AV1451 and [11C](R)-
PK11195 to compare the distribution and intensity of tau pathology and 
neuroinflammation respectively, in PSP and AD. I use both in vivo scanning and 
post mortem tissue from archival cases in the Cambridge Brain Bank. For the in 
vivo studies, I investigated whether tau accumulation and neuroinflammation 
relate to clinical measures of disease severity and cognitive impairment.  
 
My PhD was undertaken as part of the Neuroimaging of Inflammation in 
MemoRy and Other Disorders (NIMROD). Nineteen people with PSP-Richardson’s 
syndrome, 15 patients with amnestic Alzheimer’s disease and biomarker-positive 
mild cognitive impairment (MCI+) and 13 age- and sex-matched controls 
participated. Post mortem brain tissue from three subjects (one PSP case, one AD 
patient, and one control with similar age) were included. Autoradiographic and 
immunohistochemical analyses were conducted in different cases from those 
included in the [18F]AV1451 and [11C](R)-PK11195 PET in vivo studies. 
 
 [18F]AV1451 PET imaging revealed distinct patterns of tau binding in AD 
and its prodromal state of MCI+, in comparison to PSP. The clinical syndromes of 
AD and MCI+ were associated with increased [18F]AV1451 BPND in widely 
distributed subcortical and cortical areas that have been consistently implicated in 
the pathogenesis and progression of AD (e.g. hippocampus, amygdala as well as 
frontal, parietal, temporal, and occipital cortices). Conversely, PSP was associated 
with a pattern of increased [18F]AV1451 uptake in the basal ganglia, midbrain, and 
dentate nucleus of the cerebellum, consistent with the pathophysiology of the 
disease. Despite this potential of [18F]AV1451 as a tau biomarker, caution in the 
interpretation of its binding targets is indicated by the neuropathological and 
autoradiographic data. In particular, while [18F]AV1451 strongly bound to AD-
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related tau pathology, non-specific binding of the same tracer can be found in PSP 
patients and controls. Furthermore, [18F]AV1451 uptake was not correlated with 
disease severity in the clinical groups.  
 
 [11C](R)-PK11195 PET imaging revealed distinct patterns of inflammation 
in AD and PSP, and mirrored the pathological distribution for each disease seen 
by [11C](R)-PK11195 post mortem phosphor screen autoradiography and 
immunohistochemistry. In AD, microglial activation was observed in prefrontal 
cortex, and medial temporal lobe.  In PSP microglial activation was observed in 
midbrain and basal ganglia. In both clinical cohorts, disease severity correlated 
with neuroinflammation in the regions most closely associated with principal 
neuropathological markers including tau aggregates. 
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Chapter 1 
Introduction 
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1.1. Overview 
This thesis examines the cognitive and pathological features of tau and 
microglial activation (neuroinflammation) contrasting two degenerative diseases: 
progressive supranuclear palsy (PSP) and Alzheimer’s disease (AD). Although both 
of them are distinct in their clinical phenotype, both disorders have in common 
cognitive and behavioural changes, accumulation of tau aggregates, and chronic 
neuroinflammation. By contrasting, these two neurodegenerative disorders, we 
gain better insights into their pathogenesis than examination of either disorder 
alone. The joint examination of PSP and AD also raises issues regarding the 
research methods. 
 
In the introduction, I set out the background of clinical, epidemiological, 
pathological, and genetic aspects of these disorders, in turn. I then highlight the 
need for a better understanding of PSP pathology in vivo. In order to address this, 
I compare PSP with another better understood tauopathy, AD. I set out why better 
methods were required to assess the pathology of both disorders in vivo, and to 
understand the link between pathology and functional change. I end with a 
summary of the objectives of the PhD, and structure of this thesis. Both diseases 
share important similarities in terms of pathology although there are clearly major 
differences too. They also raise comparable challenges and issues pertaining to 
diagnosis, clinical criteria and biomarkers. They are both largely sporadic 
disorders. There are emerging concepts in both diseases related to spread of 
pathology, prodromal states, and variation in phenotypes.  
 
The methods used to study PSP and AD in vivo and post mortem have 
followed a very similar outline. In the following sections, I pick up on these themes 
to define and compare PSP and AD, not because they are ever to be confused 
clinically, but because of the advantage to have disease controls in investigating 
the new positron emission tomography (PET) and post mortem methods, and 
because of the similar needs of both in biomarker validation.  
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1.2. Clinical description 
1.2.1. History 
1.2.1.1. Progressive supranuclear palsy 
Dr Steele, along with Dr Richardson and Professor Olszewski (1964), first 
described progressive supranuclear palsy (PSP). They included the clinical features 
of nine cases and the neuropathological examinations from seven of them. Though 
the symptoms quantitatively varied across patients, all of them showed a vertical 
supranuclear gaze palsy, spasticity of facial musculature, progressive axial 
rigidity, bulbar palsy symptoms including dysarthria and dysphagia, severe 
postural instability with early falls (usually backwards), prominent bradykinesia. 
These features are central to the phenotype of PSP, with the addition of a poor 
response to dopaminergic drugs (De Bruin and Lees, 1992; Litvan et al., 1996; 
Riley et al., 1994; Steele et al., 1964).  
 
Cognitive impairment was significant in seven of the original nine cases with 
PSP, but PSP came to be considered as primarily a “movement disorder” and often 
managed, and taught, in the broader context of Parkinson’s disease (PD). 
However, cognitive and behavioral changes appear early and often reach the 
severity of dementia at the late stage of the disease (Brown et al., 2010; Ghosh 
et al., 2009). Cognitive slowing, impulsive behaviour, difficulty in generating 
words, and severe apathy are the most common features (Steele et al., 1964; 
Lansdall et al., 2017). By contrast, other cognitive functions, such as language 
comprehension, recognition memory, and visuospatial functions remain relatively 
well preserved (Bak et al., 2005; Bak et al., 2010).  
 
1.2.1.2. Alzheimer’s disease 
Alzheimer’s disease (AD) is named after Dr Alois Alzheimer, who noticed 
severe changes in the cerebral cortex of a 50 year old woman who had died of a 
rapid mental illness (Alzheimer, 1906). Her symptoms included memory loss, 
language problems, sleep disorders, paranoia, and unpredictable behavior such as 
aggressiveness, confusion, and crying. For several decades, Alzheimer’s disease 
was considered to be a rare, young onset dementia, resembling the case first 
described by Alzheimer.  During this period, late onset cognitive decline and 
dementia was too often regarded as “senile dementia” or “normal ageing”.  The 
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recognition of AD-pathology as the major cause of late life cognitive decline 
developed in the 1970s and 1980s. At around this time, the concept of “Mild 
Cognitive Impairment” (MCI) grew, and its link to AD in many cases. In the last 
20 years, the concept has developed of a progressive spectrum of impairment, 
from latent AD-pathology, through MCI to disabling clinical AD. Early criteria for 
MCI focused on the cognitive profile and severity, with selectively poor function in 
one cognitive domain (usually memory, but potentially another domain), or in 
some quarters, multi-domain MCI. However, such cognitively defined MCI left 
unanswered the questions of aetiology (AD pathology or not), and progression 
(stable impairments versus progression to clinical AD).  
 
1.2.2. Clinical diagnosis criteria  
1.2.2.1. Progressive supranuclear palsy 
Early and reliable diagnosis of PSP remains a major clinical challenge, but 
is justifiably demanded by patients and their carers and is highly important for 
estimation of prognosis, appropriate allocation to therapeutic trials, and 
development of new diagnostic tools. Three separate clinical diagnostic criteria 
dominate the research literature. They differ in their sensitivity and specificity, 
particularly as the breadth of phenotype of pathologically proven PSP expands.  
 
I. National Institute of Neurological Disorders and Stroke (NINDS) - Society 
for Progressive Supranuclear Palsy (SPSP) criteria (1996).  
A detailed set of criteria for the medical diagnosis of PSP was established 
during the global workshop funded by the National Institute of Neurological 
Disorders and Stroke (NINDS) and the Society for PSP (SPSP) (Litvan et al., 1996). 
The NINDS-SPSP criteria centre on the recognition of a gradual progressive 
condition beginning after age 40 with two main features:  postural instability, and 
ocular motor dysfunction. The criteria specify three degrees of diagnostic certainty 
that there are shown in Table 1.  
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PSP diagnostic 
certainty 
Definition 
Possible Either vertical supranuclear palsy or slowing of vertical saccades. 
Postural instability with falls within 1 year of disease onset . 
Probable Vertical supranuclear palsy. 
Postural instability with falls within 1 year of disease onset . 
Definite History of probable or possible PSP. 
Histopathologic evidence of typical PSP. 
Table 1: The National Institute of Neurological Disorders and Stroke (NINDS) – Society 
for Progressive Supranuclear Palsy (SPSP) criteria (1996). 
Abbreviations: PSP, Progressive Supranuclear Palsy.  
 
The NINDS-SPSP criteria have a high specificity, and good sensitivity in 
contrasting classical PSP with controls and other movement disorders like PD. 
However, their sensitivity was poor with respect to non-motor phenotypes of PSP 
(Boeve et al., 2003; Han et al., 2010; Hassan et al., 2012; Josephs et al., 2006; 
Mochizuki et al., 2003); therefore, in recent years, the classical syndrome of PSP 
has become increasingly known as Richardson’s syndrome (PSP-RS). However, as 
shown in Table 2, it is clear that pathological cases of PSP can present with very 
different phenotypes.   
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PSP predominance type Acronym Reference 
Ocular motor PSP-OM Litvan et al., 1996; Respondek et al., 
2014 
Parkinsonism resembling 
idiopathic Parkinson’s disease 
PSP-P Birdi et al., 2002; Williams et al., 
2005 
Frontal lobe cognitive or 
behavioural presentations* 
PSP-F Han et al., 2010; Hassan et al., 
2012; Litvan et al., 1996 
Progressive gait freezing PSP-PGF Compta et al., 2007; Facheris et al., 
2008; Williams et al., 2007 
Corticobasal syndrome PSP-CBS Josephs et al., 2006; Ling et al., 
2014; Tsuboi et al., 2005 
Primary lateral sclerosis PSP-PLS Josephs et al., 2006; Nagao et al., 
2012 
Cerebellar  PSP-C Iwasaki et al., 2013; Kanazawa et 
al., 2009 
Speech and language 
disorders** 
PSP-SL Boeve et al., 2003; Josephs et al., 
2006; Mochizuki et al., 2003 
Table 2: Clinical variants of Progressive Supranuclear Palsy. 
*Including behavioral variant Frontotemporal Dementia (bvFTD). **Including non-fluent/agrammatic Primary 
Progressive Aphasia (nfaPPA) and Apraxia of Speech (AoS). Abbreviations: PSP, Progressive Supranuclear Palsy.  
 
 
Respondek and colleagues assessed the phenotypic spectrum in a 
multicentre cohort of 100 autopsy-confirmed PSP patients (Respondek et al., 
2014). Their results showed that only 24% of cases were presented as PSP-RS, 
and more than half of the cases either showed overlapping features of several 
predescribed phenotypes, or features not fitting proposed classification criteria for 
PSP phenotypes. As a consequence of this, it emerged the need to review the 
current criteria.  
 
II. Neuroprotection and Natural History in Parkinson Plus Syndromes 
(NNIPPS) criteria (2005). 
The opportunity to revise the clinical diagnostic criteria for PSP arose as a 
product of a large multicentre trial (Bensimon et al., 2008). The Neuroprotection 
and Natural History in Parkinson Plus Syndromes (NNIPPS) criteria emerged 
because of the necessity of more sensitive diagnostic criteria for clinical trials of 
potential disease-modifying therapies in PSP and multiple system atrophy (MSA). 
The NNIPPS study was designed to assess the efficacy and safety of the drug 
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Riluzole, and its effect on trying to slow down PSP and MSA progression. The scale 
of the study and detailed follow-up, with pathology in 27% of cases gave the 
opportunity to revise the criteria. The principal difference was to relax the criterion 
of falls within the first year to falls within three years. However, the NNIPPS criteria 
were not designed to accommodate the rapidly expanding phenotype of PSP.  
 
III. International Parkinson and Movement Disorder Society (MDS) - 
Progressive Supranuclear Palsy Study Group (PSP) criteria (2017).  
The International Parkinson and Movement Disorder Society (MDS) and PSP 
Study Group criteria (Höglinger et al., 2017) was aiming for use in both clinical 
and research areas, including the diagnosis of early and alternative PSP 
syndromes for potential clinical trials. The MDS-PSP criteria are structured and 
operationalized in detail. The principles are: 
i. Clinical recognition of PSP pathology by keeping high diagnostic 
sensitivity for PSP-RS (Table 3). 
ii. Sensitivity for early and variant PSP profiles, including cognitive 
presentations. 
iii. High specificity with regard not only Parkinson’s disease (PD) but also 
corticobasal syndrome (CBS) attributed to corticobasal degeneration 
(CBD), and frontotemporal lobar degeneration presenting as 
behavioural frontotemporal dementia (bvFTD). 
iv. The role of biomarkers (MRI, PET), and genetics in the diagnosis of PSP. 
 
PSP diagnostic 
certainty 
Definition 
Suggestive Suggestive of PSP but not passing the threshold for possible 
or probable PSP. 
Suitable for early identiﬁcation. 
Possible Substantially more sensitive but less speciﬁc for PSP. 
Suitable for descriptive epidemiological studies and clinical 
care. 
Probable Highly speciﬁc but not very sensitive for PSP. 
Suitable for therapeutic and biological studies. 
Deﬁnite Gold standard deﬁning the disease entity. 
Table 3: The International Parkinson and Movement Disorder Society (MDS)-Progressive 
Supranuclear Palsy Study Group (PSP) criteria (2017).  
Abbreviations: PSP, Progressive Supranuclear Palsy.  
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A novel feature in these diagnostic criteria was the inclusion of a new group 
with cognitive and behavioural presentations, including PSP-CBS, PSP-F or PSP-
SL. These share a high probability of underlying PSP or CBD pathology (‘probable 
4R-tauopathies’). Another interesting conclusion of the MDS-PSP was the 
exclusion of the tau-PET as it was not well enough understood at the time; 
therefore it was shown to be likely inadequate for diagnosis even if it has a huge 
potential for understanding mechanisms of the disease in research.  
 
1.2.2.2. Alzheimer’s disease  
Alzheimer’s disease (AD) is also defined clinically, with considerable 
variation in the criteria used in recent decades. These differences reflect both 
changing concepts of AD, and new technologies. The National Institute of 
Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer's 
Disease and Related Disorders Association (ADRDA) criteria (McKhann et al., 
1984) distinguished “probable AD” (with sufficiently severe cognitive deficits for 
dementia, including memory and at least one other domain) from definite AD (with 
post mortem or rarely biopsy neuropathology).   
 
The International Working Group (IWG; Dubois et al., 2007) recognised 
three phases of AD identified by combining clinical features with biomarker 
investigations: asymptomatic biomarker-positive, positive biomarkers and mild 
cognitive deficits, and  dementia. The core features of the new criteria were: 
 
i. AD diagnosis can be now made in vivo rather than depend on autopsy 
confirmation. 
ii. Greater certainty of AD-pathology (elimination of terminology of 'probable 
AD'), even prior to the onset of dementia.  
iii. Identification of AD pathology in asymptomatic patients, and symptomatic 
AD even in the absence of dementia.  
iv. Integration of pathophysiologic (e.g., amyloid-β, tau, and CSF measures) 
and topographic (e.g., MRI, PET, and FDG) biomarkers.  
 
In parallel to the IWG, the National Institute on Aging (NIA) and Alzheimer's 
Association (AA) developed a set of criteria (Jack et al., 2011) that also recognised 
45 
 
three distinct stages of AD progression (Table 4). The NIA/AA criteria also 
incorporate biomarkers.   
 
Stages Features 
Preclinical AD Before symptoms appear but initial changes are present in 
the default mode network (DMN; Nobili & Morbelli, 2010). 
MCI Noticeable symptoms begin, and dementia is anticipated in 
three to four years (Albert et al., 2011). 
Dementia due to AD Daily function is impaired (Thies et al., 2013). 
Table 4: The National Institute on Aging (NIA) and Alzheimer's Association (AA) criteria 
(2011). 
Abbreviations: AD, Alzheimer’s Disease; MCI, Mild Cognitive Impairment.  
 
The IWG and NIA/AA have many similarities and important differences. The 
two sets of criteria concur in recognizing the onset of AD prior to dementia. The 
three phases of AD described in both sets of criteria embrace similar clinical 
entities but with different terminologies and emphases. IWG criteria emphasize a 
single clinico-biological approach that includes all symptomatic phases of AD and 
uses the same diagnostic framework across the spectrum of symptomatic disease, 
whereas the NIA/AA criteria apply different diagnostic approaches to the three 
phases. The NIA/AA MCI approach does not establish a continuity with the criteria 
suggested for preclinical AD in which both types of biomarkers are implied to be 
positive by the time the patient becomes symptomatic. A notable aspect of the 
NIA/AA criteria for the pre-dementia symptomatic phase of AD retains the concept 
of MCI (Albert et al., 2011), which is defined by using the original criteria of 
Petersen and colleagues (Petersen et al., 1999). Biomarkers are not required for 
the diagnosis of MCI, although the diagnosis of “MCI due to AD” requires 
biomarker support given the heterogeneous nature of the MCI syndrome (Ganguli 
et al., 2011; Jicha et al., 2006).  
 
1.2.2.3. Summary 
It is interesting to note the convergence in the current concepts and 
definitions of PSP and AD.  Both research communities now recognise the degree 
of heterogeneity in terms of phenotype, as well as degrees of certainty and 
severity.  Although early work focused on clinically manifest and disabling disease, 
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they have introduced operationalized terms for milder or prodromal stages of 
disease (PSP: suggestive of; AD; MCI).  
 
There is increasing interest in the pre-manifest stages of disease.  
Dominantly inherited AD makes up less than 5% of the population of patients, but 
provides an important window into the early development of pathology, with PET 
and MRI evidence of disease 10-20 years before even MCI onset.  In PSP, the lack 
of frequent autosomal dominant cases has made if it harder to study the pre-
manifest stage, but it seems likely that a long prodrome exists for PSP, as it also 
does for PD (Berg et al., 2014; Stern et al., 2012) and FTD (Cash et al., 2018; 
Rohrer et al., 2013; Rohrer et al., 2015). Currently, PSP criteria refer to PGF and 
syndromes suggestive of PSP, which although symptomatic not pre-manifest, aim 
to identify earlier stage disease that the classical descriptions.  
In my thesis, I focus on patients with the classical PSP phenotype, also 
known as PSP-Richardson’s syndrome (PSP-RS). They were initially diagnosed 
under the National Institute of Neurological Disorders and Stroke (NINDS) and the 
Society for Progressive Supranuclear Palsy (SPSP) criteria (Litvan et al., 1996)  
but reclassified according to the International Parkinson and Movement Disorder 
Society (MDS) and the Progressive Supranuclear Palsy Study Group (PSP) criteria 
(Höglinger et al., 2017).  
 
In the last decade, the concept of AD has changed again, as reflected in the 
International Working Group (IWG) criteria. These retain the concept of clinical 
AD with deficits in multiple cognitive domains; but for MCI, they distinguish MCI 
with evidence of underlying AD pathology (e.g. from amyloid PET or CSF 
biomarkers), from MCI without biomarker evidence of AD pathology.  They also 
formalize the concept of latent or pre-symptomatic AD. In this thesis, I focus on 
patients with probable AD pathology as defined by either (i) MCI with biomarker 
evidence of AD pathology, from amyloid PET; or (ii) clinically probable AD, with 
deficits in multiple cognitive domains sufficient to impair daily function (Morris, 
1993).  
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1.2.3. Epidemiology 
1.2.3.1. Progressive supranuclear palsy 
The incidence of progressive supranuclear palsy in developed countries is 
approximately 1.2 per 100,000 per year, and the prevalence of investigator-
diagnosed cases is calculated between 5.8-6.5 per 100,000 (Coyle-Gilchrist et al., 
2016; Nath et al., 2001). Earlier studies estimated prevalence from 1.3 to 4.9 per 
100,000 (Chiò et al., 1998; Schrag et al., 1999). The apparent increase may be 
due to methodological differences between studies and the low awareness and 
common misdiagnosis of PSP (Nath et al., 2001).  
 
Patients with the classic PSP-RS phenotype typically develop clinical 
features after age 60, with an average of 7 years from symptom onset to death 
over (Golbe, 2014; Williams et al., 2005). The occurrence of classic PSP-RS rises 
abruptly with age, from 1.7 at 50 to 59 years to 14.7 at 80 to 99 years (Bower et 
al., 1997; Coyle-gilchrist et al., 2016). It has also been estimated that 2.9 years 
is the average time frame from symptoms to diagnosis (Dell’Aquila et al., 2013; 
Golbe, 1994). The other clinical phenotypes of PSP differ in their clinical course 
and disease duration (O’Sullivan et al., 2008; Respondek and Höglinger, 2016), 
but systematic data on differential survival are lacking.  
 
1.2.3.2. Alzheimer’s disease 
Alzheimer’s disease is the most frequent cause of dementia in Western 
societies corresponding to about 60% of cases (Forette & Boller, 1991; Kalaria et 
al., 2008). The global prevalence is estimated to be ~24 million, and expected to 
double by the year 2050 (Alzheimer’s Association, 2017). Incidence rates for AD 
depends on the age of the population, and increases from 1% to 5% in the 
population over 65 years old, up to 20% to 25% in the population over 80 years 
old (Brickell et al., 2006; Rao et al., 2014). The rate of progression for Alzheimer's 
disease varies widely. On average, people with AD live eight to ten years after 
diagnosis, but there is a very wide range.  
 
With the new 2007 IWG and 2011 NIA criteria, recognizing pre-dementia 
states of AD, and increased global awareness of dementia, it is likely that 
prevalence and survival estimates will be revised substantially. With the long 
asymptomatic prodromal, up to 20 years before symptoms arise (Craig-Schapiro 
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et al., 2010), future epidemiological studies will need to be clear about which 
phase of disease they refer to.  
 
1.2.4. Genetics 
1.2.4.1. Progressive supranuclear palsy 
Progressive supranuclear palsy is largely a sporadic disease. It contrasts 
with some other forms of frontotemporal lobar dementia (FTLD) that have a high 
percentage of autosomal dominant disease. However, there are familial cases that 
resemble PSP in some of their clinical and pathological features. For example, 
Rojo’s confirmed PSP pathology in four family members (Rojo et al., 1999), and 
likely autosomal dominant transmission. Ros described characteristic PSP features 
in four family relatives, confirming post mortem examination in one case (Ros et 
al., 2005), and at least 5 ancestors with related diseases. More commonly 
however, familial PSP-like syndromes are related to mutations in the microtubule-
associated protein tau (MAPT) gene (Stanford et al., 2000). These are typically 
younger in onset that sporadic PSP. Less than 1% of PSP has a recognized 
autosomal dominant aetiology. However, genome wide associations (GWA) 
suggest a weak contributory role of several genetic variants to sporadic disease, 
including syntaxin 6 (STX6); eukaryotic translation initiation factor 2-α kinase 3 
(EIF2AK3), and myelin-associated oligodendrocyte basic protein (MOBP) 
(Höglinger et al., 2011). 
 
1.2.4.2. Alzheimer’s disease 
The majority of Alzheimer’s disease cases are also sporadic (>90%) and 
present considerable heterogeneity in terms of risk factor profiles and 
neuropathological features. Around 10% of people with clinical AD are diagnosed 
before age 65 years (Prince & Jackson, 2009), and about 60% of those early-
onset AD (EOAD) have a family history of dementia (Campion et al., 1999; 
Jarmolowicz et al., 2015; van Duijn et al., 1994), with 13% having a family tree 
indicative of autosomal dominant transmission (Campion et al., 1999; Jarmolowicz 
et al., 2015). Single genes causing early-onset AD were identified from linkage 
studies, including amyloid precursor protein (APP), presenilin 1 (PSEN1), and 
presenilin 2 (PSEN2) (Sorbi et al., 2001; Tanzi & Bertram, 2005). Although a major 
breakthrough for understanding and modelling AD in research, these three genes 
contribute less than 5% of AD cases. In contrast, late-onset AD may be 
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determined by apolipoprotein E (ApoE ε4), which has consistently been identified 
as a risk factor for death in the genome-wide association study (GWAS) of 
longevity (Deelen et al., 2011; Sebastiani et al., 2012). GWAS are used to identify 
common genetic variants associated with disease susceptibility.  
 
Recent research has also shown a significant etiological role for immune-
related processes and inflammation in AD. Triggering receptor expressed on 
myeloid cells 2 (TREM2) is expressed in microglia. Studies have shown that certain 
TREM2 variants have an important effect on AD, and that effect is similar to that 
of APOE (Jonsson et al., 2013; Neumann & Daly, 2013). They are all the risk 
factors of AD. TREM2 and ApoE ε4 may interact synergistically in the preclinical 
stage of AD (Casati et al., 2018). GWAS results such as these, even though a huge 
success and of great importance to the field, still only explain a very small amount 
of the genetic risk in AD.  
 
None of the cases in my study had familial PSP or familial AD in terms of 
their family histories, or were known to be positive for mutations in MAPT, APP, 
PSEN1, PSEN2, TREM2 or ApoE ε4. Cases were not selected or excluded by genetic 
criteria. 
 
 
1.3. Pathology 
1.3.1. Microtubule associated protein Tau 
Tau is a neuronal protein associated to microtubules (Weingarten et al., 
1975). Whereas phosphorylation is essential for the normal function of tau protein, 
hyperphosphorylation has been proposed to play a crucial role of the aggregation 
of tau isoforms into intraneuronal filamentous inclusions (Buée et al., 2000; 
Martin, 2011). A growing body of evidence suggests that the generation of toxic 
tau aggregation represents the leading hallmark of the pathological process in 
several tauopathies, including PSP and AD (D’Souza and Schellenberg, 2005; 
Goedert & Jakes, 2005; Kaat et al., 2009; Martin et al., 2011; Spillantini et al., 
1998); therefore it is of major interest as an indicator of neurodegenerative 
mechanisms.  
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  Human tau is encoded by the MAPT gene that is located on chromosome 
17q21 (Neve et al., 1986). This is transcribed and yields six different isoforms, 
lacking or containing exons 2, 3, and 10 by alternative splicing (Andreadis, 2005; 
Avila et al., 2004). Exon 10 contains a microtubule-binding region similar, but not 
identical, to other three additional microtubule-binding regions. Thus, isoforms 
containing exon 10, resulting in tau with four microtubule (tubulin)-binding 
regions (repeats) are known as tau 4R, whereas alternative spliced isoforms, 
lacking exon 10, are known as tau 3R. Ultrastructural examinations reveal that 
neurofibrillary tangles in PSP and AD have a different composition. Pathological 
tau deposits in PSP are composed of straight filaments with a diameter between 
16-18nm of predominantly four repeats tau (Buée and Delacourte, 1999; Dickson 
et al., 1987). In contrast, AD is characterized by paired helical filaments of tau 
with a diameter between 10-20 nm of both three (3R) and four (4R) repeats in 
the microtubule-binding domain (Liu et al., 2001; Sisodia et al., 1990).  
 
1.3.1.1. Progressive supranuclear palsy 
Major advances have led PSP to be defined by intracerebral aggregation of 
the microtubule-associated protein tau, predominantly involving isoforms with 
four microtubule-binding repeats (4R-tau), in neurofibrillary tangles, 
oligodendrocytic coils, and, specifically, astrocytic tufts (Dickson et al., 2007; 
Hauw et al., 1994; Kovacs, 2014). Currently a neuropathological examination is 
the diagnostic ‘gold standard’ for PSP (Litvan et al., 1996; Dickson, 1999; 
Respondek, 2014). 76% of autopsy-confirmed PSP cases were patients with 
presentations other than PSP-RS (see 1.2.2. for more detailed information). 
 
Macroscopically, the hallmarks of PSP is degeneration of the substantia 
nigra, the subthalamic nucleus and globus pallidus (Hauw et al., 1994; Kovacs, 
2014), the superior cerebellar peduncle, and the dentate nucleus of the cerebellum 
(Hauw et al., 1994; Kovacs, 2014; Tsuboi et al., 2003). The substantia nigra and 
locus coeruleus usually displays marked pallor due to the loss of neuromelanin-
containing neurons in these regions (Dickson et al., 2010) (Figure 1).  
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The overall brain weight (1170 ± 150 grams) can be within normal limits 
(Dickson et al., 2007) although many PSP cases have mild frontotemporal and 
precentral gyrus atrophy (Figure 2). The third ventricle and aqueduct of Sylvius 
may be dilated (Dickson et al., 2007).  
 
 
 
 
 
 
Figure 2: Midsagittal view of a Progressive 
Supranuclear Palsy brain. 
The medial surface of the left hemisphere shows marked atrophy of 
the precentral gyrus, with lesser degrees of gyral atrophy of frontal 
and superior parietal areas. Image provided by Dr Kieren Allinson 
from the Cambridge Brain Bank. 
 
 
Figure 1: Midbrain of a PSP patient. 
This image shows severe degeneration of the locus coeruleus, which reflects loss of 
neuromelanin and neurons (inset) due to tau pathology. Images provided by Dr Sanne 
Kaalund. 
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Classical histopathological features comprise neuronal loss, gliosis, and 
globose neurofibrillary tangles (NFTs) affecting the basal ganglia, cortex and 
brainstem nuclei. Figure 3 shows the anatomical regions, which are most severely 
affected; in the basal ganglia these are the subthalamic nucleus, substantia nigra, 
and globus pallidus, whereas striatum is relatively spared. Affected brainstem 
regions include the superior colliculus, periaqueductal gray matter, oculomotor 
nuclei, pontine tegmentum and vestibular nuclei. Hypertrophy of the inferior 
olivary nucleus in the medulla oblongata may be also noted. The cerebellar dentate 
nucleus is frequently involved and may show clusters of degenerating presynaptic 
terminals around dentate neurons (Ishizawa et al., 2000). The cerebral cortex is 
less affected by neuronal loss and gliosis, although atrophy may be observed in 
the central fissure (Josephs et al., 2006), frontal cortex and angular gyrus 
(Schofield et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Pathological changes in Progressive Supranuclear 
Palsy. 
This illustration represents the areas affected in Progressive Supranuclear 
Palsy, which can be divided into those that are consistently and severely 
affected, and those that are less consistently affected. Figure provided by 
Ellison & Love 2004, and reprinted with permission. 
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The neuropathological hallmarks are tau inclusions in glia cells, and 
neurons. With immunohistochemistry these inclusions can be seen as tufted 
astrocytes, coiled-bodies in the oligodendrocytes (Nishimura et al., 1992; Yamada 
et al., 1993), and neurofibrillary tangles in neurons. Glial tau inclusions are 
primarily localized in the motor cortex, striatum, and superior colliculus in the 
midbrain (Matsusaka et al., 1998). In addition, the coiled bodies are often found 
in the white matter, especially in the midbrain and the cerebellum (Braak and 
Braak, 1989). The neurofibrillary tangles are frequent in basal ganglia, 
diencephalon, brainstem and spinal cord. The NFTs and glial tau inclusions in PSP 
are made up of almost entirely 4R tau, which is different from the NFTs of AD, 
which is made up of 50/50 3R and 4R tau (Hauw et al., 1994). Additional neuronal 
tau pathology in the form of diffuse granular cytoplasmic immunoreactivity of 
neurons can be seen in the striatum, globus pallidus, substantia nigra, oculomotor 
complex, locus coeruleus, pontine base, and dentate nucleus (Figure 4). 
 
 
1.3.1.2. Alzheimer’s disease 
Like PSP, the unquestionable diagnosis of AD is still only possible during a 
post mortem examination. Certain neuropathological changes attributed as 
hallmark lesions of AD have been specifically associated to AD dementia, while 
clinical signs of dementia can be caused by several diseases (Albert et al., 2011; 
McKhann et al., 2011). Autopsy and neuropathological examination are therefore 
considered the ‘gold standard’ of AD diagnostics and allow for assessment of AD 
years to decades before clinical onset (Sperling et al., 2011).  
 
Figure 4: Tau-positive inclusion in Progressive Supranuclear Palsy brain. 
Neurofibrillary tangles of tau are shown in brown in the oculomotor (left), substantia nigra (middle) and pontine 
base (right) brain structures in haematoxylin and eosin staining. Images provided by Dr Kieren Allinson from the 
Cambridge Brain Bank.  
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Neuropathologically, AD is defined by the accumulation of two types of 
insoluble fibrous material: extracellular amyloid-β (Aβ) protein in the shape of 
senile plaques (SP), and NFTs made of abnormally and hyperphosphorylated tau 
protein. The manner in which NFT formation spreads to various brain areas during 
the course of AD follows a stereotyped pattern which has been used to define six 
neuropathological stages, the Braak stages (Braak & Braak, 1991) (Figure 5). 
Earliest NFTs are observed in the transentorhinal and entorhinal cortex (stages I 
and II; transentorhinal stages). A more extensive involvement of the entorhinal 
cortex and the formation of NFTs in sector CA1 of the hippocampus correspond to 
stages III and IV or to limbic stages. At stages I and II, patients are cognitively 
unimpaired whereas subjects with limbic stages III and IV may present with mild 
cognitive impairment. The main feature of stages V and VI is the development of 
abundant NFTs in neocortical association areas (isocortical stages). Subjects with 
stages V and VI meet the neuropathological criteria for the diagnosis of AD and 
are severely demented at the time of death. In contrast to NFTs, the density and 
distribution of SP follows a different and much more variable pattern. In general, 
they are first found in isocortical areas of frontal, temporal and occipital lobes 
(Braak & Braak, 1991; Price et al., 1991). Moreover, abundant amyloid deposits 
may also found in cognitively normal elderly subjects (Dickson et al., 1992).  
 
 
Figure 5: Pathological evolution of Alzheimer’s disease.  
a) Amyloid plaques and neurofibrillary tangles spread through the brain as the disease progresses b) Typical AD 
case with amyloid-β deposition (top row) and neurofibrillary tangles degeneration (bottom row). Figure provided 
by Masters et al., 2015, and reprinted with permission.  
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Tau has often been suggested as a facilitator of the downstream effects of 
β-amyloid in AD (Desikan et al., 2012; Jack & Holtzman, 2013). Moreover, it has 
been shown that tau pathology has a devastating effect on synaptic function 
(Beharry et al., 2014; Gómez-Isla et al., 1997; Spires-Jones & Hyman, 2014), and 
relates more strongly to cognitive functions during life than does β-amyloid 
(Arriagada et al., 1992; Nelson et al., 2012; Rolstad et al., 2013). In addition, 
mapping the distribution of tau pathology may further our understanding of 
disease mechanisms in distinct clinical variants of AD, including posterior cortical 
atrophy (PCA) and logopenic variant primary progressive aphasia (lvPPA). For 
instance, in a recent case study of a patient with PCA using tau targeting PET 
ligand ([18F]AV1451) was found to be more closely linked to hypometabolism and 
cognitive deficits than was amyloid-β (Ossenkoppele et al., 2015).  
 
1.3.2. Amyloid 
1.3.2.1. Progressive supranuclear palsy 
PSP is characterized by the presence of tau isoforms with 4-repeats in the 
microtubule binding domain (Dickson et al., 2010), and is hence considered a 4R 
tauopathy (Baker et al., 1999). However, autopsy studies have identiﬁed the 
presence of concomitant amyloid-β proteins in the brains of some subjects with 
PSP (Dugger et al., 2014; Tsuboi et al., 2003). Whitwell and colleagues (2018) 
have shown that β-amyloid deposition occurs in a relatively high proportion of PSP 
subjects as an age-related phenomenon. Unlike in AD, however, there is little 
evidence that amyloid-β, and PHF-tau, play a significant role in neurodegeneration 
in PSP (Whitwell et al., 2018). As a consequence, amyloid is not considered further 
in my thesis as a major contributor to PSP. 
 
1.3.2.2. Alzheimer’s disease 
The conventional view of AD is that much of the pathology is driven by an 
increased load of amyloid-β in the brain of AD patients. This view is known as the 
“amyloid cascade hypothesis”, and suggests that the formation of amyloid-β fibrils 
(Aβ) is directly responsible for triggering tau phosphorylation and neurofibrillary 
tangle formation leading to neuronal death and dementia (Beyreuther & Masters, 
1991; Hardy & Allsop, 1991). Detailed analysis of the amyloid-β hypothesis and 
its limitations is beyond the scope of my thesis, but, of relevance as it has been 
the basis of several major trials (as yet unsuccessful), e.g. solanezumab, 
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bapineuzumab. Their failure may be related to design and stage rather than a 
refutation of the amyloid-β hypothesis.  
 
Given the correlation between the NFTs depositions in AD patients, with the 
degree of cognitive impairment, while the burden of amyloid plaque correlates 
poorly with AD severity (Arriagada et al., 1992; Buchhave et al., 2012), I focus 
on tau. Ossenkoppele has suggested that AV imaging (Ossenkoppele et al., 2015) 
alone would be enough for AD differential diagnosis. However, amyloid imaging is 
important for the AD arm of this thesis, in distinguishing the MCI cases with AD 
pathology from MCI cases without. This is critical. The literature has clearly 
indicated that a high proportion of people clinically diagnosed with MCI do not 
have AD pathology, and amyloid status predicts cognitive change over 2-5 years 
from MCI diagnosis (Flicker et al., 1993; Gauthier et al., 2006; Reisberg et al., 
1982; Wisse et al., 2015). Therefore, my thesis uses amyloid imaging in MCI 
cases, and my analyses only include cases with positive amyloid scans, PiB has 
the longest history as a amyloid biomarker for in vivo use (Mathis et al., 2002), 
although [18F] compounds are also now available, e.g. flutemetamol, florbetaben, 
florbetapir (Martinez et al., 2017; Ong et al., 2013; Thurfjell et al., 2012; 
Villemagne et al., 2011).  
 
1.3.3. Neuroinflammation  
A substantial amount of data supports the idea that inflammation may play 
a role in many neurodegenerative diseases, with activated microglia being the 
common denominator (Dheen et al., 2007; Wyss-Coray & Mucke, 2002). Although 
inflammation in the body is intended to be protective, an excessive inflammatory 
response can cause or contribute to tissue damage and disease pathology (Lyman 
et al., 2014). While it is clear that not all activation of microglia results in neuronal 
cell death, unregulated or overactive microglia are indeed capable of neurotoxic 
effects (Block & Hong, 2005). Activation of microglia may be induced by infectious 
agents, injury or chronic accumulation of abnormal protein aggregates (Rivest, 
2009). The chronic release of inflammatory mediators, such as pro-inflammatory 
cytokines, reactive oxygen and nitrogen intermediates and arachidonic acid 
metabolites may promote the abnormal activation of microglia and astroglia, 
recruitment of inflammatory cells and destruction of normal neurons and synapses 
(Frank-Cannon et al., 2009).  
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1.3.3.1. Progressive supranuclear palsy 
Microglial activation and inflammatory cytokine expression have been 
shown to be pathological features of PSP (Ishizawa & Dickson, 2001; Kreutzberg, 
1996). Fernández-Botrán and colleagues (2011) also showed different patterns of 
cytokine expression in each group, with significantly higher microglial burdens in 
the substantia nigra of PSP than in the control group. PET studies have also 
revealed evidence of activated microglia in relevant structures in the brain of PSP 
patients involving cortical and subcortical regions such as frontal lobe, caudate 
nucleus, pallidum, putamen, substantia nigra and midbrain (Gerhard et al., 2006).  
 
1.3.3.2. Alzheimer’s disease  
Increasing evidence suggests that AD pathogenesis is not restricted to the 
presence of the two core pathologies, amyloid-β plaques and neurofibrillary 
tangles. Over the last decade, the presence of a chronic neuroinflammation 
attributed to activated microglia cells has emerged as a third core pathology in AD 
(Akiyama et al., 2000; Tuppo et al., 2005; Walters et al., 2016). The inflammatory 
response has now been observed in multiple studies of post mortem tissues of AD 
patient samples (Sudduth et al., 2013; Itakagi et al., 1989; Knezevic et al., 2018). 
The sustained activation of the microglia has been demonstrated to exacerbate 
both β-amyloid and tau pathology and may serve as a link in the pathogenesis of 
the disorder. It has also been suggested that, in AD, a key factor in the 
accumulation of β-amyloid throughout the brain is the failure of microglia to 
remove extracellular amyloid (Hickman et al., 2008; Theriault et al., 2015; Weiner 
et al., 2006). Indeed, in cortical tissue specimens from patients with AD, the 
microglia surrounding plaques are impaired at amyloid-β uptake (Frackowiak et 
al., 1992; Krabbe et al., 2013).  
 
 
1.4. Imaging biomarkers of PSP and AD/MCI+ 
1.4.1. What does a biomarker mean? 
Biomarkers are objective measures reflecting normal biological processes, 
pathological changes, or pharmaceutical responses to a therapeutic intervention 
(Atkinson et al., 2001). Biomarkers may have different properties and be relevant 
at different stages of the disease process. For instance, [18F]AV1451 radioligand 
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may be great to localize and quantify tau, but it is less able distinguish Tau from 
TDP-43 pathology especially in non-Alzheimer’s settings such as in FTD (Bevan-
Jones et al., 2017). In this way, distinct biomarkers are suited to distinct 
applications including prediction, diagnosis, phenotyping, prognosis, and 
stratification for clinical trials. 
 
A full discussion of so-called ‘wet’ biomarkers (e.g., CSF of blood) is beyond 
the scope of this thesis. I will concentrate on the role of neuroimaging as a 
biomarker in neurodegenerative disease. 
 
1.4.2. Neuroimaging of PSP and AD 
The differential diagnosis of neurodegenerative disorders is largely based 
on careful clinical assessment, but imaging techniques may provide useful 
adjunctive information.  
 
1.4.4.1. Structure 
I. Magnetic resonance imaging (MRI) 
The use of magnetic resonance imaging (MRI) has become a standard 
imaging technique in both clinical neurology and research. MRI enables the 
visualization of degenerative process most readily by showing atrophy in disease-
specific patterns. Identifying such patterns not only facilitates the process of 
clinical diagnosis, but also provides insight into the underlying pathophysiologic 
mechanisms (Iwata, 2005).  
 
The common MRI features of PSP (Höglinger et al., 2017) are atrophy of 
the most rostral midbrain, the midbrain tegmentum (MT), the pontine base and 
third ventricular dilatation with sparing of the cerebellum (Gimenez-Roldan et al., 
1994; Savoiardo et al., 1989; Steele et al., 1964). The mid-sagittal T1 MRI 
sections in PSP patients show atrophy of the midbrain as seen in Figure 6-A. The 
morphologic features of midbrain atrophy create a specific architecture referred 
to as the ‘Hummingbird’ sign (Gröschel et al., 2006). The preserved volume of the 
pons forms the body of the bird while the atrophied midbrain forms the head and 
the beak extending towards the optic chiasm (Kato et al., 2003). The 
‘Hummingbird’ sign is sensitive in diagnosing PSP (Kato et al., 2003) because it 
represents focal atrophy of the rostro-dorsal portion of MT where the neural 
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centers for vertical gaze specifically affected in PSP are located (Büttner-Ennever 
and Büttner, 1978). The same pattern of atrophy can be seen on T2-weighted 
axial sequences with thinning of the cerebral peduncles that result in a concave 
dorso-lateral midbrain margin (Berg et al., 2011). It is also possible to identify the 
wide cavity of the deep interpeduncular cistern on the ventral access of the pons 
(Pandey, 2012). These neurological changes combined give the classic radiological 
sign have become known as the ‘Mickey Mouse’ sign (Figure 6-B) (Itolikar et al., 
2012).  
   
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Alzheimer’s Disease Neuroimaging Initiative (ADNI; Mueller et al., 
2005) is a 5-year consortium study designed to assess the utility of various 
biomarkers for detecting early changes associated with MCI and AD, and 
predicting disease course over time, including cross-sectional and longitudinal 
neuroimaging biomarkers from structural MRI and PET, genetic factors, 
psychometric scores, and CSF markers. A number of studies utilizing MRI data 
from this cohort have been published. For instance, using both ROI and three-
dimensional mapping techniques differences in structural MRI markers have been 
found between diagnostic groups (AD, MCI, health control) at baseline 
assessment, including atrophy in hippocampal and other medial temporal lobe 
(MTL) regions and enlarged ventricles in patients with AD and MCI (Chou et al., 
Figure 6: Magnetic resonance imaging of the Progressive 
Supranuclear Palsy brain. 
A) On T1-weighted sagittal MRI image demonstrates abnormal morphology from 
shortened anteroposterior midbrain diameter, third ventricular dilatation, and flat or 
concave midbrain in PSP patients corresponding to a shape of a hummingbird (left). B) 
On T1-weighted axial MR image, the atrophic pattern associated with PSP creates the 
appearance of ‘Mickey mouse’ face resulting from concavity of the lateral margin of the 
midbrain tegmentum (right). Images provided by the NIMROD study.  
 
A) B) 
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2009; Nestor et al., 2008; Risacher et al., 2009; Risacher et al., 2010). 
Hippocampal volume is sensitive and specific for predicting 1-year conversion from 
MCI to probable AD (Calvini et al., 2009; Misra et al., 2009). Longitudinal data 
from the ADNI cohort has been examined to identify change in brain volume using 
ROI and whole-brain structural change techniques. These studies have detected 
differences in annual change in whole brain volume, hippocampal volume, and 
ventricular volume as a function of baseline diagnostic group (Evans et al., 2010; 
Ho et al., 2010; McEvoy et al., 2009; Morra et al., 2009).  
In my thesis, MRI is primarly used for analysis of PET data and has been 
published separately (Mak et al., 2018). The results showed that compared with 
the amyloid-β group, tau was increased in widespread regions whereas cortical 
thinning was restricted to the temporal cortices. Increased tau binding was 
strongly associated with cortical thinning in each amyloid-β group. Locally, 
regional tau was associated with temporoparietal atrophy. 
 
II. Voxel-Based Morphometry (VBM) 
MRI based measures of atrophy are regarded as valid markers of disease 
state and progression (Frisoni et al., 2010). The importance of the voxel-based 
morphometry (VBM) approach (Ashburner & Friston, 2000) is that it is not biased 
to one particular structure and gives an even-handed and comprehensive 
assessment of anatomical differences throughout the brain (Ashburner & Friston, 
2001).  
Since the first VBM based studies in PSP cohorts, many leading research 
groups have demonstrated subcortical and cortical atrophy (Brenneis et al., 2004; 
Josephs et al., 2008). Gray matter alterations have been reported in various brain 
regions, including the frontal/parietal/temporo-occipital lobes, insular cortex, 
basal ganglia, thalamus, midbrain, pontine, cerebellum, and medial temporal 
lobe (Agosta et al., 2010; Brenneis et al., 2004; Cordato et al., 2005; Ghosh et 
al., 2012; Padovani et al., 2006; Price et al., 2004; Saini et al., 2012; Takahashi 
et al., 2011; Whitwell et al., 2011). Also degeneration of white matter tracts have 
been identified (Padovani et al., 2006; Whitwell et al., 2011), particularly in the 
dentatorubrothalamic tract running from the dentate nucleus of the cerebellum, 
through superior cerebellar peduncles to ventrolateral thalamus.  
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Progression of atrophy measured by VBM in AD patients matches the 
stereotypical pattern of an increase in neurofibrillary tangles described by the 
Braak staging scheme (Braak & Braak, 1995). Atrophy is initially seen in medial 
temporal structures in early AD/MCI+. As AD progresses, atrophy of medial 
temporal structures becomes more prominent extending into lateral temporal 
cortex, parietal and frontal association cortex, and posterior cingulate gyrus, and 
precuneus. Precentral and occipital cortex and cerebellum are spared atrophy (Di 
Paola et al., 2007; Hirao et al., 2006; Matsuda et al., 2002; Ohnishi et al., 2001; 
Schmidt-Wilcke et al., 2009). 
 
III. Diffusion Weighted Imaging (DWI) 
Diffusion weighted imaging (DWI) is a form of MR imaging based upon 
measuring the random Brownian motion (Einstein, 1905) of water molecules 
within an imaging voxel of biological tissue (Hagmann et al., 2006). DWI enables 
the assessment of the water apparent diffusion coefficient (ADC), a measure of 
tissue water diffusivity, and may detect changes in the microstructural integrity of 
nervous tissue earlier than conventional T1- or T2- weighted MRI (Eastwood et 
al., 2003; Yoshikawa, 2004). Regional ADC (rADC) depends on the interactions 
between water molecules and the chemical environment as well as the structural 
barriers at the cellular and subcellular level hindering their motion in vivo (Le 
Bihan et al., 1992). A change of rADC is thought to reflect ultrastructural tissue 
damage (Paviour et al., 2007).   
DWI has been assessed in gray and white matter structures in PSP-RS, 
showing elevated ADC values in putamen, caudate, globus pallidus, midbrain, SCP 
and prefrontal and precentral white matter (Nicoletti et al., 2008; Ohshita et al., 
2000; Paviour et al., 2007; Tsukamoto et al., 2012). In contrast, previous studies 
in AD revealed increased diffusivity of water in the temporal stem, posterior 
cingulate, occipital and parietal white matter pathology compared to controls 
(Hanyu et al., 1998; Kantarci et al., 2005; Sandson et al., 1999).  
 
1.4.4.2. Metabolic 
I. 2-deooxy-2-fluoro-d-glucose (FDG) 
The positron emission tomography (PET) tracer [18F]fluorodeoxyglucose 
(FDG) allows the measurement of glucose consumption. FDG is a glucose analog 
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with physiological properties almost identical to glucose, which is transported from 
the blood to the brain by a carrier-mediated diffusion mechanism. Measurement 
of glucose consumption with FDG-PET imaging allows us to identify disease-
specific cerebral metabolic brain patterns in several neurodegenerative brain 
diseases at even an early disease stage (Mosconi & McHugh, 2011). Since the first 
FDG-PET study in man (Reivich et al., 1979), regional differences in cerebral 
glucose metabolism have been reported in various neurodegenerative brain 
diseases including parkinsonian syndromes (Teune et al., 2010).  
For example, FDG-PET studies have shown hypometabolism in the 
midbrain, basal ganglia, thalamus and frontal lobes in PSP-RS (Hosaka et al., 
2002; Juh et al., 2005; Mishina et al., 2004; Nagahama et al., 1997; Salmon et 
al., 1997; Yamauchi et al., 1997), with frontal involvement particularly targeting 
premotor, precentral and prefrontal regions (Garraux et al., 1999), and anterior 
cingulate (Klein et al., 2005). FDG-PET has been proven to be a promising 
modality for detecting functional brain changes in AD too, identifying changes in 
early AD, and helping to differentiate AD from other causes of dementia 
(Shivamurthy et al., 2015). In patients with early AD, the areas of glucose 
hypometabolism have been commonly observed in the parieto-temporal 
association cortices, posterior cingulate cortex, and the precuneus (Fukai et al., 
2008; Minoshima et al., 1997).  
 
II. DATscan 
This type of imaging uses the radioactive compound, (123I)ioflupane, which 
has a high binding affinity for presynaptic dopamine transporters (DAT), in 
particular the striatal brain region associated with parkinsonian syndromes such 
as PSP, Parkinson’s disease (PD), and multiple system atrophy (MSA) (Benamer 
et al., 2003; Seifert & Wiener, 2013; Tolosa et al., 2007).  
Examinations in PSP and MSA versus PD using (123I)ioflupane SPECT have 
shown reduced striatal binding as a feature of all three disorders, although this 
was more significant in PSP with no statistical difference between binding in MSA 
versus PD cases (Antonini et al., 2003). A more recent (123I)ioflupane PET study 
has reported that PSP cases had more prominent and earlier dopamine transporter 
loss in the anterior caudate compared with the MSA and PD cases (Oh et al., 
2012). Whilst DATscan is not abnormal in AD (Piggott et al., 1999; Suzuki et al., 
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2002), a common diagnostic conundrum is to differentiate AD from dementia with 
Lewy bodies (DLB) (Lopez et al., 2002; Mak et al., 2014) since they share clinical, 
neuropsychological and pathological features. In this situation a DATscan can be 
helpful in identify loss of dopaminergic neurons in DLB. As result, an improvement 
in clinical accuracy when AD is part of the differential diagnosis, DATscan seems 
to be worthwhile. 
 
1.4.4.3. Neurophysiology 
A key challenge to understanding the effects of neurodegeneration is to 
characterise the changing patterns of brain network connectivity, in response to 
both the disease and its treatment (Pievani et al., 2011; Seeley et al., 2009; 
Warren et al., 2012). Many studies examine macroscopic networks using task-free 
‘resting state’ paradigms, in which coactivation of distributed regions, or 
coherence among spontaneous neural oscillators, is thought to reflect functional 
networks (Corbetta, 2012). In response to task demands or experimental 
conditions, these networks are rapidly reconfigured to create a dynamic neuronal 
workspace for cognitive processing (Kitzbichler et al., 2011).  
 
I. Functional magnetic resonance imaging (fMRI) 
Functional magnetic resonance imaging (fMRI) measures brain activity 
indirectly by detecting changes associated with blood flow (hemodynamic 
response) related to neuronal energy use (Ogawa & Sung, 2007). The primary 
form of fMRI uses the blood-oxygen-level dependent (BOLD) contrast. In addition 
to detecting the BOLD responses from activity due to tasks/stimuli (Huettel et al., 
2004), the fMRI paradigm includes also resting-state fMRI (Fox & Raichle, 2007). 
These networks relate to structurally connected neuroanatomical systems 
(Greicius et al., 2009; Van Den Heuvel et al., 2009), and it has been shown that 
these networks are altered in subjects with neurodegenerative disease. For 
instance, PSP has been proposed as a network-based disorder (Chen et al., 2010; 
Gardner et al., 2013; Rittman et al., 2016; Salmon et al., 1997). It may be 
possible to link changes in networks to underlying genetic and molecular process. 
For example, Rittman and colleagues (2016) measured functional connectivity 
among gray matter regions during task-free fMRI in subjects with PSP, PD, and 
healthy controls. They showed that the regional expression of the MAPT gene in 
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health is associated with regions of high connectivity, which predict the 
functionally relevant loss of connectivity in PSP.  
 
It may also be possible to investigate potential mechanisms of disease using 
network analysis and multimodal imaging. For example, Cope et al. assessed the 
relationship between tau burden and brain connectivity in patients with PSP, AD, 
and healthy controls (Cope et al., 2018). The results showed strongly connected 
nodes displayed more tau pathology in AD independent of intrinsic connectivity 
network. Conversely, in PSP, unlike in AD, those nodes that accrued pathological 
tau were those that properties associated with increased metabolic demand and a 
lack of trophic support rather than strong functional connectivity. 
 
1.4.4.4. Electrophysiology 
EEG/MEG is a functional neuroimaging technique for mapping brain activity 
by recording magnetic fields produced by electrical currents occurring naturally in 
the brain, using very sensitive magnetometers (Cohen, 1968). MEG studies have 
helped to identify neurophysiological network signatures of neurodegenerative 
diseases leading to dementia, characterized by altered spectral properties of 
oscillatory brain activity (Hughes et al., 2018; Hughes & Rowe, 2013; Sami et al., 
2018). Using MEG it is possible to identify characteristics of altered connectivity 
that are the result of differential disruption of neuronal microstructure and 
synaptic physiology by AD versus frontotemporal lobar degeneration, including 
PSP (Sami et al., 2018).  
 
 
1.5. Positron emission tomography (PET) and imaging 
biomarkers  
Positron emission tomography (PET) is a non-invasive diagnostic imaging 
modality utilizing isotope-labelled molecular probes that bind to biomolecules with 
both high specificity and affinity. This is a technique that may enable longitudinal 
in vivo investigations (Matthews et al., 2012). The development of dedicated PET 
scanners suitable for imaging animals as small as mice (Bao et al., 2009; Cherry 
& Gambhir, 2001; Myers & Hume, 2002) has paved the way for researchers to 
investigate the suitability of PET tracers that could potentially enable visualization 
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of the density of markers associated with tau (Agosta et al., 2010; Bevan-Jones 
et al., 2017; Chien et al., 2014; Dickerson et al., 2014; Passamonti et al., 2017), 
and neuroinflammation (Fan et al., 2015; Gerhard et al., 2006b; Kumar et al., 
2012; Venneti, et al., 2009). 
 
At the time I started my thesis in 2015, there were only a few studies on 
tau pathology and neuroinflammation using PET imaging biomarkers in vivo in 
patients with AD, and even less in PSP cohorts. In the last 4 years, the field of tau 
PET imaging has expanded greatly, which I review in more detail in chapters 4 
and 6.  
 
These biomarkers have the capacity to improve our understanding and 
management of these neurodegenerative diseases. In order to fulfill this potential, 
several important questions need to be answered. Among these, are the ability of 
ligands to quantify and localize tau and neuroinflammation in vivo, and ultimately 
track these changes longitudinally. They should also relate to clinical features and 
severity. In this section, I will start stating the literature of PET biomarkers for tau 
and inflammation in both PSP and AD at the time of beginning this project. I will 
then reference some of the research work that has been undertaken in the field 
since including other PET radioligands.  
 
1.5.1. Tau pathology 
The last two decades have been focused on developing novel radioligands 
for the non-invasive detection of β-amyloid deposition in the brain. While there 
are a number of PET ligands (Ashford et al., 2011; Herholz & Ebmeier, 2011; 
Vallabhajosula, 2011) designed to target β-amyloid plaques including [18F]FDDNP 
(Shin et al., 2011), [11C]PIB (Klunk et al., 2004), Flutemetamol (Vandenberghe et 
al., 2010), [18F]Florbetaben (Barthel & Sabri, 2011), and [18F]Florbetapir (Clark et 
al., 2011), there have been very few reports on imaging agents selectively 
targeting tau aggregates. This has led to a renewed international effort to develop 
selective tau radiotracers to achieve a more profound understanding of the 
pathophysiology of PSP, AD, and other neurodegenerative conditions in which tau 
plays a role. However, given that the ultrastructural form that tau aggregates 
adopt in AD is PHF, most of the efforts for developing selective tau imaging 
radiotracers were focused on PHF tau.  It was not clear at that stage (and time) if 
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or how well these tracers will recognize the other conformations of tau aggregates 
present in non-AD tauopathies, such as PSP. Determining how tau-PET imaging 
behaves in patients with PSP was one of my main aims in my PhD thesis.  
 
1.5.1.1. [18F]AV1451 (formerly called [18F]T807) 
Since [18F]AV1451 (formerly called [18F]T807) was introduced for AD and 
MCI populations, many research groups have presented their data with this ligand. 
Back in 2014, Chien and his collaborators concluded that cortical [18F]AV1451 
retention follows the known distribution of PHF tau in the brain, where higher 
[18F]AV1451 cortical uptake was significantly associated with increasing disease 
severity (Chien et al., 2014), consistent with post mortem studies showing the 
strong association of tau pathology with severity of dementia (Devous et al., 
2014). Furthermore, Schöll’s recent paper (2017) has concluded that patients with 
early-onset AD were more prone to tau aggregation in widespread neocortical 
regions, while the medial temporal lobe showed peak [18F]AV1451 uptake in late-
onset AD (Schöll et al., 2017).  
 
Although predominantly tested in AD and MCI patients, Dickerson and 
colleagues (2014) reported positive results when they tested [18F]AV1451 in 
patients with PSP. There was increased binding of the radiotracer in the brainstem, 
basal ganglia, subthalamic nucleus, cerebellum, and frontal cortex. This pattern 
of binding was consistent with the spatial distribution of tau in PSP. However, 
Smith et al. found higher [18F]AV1451 binding in the basal ganglia of PSP patients 
when compared with healthy elderly controls, but also increased with age in both 
controls and patients (Smith et al., 2017).  
 
Other pathologies such as dementia with Lewy Bodies (DLB), PD and PD 
with dementia (PPD) have been also investigated using [18F]AV1451. The results 
showed that parietal [18F]AV1451 binding was increased in patients with DLB 
compared to controls and PD patients, while [18F]AV1451 uptake was reduced in 
the substantia nigra in PDD (Smith et al., 2018). The degree to which this reflects 
off-target binding, or concurrent AD pathology, remains controversial. 
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1.5.1.2. [18F]THK523, [18F]THK5105, and [18F]THK5117 
Preclinical analyses of [18F]THK523 indicated that this tracer selectively 
labels tau pathology in the AD brain. For instance, autoradiographic and 
histofluorescence examinations of THK523 in human AD hippocampal brain 
sections have demonstrated its high affinity and selectivity for tau pathology 
(Fodero-Tavoletti et al., 2011). However, the preclinical data suggested that the 
pharmacokinetics and binding characteristics of [18F]THK523 did not reach the 
necessary optimal levels required for PET tracers. Villemagne’s paper (2011) 
concluded that the tracer’s uptake pattern in AD patients was not distinguishable 
from healthy control. Testing in PSP and CBD brain slices revealed no THK523 
fluorescence, suggesting that the lack of binding in these straight filament 
tauopathies may be due to a specificity of THK523 for PHF tau conformation 
(Fodero-Tavoletti et al., 2014).  
 
Despite [18F]THK523 compound optimization and [18F]THK5105 and 
[18F]THK5117 were developed (Okamura et al., 2013), it has been shown that the 
interpretation of [18F]THK523 PET images, with respect to tau, is confounded by 
the high monoamine oxidase-B (MAO-B) availability across the entire brain  
(Gulyás et al., 2011; Hirvonen et al., 2009; Ng et al., 2017). 
 
1.5.1.3. [11C]PBB3 
In vitro and animal data indicated that [11C]PBB3 binds reversibly to 
neurofibrillary tau tangles with high affinity and selectivity in AD (Hashimoto et 
al., 2014; Maruyama et al., 2013). Moreover, accumulation of [11C]PBB3 was seen 
in the medial and lateral temporal cortices, and the frontal cortex—consistent with 
the Braak staging theory of AD (Maruyama et al., 2013).  
 
[11C]PBB3 recently underwent clinical testing in patients with PSP and the 
highest retention was associated with brain regions responsible for clinical 
symptoms (Sahara et al., 2017). Another study with PSP patients reported 
significantly higher binding of [11C]PBB3 in globus pallidus, putamen, thalamus, 
subthalamus, midbrain, pons, and perirolandic areas compared with healthy 
controls (Shimada et al., 2016). When tested in a CBD patient, [11C]PBB3 
retention was high in the neocortex and subcortical structures. The signal was 
greater in the right basal ganglia as compared to the left, which was consistent 
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with the atrophy displayed on the patient’s MRI (Maruyama et al., 2013). Another 
recent studies have reported significantly increased binding in the supplementary 
motor area, subthalamus, midbrain, and perirolandic areas of CBD patients 
compared with healthy controls  (Sahara et al., 2017; Shimada et al., 2016).  
 
The NIMROD study chose to use [18F]AV1451, which has most extensive 
evidence internationally so far. Subsequently, the severity of displacement of 
THK5351 by selegiline (acting on MAO-B), and lack of large scale data with PBB3, 
have left [18F]AV1451 the lead compound despite its controversies, while second 
generation ligands are developed and validated. 
 
1.5.2. Inflammation 
As well as tau pathology, neuroinflammation is increasingly recognized as 
a key factor in the pathogenesis of neurodegenerative conditions such as PSP and 
AD (Agostinho et al., 2010; Fernández-Botrán et al., 2011; Wiley et al., 2009). 
Deficits in neuronal function and synaptic plasticity in these disorders are believed 
to be linked to microglial activation. Most of the PET ligands targeting presumed 
inflammatory targets that have previously been used in animals or humans, have 
labelled the 18kDa mitochondrial translocator protein (TSPO), formerly known as 
the peripheral benzodiazepine receptor (PBR) (Chen & Guilarte, 2008; 
Papadopoulos et al., 2006).  
 
I will next focus on the most studied PET tracers binding to TPSO which are 
[11C](R)-PK11195 (Roeda et al., 2012), and [11C]PBR28 (Dedeurwaerdere et al., 
2012; Hannestad et al., 2012). 
 
1.5.2.1. [11C](R)-PK11195 
Using a first-generation TSPO tracer, [11C](R)-PK11195, has been 
extensively used with PET to evaluate microglial activation in several neurologic 
disorders, such as stroke (Price et al., 2006), multiple sclerosis (Banati et al., 
2000), Alzheimer’s disease (Cagnin et al., 2001), Parkinson’s disease (Gerhard et 
al., 2006b), corticobasal degeneration (Gerhard et al., 2004), and Huntington’s 
disease (Pavese et al., 2006). Also, previous in vivo [11C](R)-PK11195 PET studies 
69 
 
demonstrated an increased TSPO density accompanying normal aging of the brain 
(Kumar et al., 2012).  
 
Microglial activation has been detected through in vivo studies in very early 
clinical stages of AD disease showing significant increased [11C](R)-PK11195 
binding in the entorhinal, temporoparietal, and cingulate cortex suggesting that 
neuroinflammation is a first sign in the pathogenesis of the disease (Cagnin et al., 
2001; Okello et al., 2009). In addition, post mortem data have revealed increase 
microglia in the frontal cortex, parietal and occipital cortices (Fernández-Botrán et 
al., 2011). These results agreed with another study, which combine post mortem 
and animal model. It has been suggested that PK11195 binding in AD post mortem 
tissue and transgenic mice in vivo correlates with the extent of TSPO expression 
in the hippocampus, frontal, temporal, and parietal cortices (Venneti et al., 2009). 
It has also been reported that TSPO ligand [11C](R)-PK11195 detected 
neuroinflammation in patients with MCI (Cagnin et al., 2006).  
Although the small numbers of PSP patients in the Gerhard’s study (2006), 
their findings show a pattern of increased TSPO expression in PSP patients 
including cortical and subcortical areas that agrees with the known distribution of 
neuropathological changes (Dickson, 1999). Previous post mortem findings 
demonstrated that microglial burden in brain tissue were increased in the 
subthalamic nucleus and substantia nigra of PSP (Fernández-Botrán et al., 2011) 
indicated a disease-specific topological relationship with the pathological 
hallmarks of PSP (Fernández-Botrán et al., 2011).  
 
1.5.2.2. [11C]PBR28 
The field of TSPO radioligands has been quickly extended, with several of 
so-called ‘second-generation’ TSPO ligands such as [11C]PBR28 that appeared to 
be an improved radioligand (Briard et al., 2008). Animal research has concluded 
that [11C]PBR28 appears to be much better tracer than [11C](R)-PK11195 to image 
TSPO in monkey brain (Imaizumi et al., 2008). In human studies, Lyoo and his 
collaborators (2015) reported greater binding in AD patients than controls, 
particularly in temporal and parietal cortices. In addition, Kreisl’s group (2013) 
showed that neuroinflammation, indicated by increased [11C]PBR28 binding, 
occurs after conversion of MCI to AD and worsens with disease progression.  
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1.5.3. Limitations of current PET ligands 
1.5.3.1. Tau PET tracers 
The discrimination of the existing tau-PET tracers for non-AD tauopathies is 
not well understood. Previous post mortem studies using [18F]AV1451 have shown 
high affinity for the AD tauopathy (Lowe et al., 2016; Marquié et al., 2015). 
However, [18F]AV1451 binding was not observed for the 4R tau aggregates such 
as PSP, where  autoradiographical results indicate less robust staining (Josephs et 
al., 2006; Lowe et al., 2016). Another area of concern is related to non-specific 
tau PET binding in subcortical structures in healthy controls, which may suggest 
that the current tau radioligand could present off-target binding, such as to 
neuromelanin (Marquié et al., 2015). The possibility that tau PET ligands present 
non-specific binding is supported by a recent study showing that selegiline, a 
monoamine oxidase-B (MAO-B) inhibitor, significantly reduces brain AV1451 
uptake (Hostetler et al., 2016). Another issue in tau PET quantification is 
represented by the time window adopted for standardized uptake value ratio 
(SUVR) semi-quantification. As for [18F]AV1451, the 80- to 100-minute SUVR, 
commonly adopted in previous research studies (Saint-Aubert et al., 2017), might 
be not optimal given the evidence for a further 30% increase of SUVR values up 
to 180 minutes from injection (Barret et al., 2017).  
 
1.5.3.2. Microglial activation PET tracers 
PET imaging with TSPO ligands are potential in vivo tools for tracking the 
progression of neuroinflammation in neurodegenerative disorders such as PSP and 
AD; however there are several limitations in the first-generation TSPO ligand such 
as [11C](R)-PK11195, as Zhang and Dupont indicated in their papers. The main 
concerns are high non-specific binding, low brain penetration, and high plasma 
protein binding (Zhang, 2015), and such as limited availability of [11C] ligands in 
clinical settings and low signal-to-noise ratio (Dupont et al., 2017), which may 
clarify the negative results in others studies using [11C](R)-PK11195 
(Schuitemaker et al., 2013; Wiley et al., 2009). Then a second generation of 
radioligands has been introduced, mainly to overcome some of the [11C](R)-
PK11195 limitations, such as [11C]PBR28 that overall displays higher binding 
affinities (Dupont et al., 2017). However, it was shown that a single-nucleotide 
polymorphism (that is, rs6971) in the TSPO gene can considerably influence the 
uptake of the second-generation tracers, making genetic testing mandatory 
71 
 
(Owen et al., 2010, 2012); therefore [11C](R)-PK11195 remains (so far) the best 
validated and diffusely adopted in human studies, as it does not required TSPO 
genotype evaluation. 
 
 
1.6. Aims 
My PhD aims to extend the current knowledge on tau pathology and the 
presence of neuroinflammation in PSP and AD in both in vivo and post mortem. 
The first objective was to define the clinical populations focusing on disease 
phenotype and severity (Chapter 2). Then I examined the cognitive features 
including the executive function, memory and behaviour, and motor impairments 
of patients in the NIMROD study, and how they relate to other measures of disease 
severity in PSP and AD/MCI+ (Chapter 3). I assessed the magnitude and patterns 
of [18F]AV1451 binding in PSP and AD/MCI+, and related them with cognitive 
impairment and disease severity (Chapter 4). In order to evaluate this in vivo 
work, post mortem studies were also completed. Finally, I measured 
neuroinflammation in terms of microglial activation and linked it with cognitive 
and motor decline (Chapter 5). Post mortem work was undertaken to validate 
these results (Chapter 4 and 5).  
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Chapter 2 
Neuroimaging of Inflammation in 
Memory and Related Other Disorders 
(NIMROD) study protocol 
 
Material in this chapter has been published as part of the full study protocol paper:  
 
Bevan-Jones, R. W., Surendranathan, A., Passamonti, L., Vázquez Rodríguez, P., 
Arnold, R., Mak, E., Su, L., Coles, J. P., Fryer, T. D., Hong, Y. T., Williams, G., 
Aigbirhio, F. I., Rowe, J. B. & O’Brien, J. T. (2017). Neuroimaging of Inflammation 
in Memory and Related Other Disorders (NIMROD) study protocol: a Study of the 
Role of Brain Inflammation in Dementia, Depression and Other Neurological 
Illnesses. BMJ Open, 7(1). doi: 10.1136/bmjopen-2016-013187 
 
 
 
 
 
 
 
 
 
 
 
 
 
74 
 
2.1. Introduction 
The Neuroimaging of Inflammation in Memory and Related Other Disorders 
(NIMROD) study was established to test the hypotheses that abnormal tau folding 
and neuroinflammation play critical roles in the pathogenesis of different forms of 
dementia and related disorders. For the purpose of my thesis, I will focus on the 
general research methods related to my study cohorts which were patients with 
PSP, AD and MCI (amyloid-beta positive, MCI+), and healthy control groups. 
 
2.1.1. Contributions 
Part of the recruitment of the disease groups (PSP, AD and MCI+) was 
conducted by our medical team during the participant’s clinic visits. During the 
first year of my PhD, I recruited the majority of the PSP cohort while Mr Robert 
Arnold and Dr Bevan-Jones were in charge of enrolling participants for the AD and 
MCI+ groups through our database and via DeNDRoN and JDR. I also helped them 
increase the numbers of patients with AD in particular. Control participants were 
recruited by Mr Robert Arnold and Dr Ajenthan Surendranathan from healthy 
adults who have indicated a willingness to participate in dementia research via 
DeNDRoN or JDR. They also recruited healthy friends and non-blood-related family 
members of patients. 
 
Chapter 3 includes neuropsychological data obtained under the NIMROD 
research study collected partly by me (mainly PSP cases) with normative and 
Alzheimer case data by Mr Robert Arnold, and Dr Richard Bevan-Jones. The 
analysis, interpretation and writing represent my own work. 
 
Chapters 4 and 5 draw on data from a large NIMROD study team 
collaboration, with multiple researchers affiliated with the Wolfson Brain Imaging 
Centre (WBIC) at Cambridge University, and the departments of PET-CT and 
Pathology at Addenbrooke’s hospital. The patients were recruited by me (PSP 
cases), and Mr Robert Arnold. PET data pre-processing was carried out by Dr Tim 
Fryer and Dr Young Hong.  Analysis and interpretation was the result of joint work 
by Dr Luca Passamonti and myself. Dr Kieren Allison from the Department of 
Pathology provided specific brain tissue needed for both of my studies, which I 
took forward with advice and help from Dr David Wilkinson for the phosphor screen 
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autoradiography and immunohistochemistry in Chapter 4. Dr Robert Finchman 
and Mr Oliver Green kindly agreed to perform the staining in the post mortem 
tissue in Chapter 5.  Dr Allinson also helped with the manual counting of the 
microglia in Chapter 5. 
 
 
2.2. General research methods 
2.2.1. Ethics statement 
NIMROD study has been carried out in accordance with favourable opinions 
given by the NIHR National Research Ethic Service Committee, East of England - 
Cambridge Central, under reference 13/EE/0104. Conduct of the study was 
approved by the Cambridge University Hospital Trusts’ Research and Development 
Departments. 
 
2.2.2. Site and support 
The School of Clinical Medicine at the University of Cambridge has led the 
study in collaboration with Cambridge University Hospitals National Health Service 
Foundation Trust (CUH). The funding has been provided by the National Institute 
for Health Research (NIHR) Biomedical Research Unit (BRU) in Dementia, PSP 
Association, and Wellcome Trust. CUH and University of Cambridge have been 
collectively acted as the sponsor for this study. 
 
NIMROD has been based at the Addenbrooke's Hospital site in Cambridge. 
This site includes the Wolfson Brain Imaging Centre (WBIC) where Magnetic 
Resonance (MR) and Positron Emission Tomography (PET) imaging assessments 
have taken place, including the production of the PET radiotracers. Cognitive 
testing has mainly engaged in the CUH premises, in the adjacent Herchel Smith 
Building (HSB), and department of neurology at University of Cambridge, and/or 
in participants' own homes. However, as study subjects have been recruited from 
clinical services within CUH and Cambridgeshire and Peterborough NHS 
Foundation Trust (CPFT), as well as neighbouring Trusts throughout the region, 
assessments for some subjects have been undertaken at the location of their local 
services, or in the participants’ homes, if most expedient and convenient to the 
participant. 
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2.2.3. Recruitment and selection of study participants 
PSP, AD and MCI+ participants were recruited from cognitive disorder clinics 
in neurology, and related services at CUH and other trusts within the region 
including Cambridgeshire, Lincolnshire, Bedfordshire, Norfolk, Suffolk, 
Hertfordshire and Essex, where participants are willing to travel to Cambridge for 
imaging studies. Case registers held by the Dementias and Neurodegeneration 
specialty of the UK Clinical Research Network (DeNDRoN) and the Join Dementia 
Research (JDR) platform (www.joindementiaresearch.nihr.ac.uk) were other 
sources of participants. All participants had mental capacity and provided written 
informed consent. 
 
2.2.4. Eligibility criteria 
Participants were to be included in the study if they were aged over 50 and 
had sufficient proficiency in English to allow standardised cognitive testing. All 
participants except controls must have had a reliable informant who was able to 
complete questionnaires for informant-related scales and provide a background 
history in order to be included. Further specific inclusion criteria for each cohort 
are listed below under section 2.2.6. For the cohorts including participants with 
dementia, we had included only participants with mild-to-moderate dementia, as 
our experience is that severely impaired participants are highly unlikely to comply 
with the study protocol. Mild to moderate dementia were defined in this study as 
mini mental state examination (MMSE) > 12. 
 
2.2.5. Exclusion criteria 
Potential participants were excluded if they had a concurrent major 
psychiatric illness. They were also excluded if they had a contraindication to an 
MRI scan (e.g., permanent pacemaker), were unable to tolerate an MRI (e.g., 
claustrophobia) or if they had a comorbidity that limits their ability to take part in 
the study. Potential participants were also excluded if they had atypical or focal 
parenchymal appearances on MRI, which were not in keeping with their diagnosis. 
Systemic inflammatory disease was also an exclusion criterion (e.g. Rheumatoid 
arthritis, Crohn’s disease, active psoriasis), or immunomodulatory medications 
(e.g., corticosteroids). 
 
77 
 
2.2.6. Study cohorts  
Participants were enrolled into four separate study cohorts (Table 5).  
 
I. Participants with progressive supranuclear palsy (PSP) fulfilled the 
NINDS-SPSP criteria (Litvan et al., 1996), modified by a relaxation of the falls 
criterion to falls within 3 years, rather than 1 year, as suggested by the NNIPPS-
PSP study group (Bensimon et al., 2008). Our participants were later reclassified 
according to the MDS-PSP revised clinical diagnostic criteria for the classical PSP 
phenotype, also known as PSP-Richardson’s syndrome (PSP-RS) (Höglinger et al., 
2017). 
 
II. Participants with Alzheimer’s disease (AD) met the diagnostic 
criteria for probable AD pathology as defined by National Institute on Aging-
Alzheimer's Association workgroups on diagnostic guidelines for AD (McKhann et 
al., 2011).  
 
III. Participants with biomarker positive mild cognitive impairment 
(MCI+) were defined by MMSE > 24 with a memory impairment at least 1.5 
standard deviations below that expected for age and education (Petersen et al., 
1999). Amnestic MCI is a condition typically involving a degree of episodic memory 
deficiency beyond that expected for age and education but without dementia and 
where no alternative diagnosis may be made (Gross et al., 2017). The condition 
is recognised as a predictor, though not invariably so, of progression to AD (around 
50% of subjects will develop dementia within 3 years). Individuals with MCI who 
do progress are assumed to have had undetected AD pathology before diagnosis 
with AD (Li et al., 2013). To select the subgroup with emerging symptoms of AD 
pathology, we included only people with amnestic MCI who also had biomarker 
evidence of β-amyloid, in terms of  a positive Pittsburgh Compound-B (PiB) PET 
scan (SUVR > 1.5).  
 
IV. Healthy control (HC) participants are  defined as participants with 
MMSE scores > 26 and without (i) regular memory symptoms, (ii) signs or 
symptoms suggestive of dementia or (iii) unstable or significant medical illnesses. 
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 PSP AD MCI+ HC 
Chapter 3 
(Cognition) 
20 9 6 13 
Chapter 4  
(Tau) 
19 9 6 13 
Chapter 5 
(Inflammation) 
16 9 7 13 
Table 5: Study sample sizes for chapters 3, 4 and 5.  
Abbreviations: PSP, Progressive Supranuclear Palsy; AD, Alzheimer’s Disease; MCI+, Mild Cognitive Impairment 
with positive β-amyloid; HC, Healthy Control.  
 
All, except healthy control subjects, had a reliable informant able to 
complete questionnaires for informant-rated scales and provide background 
history. For analysis purposes, we combined patients with clinical diagnostic 
criteria for AD and MCI+ patients on the grounds that these two groups represent 
a continuum of disease (Okello et al., 2009). 
 
 
2.3. Overview of protocol 
Participants underwent an initial clinical assessment, including the collection 
of medical and demographic information (e.g., medication, smoking, alcohol and 
family history), and disease severity evaluation for PSP and AD/MCI+ group; a 
neuropsychological assessment battery described in detail below (tailored to each 
cohort). Participants made between two and four visits for imaging sessions 
depending on their group.  
 
All participants had an MRI scan. HC participants underwent one PET scan 
either with [18F]AV1451 or [11C](R)-PK11195. MCI group had three PET scans: 
[18F]AV1451, [11C](R)-PK11195, and [11C]PiB. For PSP and AD participants 
completed [18F]AV1451 and [11C](R)-PK11195 PET scanning sessions instead. 
  
 
2.3.1. NIMROD assessments 
NIMROD study used a combination of neuropsychological screening tests 
focused on global cognition and executive domain-based evaluations. Carer-
reported assessments were also completed by the patient’s next of kin. While 
anxiety was explicitly measured through a questionnaire, mood and sleep 
disturbances were estimated using indirect measures instead. These evaluations 
are shown in Table 6, and did not include more than two hours of testing with 
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additional time for breaks as needed by all participants, and were done at the 
participant’s home or in our clinic.  
 
 
Test format Assessments Cohort 
Global cognitive 
tests 
 
Executive 
domain-based 
tests 
Addenbrooke's cognitive examination-revised 
(ACE-R) 
Mini mental state examination (MMSE) 
 
INECO frontal screening (IFS) 
Trial Making Test (TMT) 
Stockings Of Cambridge (SOC) 
PSP, AD/MCI+ 
and HC 
 
PSP, AD/MCI+ 
and HC 
Carer-reported 
questionnaires 
Cambridge Behavioural Inventory-Revised  
(CBI-R) 
Neuropsychiatry Inventory (NPI) 
PSP and 
AD/MCI+ 
Mood scale Hospital Anxiety and Depression Scale (HADS) PSP, AD/MCI+ 
and HC 
Sleep 
disturbances 
(indirectly) 
Cambridge Behavioural Inventory-Revised  
(CBI-R) 
Neuropsychiatry Inventory (NPI) 
PSP and 
AD/MCI+ 
Table 6: Neuropsychological, carer-reported, mood, and sleep assessments. 
Abbreviations: PSP, Progressive Supranuclear Palsy; AD, Alzheimer’s D isease; MCI+, Mild Cognitive Impairment 
with β-amyloid positive; HC, Healthy Controls.  
 
Disease severity was also gathered in the NIMROD study but only in the 
patient group by the clinician before the MRI session (Table 7). 
 
 
Disease severity Assessments Cohorts 
Clinical PSP-Rating Scale (PSP-RS) 
 
PSP 
 
Cognition Clinical Dementia Rating (CDR) 
Rey Auditory Verbal Learning  Test (RAVLT) 
AD/MCI+ 
AD/MCI+ 
Table 7: Disease severity measures 
Abbreviations: PSP, Progressive Supranuclear Palsy; AD, Alzheimer’s D isease; MCI+, Mild Cognitive Impairment 
with β-amyloid positive; HC, Healthy Controls.  
 
2.3.1.1 Neuropsychology 
I. Global cognitive function 
Addenbrooke’s Cognitive Examination Revised (ACE-R) & Mini Mental State 
Examination (MMSE) 
The Addenbrooke’s cognitive examination (ACE; Mathuranath et al., 2000) 
was developed to offer a brief test sensitive to the early stages of dementia, and 
differentiating subtypes of dementia including PSP, AD, frontotemporal dementia 
(FTD), and other parkinsonian syndromes (Bier et al., 2004; Dudas et al., 2005; 
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Galton et al., 2005; Larner, 2006; Mathuranath et al., 2000). A few years later, 
Prof Mioshi and colleagues (2006) agreed to review the ACE to include some 
changes. As a result, ACE revised (ACE-R) was easier to administer, and most 
importantly, accomplished standards of a valid dementia-screening test, sensitive 
to early cognitive dysfunction. Like the ACE, the overall ACE-R score is 100 from 
5 subscores, each one representing one cognitive domain including 
attention/orientation, memory, fluency, language and visuospatial (Mathuranath 
et al., 2000) displayed with more detail in Table 8. This new version introduced 
cut-off scores for the diagnosis of dementia of 88 (sensitivity = 0.94; specificity 
= 0.89) and 82 (sensitivity = 0.84; specificity = 1.00) (Miosh et al., 2006). The 
ACE-R is relatively quick to administer as it takes approximately 15 minutes to 
complete in a clinical setting (Mioshi et al., 2006). Like the ACE, the ACE-R also 
incorporates the Mini mental state examination (MMSE; Folstein et al., 1975), so 
this score may be also be produced and 30 points is the maximum total.  
 
II. Executive domain-based 
INECO Frontal Screening (IFS) 
Torralva and colleagues (2009) designed a tool aimed at detecting 
executive dysfunction: the INECO Frontal Screening (IFS). This specific screening 
test was designed to determine executive frontal dysfunction in patients with 
dementia. The executive domain encompasses several subtests that are in turn 
drawn from well-established clinical tests (Table 9). 
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Domains Purpose Maximum 
score 
Attention and 
orientation 
Orientation in time and space. 
Registration of three words (i.e., lemon, key, ball). 
Serial subtraction (i.e., ‘could you take seven away from a hundred?’ and/or backward 
spelling (i.e. WORLD). 
18 
Memory Recall of the three items (i.e., lemon, key, ball) after a long delay (10 minutes). 
Learn the name and address of a fictitious person and recall it at the end of the assessment. If the 
patient fails to recall one or more items, the recognition part offers three options from which the correct 
one can be selected. 
Four general knowledge questions (e.g., ‘name of the current Prime Minister’). 
26 
Verbal fluency Participants are given one minute to produce as many unique words as possible starting with a given 
letter (i.e., letter ‘P’) or with a semantic category (i.e., ‘animals’). 
14 
Language Follow an instruction (i.e., ‘close your eyes’, ‘take the paper in your left hand. Fold the paper 
in half. Put the paper on the floor’). 
Writing a sentence. 
*Repetition of single words and/or phrases (e.g., 'statistician', ‘no ifs, ands or buts’). 
**Naming 10 pictures of low frequency items (e.g., ‘anchor’, ‘rhinoceros’). 
Answering four questions related to these items (e.g., ‘point to the item with a nautical connection’).  
Reading five irregular words (e.g., ‘pint’, ‘height’). 
26 
Visuospatial ***Drawing of overlapping pentagons, and also a cube and a clock. 
Counting dots (4 arrays). 
Naming four incomplete letters. 
16 
Table 8: Addenbrooke’s Cognitive Examination-Revised (ACE-R) domains and its testing purposes. 
Note that items in bold are asked in the Mini mental state examination (MMSE) being the total score 30 points . *Repetition of ‘no ifs, and or buts’. **Naming ‘pencil’ and 
‘watch’. ***Drawing of overlapping pentagons. 
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Test name Purpose Maximum  
score 
Motor sequencing Patient performs the Luria series: “fist, edge, palm” by initially copying the administrator. 
Repeating the series six times alone 
3 
Conflicting 
instructions 
Variant of interference sensitivity task from the Frontal Assessment Battery  (FAB; Dubois et al., 2000). 
Subject is asked to hit the table once when the administrator hit it twice, or to hit the table twice when 
the examiner hits it only once. 
3 
Go/No-Go Stop-signal paradigm is most suitable for the study of response inhibition. 
When the examiner hits the table once, the participant should hit it once as well, but when the examiner 
hits twice, he/she should do nothing. 
3 
Backward digit 
span 
Subject is asked to repeat a progressively lengthening string of digits in the reverse order (Wechsler, 
1939). 
Two trials were given at each successive list length, from two to seven digits. 
If subject passes either trial at a given list length, the next length is administered (maximum six trials).  
6 
Verbal working 
memory (VWM) 
Evaluates the same function as the previous test but with a slightly different load because the series is 
highly overlearned for most individuals. 
Patient is asked to list the months of the year backward, starting with December. 
2 
Spatial working 
memory (SWM) 
Task is derived from the Wechsler Adult Intelligence Scale (WAIS; Wechsler, 1939) but simplified for the 
screening test. 
Examiner presents the subject with four cubes and points at them in a given sequence, then the subject 
is asked to repeat the sequence in reverse order. 
There are four trials, with sequences of two, three, four, and five cubes. 
Number of 
correct 
completed 
sequences 
Proverb 
interpretation 
Three similarities (e.g. ‘in what way a banana and an orange are alike?’) or proverbs (e.g. ‘a bird in the 
hand is worth two in the bush’) are read to the subjects and they are asked to explain their meaning.  
1 
Verbal response 
inhibition 
Task inspired by the Hayling test (Burgess & Shallice, 1997) measuring subject’s capacity to inhibit an 
expected response. 
Examiner reads aloud six sentences, each missing the last word (e.g., ‘it was raining cats and …’), and 
participant is constructed to constrain the likely final word. 
In the first part, subject is read each sentence and ask to complete it correctly while in the second part, 
subject is asked for a completion word that is syntactically correct but unrelated to the sentence in 
meaning (e.g., ‘apples’). 
2 
Table 9: INECO Frontal Screening (IFS) subtests. 
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Trail Making Test (TMT)  
The Trail Making Test (TMT) is a neuropsychological test of visual search 
speed, scanning, speed of processing, mental flexibility, as well as executive 
functioning (Arnett & Labovitz, 1995). It consists of two parts (A and B) in which 
the subject is instructed to connect a set of 25 dots as quickly as possible while 
still maintaining accuracy. The difference in times to complete the two parts of the 
test is usually attributed to the increased cognitive demands of Part B.  
 
Stockings of Cambridge (SOC) 
The Cambridge neuropsychological test automated battery (CANTAB; 
Robbins et al., 1994) is a widely used, validated, and reliable neuropsychological 
battery to assess cognitive dysfunction (Sahakian & Owen, 1992; Bozeat et al., 
2000; Egerházi et al., 2007; Robbins et al., 2010; Wild et al., 2008). The CANTAB 
includes a variety of subtests, such as the Intra/Extra-dimensional (IED) set shift 
test, stop signal test (SST), stockings of Cambridge (SOC) test, spatial working 
Memory (SWM) test, and Cambridge gambling task (CGT), that evaluate executive 
function and measure decision-making ability, response inhibition, and working 
memory. Each sub-battery employs a touch-sensitive screen and begins with 
preliminary tests of sensorimotor function. 
 
In this study, SOC task was administered to assess the executive function 
of the recruited patients. The SOC test examines spatial planning and motor 
control and is similar to the Tower of London test (Shallice, 1982). The participant 
is shown two displays. In each of these displays, three stockings - containing three 
coloured balls - are suspended from a beam. The two displays appear at the top 
and bottom of the screen. The balls are arranged in different patterns in each 
display. The participant must move the balls in the bottom display to copy the 
pattern shown in the top display. The balls are moved one at a time by selecting 
the required ball, then selecting the position to which it should be moved. The 
participant is instructed to make as few moves as possible to match the two 
patterns. Movement time is discounted in a distinct phase of task, in which 
participants simply copy moves made by the computer. The moves shown by the 
computer mimic the moves the participant made when originally solving the 
problem. 
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2.3.1.2. Carer-reported questionnaires 
Carers’ reports are also hugely important as they provide a better 
understanding of the cognitive, behavioural, and emotional symptoms seen often 
in PSP and AD patients. The role of carers can range from help with everyday tasks 
such as getting out of bed and personal care such as bathing, to emotional support; 
therefore their feedback and information are very helpful in describing patient 
disease progression. The two carer-reported scales used in NIMROD were 
Cambridge Behavioural Inventory Revised (CBI-R) and NPI that I briefly describe 
below.  
 
Cambridge Behavioural Inventory - Revised (CBI-R)  
The Cambridge Behavioural Inventory (CBI; Bozeat et al., 2000) comprises 
81 items aiming to capture cognitive, behavioural and affective symptoms as well 
as activities of daily living (ADL). It evaluates 13 domains including memory, 
orientation and attention, everyday skills, self-care, mood, challenging behaviour, 
disinhibition, eating habits, sleep, stereotypic and motor behaviour, motivation, 
insight and awareness. The CBI rates the frequency of each particular domain 
scores from 0 (no impairment) to 4 (severe behavioural deficit). A few years later, 
Wedderburn and colleagues (2008) derived a shorter version of the CBI that is still 
detecting behavioural dysfunction as well as its ability to identify disease specific 
patterns of behaviour. The CBI-R has been reduced to 45 items, minimising 
administration time and making it more user friendly.  
 
The results of the CBI-R in patients with PSP show the highest prevalence 
of behavioural symptoms, with high rates of apathy, stereotypic behaviours, 
disinhibition, and abnormal eating (Aarsland et al., 2001), while in AD, deficits in 
memory, orientation, everyday skills and self-care are more dominant, reflecting 
medial temporal and posterior association cortical pathology (Nagahama et al., 
2006).  
 
Neuropsychiatric Inventory (NPI)  
The Neuropsychiatric Inventory (NPI; Cummings et al., 1994) was mainly 
designed to detect a range of neuropsychiatric features including delusions, 
hallucinations, agitation, dysphoria, anxiety, euphoria, apathy, disinhibition, 
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irritability, and aberrant motor activity. Two more domains have been added later 
on such as night-time behavioural disturbances and appetite and eating 
abnormalities (Cummings, 1997). A question is asked about each domain. If the 
responses to these questions indicate that the patient has problems with a 
particular domain of behaviour, the caregiver is only then asked all the questions 
about that domain, rating the frequency of the symptoms (4-point scale), their 
severity (3-point scale), and the symptom distress (5-point scale).  
 
2.3.1.3. Mood and sleep disturbances 
Several cognitive domains may be influenced by affective disorders. Anxiety 
and depression were assessed in NIMROD by Hospital Anxiety and Depression 
Scale (HADS), and indirectly measured sleep quality by CBI-R and NPI. Anxiety is 
uncommon in patients with PSP (Aarsland et al., 2001; Litvan et al., 1996), but 
the majority of AD patients report anxiety or manifest anxiety (Apostolova & 
Cummings, 2008; Spalletta et al., 2010) including worried appearance, fear of 
being left alone, tension, restlessness, and fidgeting. 
 
The relationship between depression and dementia is complex. Depression 
is also one of the most frequent affective symptoms in subjects with AD. For 
example, Lyketsos (2002) has estimated in his study that 20% of persons with AD 
suffered from dysphoria whereas 20% percent suffered from irritability, another 
likely manifestation of depression. There is inconsistent evidence for depression in 
PSP, (Menza et al., 1995; Millar et al., 2006; Schrag et al., 2010) in part from the 
misinterpretation of somatic symptoms as depression.  
 
Hospital Anxiety and Depression Scale (HADS) 
Hospital Anxiety and Depression Scale (HADS) was originally developed by 
Zigmond and Snaith (1983) and is commonly used to determine the levels 
of anxiety and depression that a patient is experiencing. The HADS is a 14-item 
scale in which seven of the items relate to anxiety and seven relate to depression. 
Each item on the questionnaire is scored from 0 to 3. Scores for each subscale 
(anxiety and depression) range from 0 to 21 with scores categorized as follows: 
0-7 (normal), 8-10 (mild), 11-14 (moderate), and 15-21 (severe). 
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2.3.1.4. Disease severity 
Disease severity can be described in many ways, e.g. severity of atrophy 
(MRI) or pathology (PET or post mortem). But, here I focus on clinical and cognitive 
severity scales that are in common use. Disease severity assessments differed 
between PSP and AD/MCI+ due to their different impairment-specific domains.  
 
Progressive Supranuclear Palsy Rating Scale (PSP-RS) 
The Progressive Supranuclear Palsy – Rating Scale (PSP-RS; Golbe & 
Ohman-Strickland, 2007) is a clinician-rated instrument to assess disability and 
severity of PSP. Administration of the scale takes approximately 15 minutes and it 
consists of 28 items dividing in six categories: history (daily activities), mentation 
(behaviour), bulbar, supranuclear ocular motor, limb motor, and gait and midline. 
The total score is ranging from 0 to 100, and with higher scores indicating more-
severe disability or movement abnormality.   
 
Clinical Dementia Rating (CDR) 
The Clinical Dementia Rating (CDR) is a clinical global scale to indicate the 
severity of AD (Hughes et al., 1982), and also to validate the clinical diagnostic 
criteria for AD (Morris et al., 1988). The assessment consists of semi-structured 
interviews between the patient and informant to rate the subject's cognitive 
performance in memory, orientation, judgment and problem solving, community 
affairs, home and hobbies, and personal care domains. The level of impairment for 
each domain scores from 0 (no dementia) to 3 (severe dementia).  
 
Rey’s Auditory Verbal Learning Test (RAVLT) 
Rey's Auditory Verbal Learning Test (RAVLT; Rey, 1958) is a 
neuropsychological assessment to evaluate cognitive functions such as attention 
and concentration, and memory. Several studies have shown that an impairment 
in RAVLT scores reflects well the underlying pathology caused by AD. For instance, 
studies lead by Tierney (1994) and Estévez González (2003) have shown that the 
RAVLT score is an effective early marker to detect AD in individuals with memory 
complaints.  
 
Briefly, the RAVLT consists of presenting a List A of 15 words that is read 
aloud to the participant, and then the participant is immediately asked to recall as 
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many as words from the List A. This procedure is repeated for five consecutive 
trials. After that, a new List B of 15 new words is read to the participant, who then 
is immediately asked to recall the words. After the List B trial, the examiner asks 
participant to recall the words from the first list (List A). After 30-minutes of 
interpolated testing (timed from the completion of List B recall), the participant is 
again asked to recall the words from the List A (delayed recall). 
 
2.3.2. Neuroimaging 
All participants (PSP, AD/MCI+ and healthy controls) were invited to undergo 
MR and PET imaging procedures, some of which were not conducted the same day. 
In this methods chapter, I summarise the protocol for acquisition and pre-
processing of MRI and PET data. The analysis of methods and statistical inferences 
are described in detail in chapters 4 and 5, where the procedures necessary differ 
in relation to tau and neuroinflammation imaging. See sections 4.4.1 and 5.4.1 for 
details.  
 
2.3.2.1. Magnetic resonance imaging data acquisition 
Magnetic resonance imaging (MRI) scanning was carried out at the Wolfson 
Brain Imaging Centre (WBIC), and all images were examined by a consultant 
radiologist at Cambridge University Hospitals (CUH) to exclude unexpected brain 
abnormalities in recruits. Participants with significant abnormalities have been 
excluded from the study.  
All participants underwent an MRI session acquired either on a 3 Tesla (3T) 
Siemens Magnetom Tim Trio or a Verio scanner (www.medical.siemens.com), 
using a magnetization-prepared rapid acquisition gradient-echo (MPRAGE) T1-
weighted sequence (all groups) with TR = 2300ms, TE = 2.98ms, FOV = 
240x256mm2, 176 slices of 1mm thickness, and flip angle = 9°. 
 
2.3.2.2. Magnetic resonance imaging data pre-processing 
The T1-weighted images were used to facilitate tissue class segmentation 
(grey- and white-matter, together with cerebro-spinal fluid; CSF), and to allow 
inverse normalisation of template space regions of interest (ROIs) defined by 
modified Hammers atlas (Hammers et al., 2003) to subject MRI space. The left 
and right ROIs were combined. The brainstem of the atlas was split into midbrain 
(z ≥ 22mm), pons (z ˂ -22mm) and medulla oblongata (z = -49mm). Each T1 
88 
image was non-rigidly registered to the ICBM2009a template brain using ANTS 
(http://www.picsl.upenn.edu/ANTS/) with default settings, and the inverse 
transform was applied to the modified Hammers atlas (resliced from MNI152 to 
ICBM2009a space) to bring the ROIs to subject MRI space. For 30% of the study 
cases, ANTS default settings applied to T1 normalisation did not converge 
adequately so ANTS parameters were adjusted to normalise the skull stripped T1 
to skull stripped template. 
 
2.3.2.3. Positron emission tomography data acquisition 
PET scanning was performed either on a GE Advance PET scanner (GE 
Healthcare, Waukesha, WI) at the WBIC or in the GE Discovery 690 PET/CT 
scanner at Addenbrooke’s hospital. A 15 minutes 68Ge/68Ga transmission scan 
was used for attenuation correction on the Advance, which was replaced by a low 
dose computed tomography (CT) scan on the Discovery 690. The emission 
protocols were the same on both scanners.  
 
The radiotracers were produced at the WBIC Radiopharmaceutical 
Chemistry laboratories with high radiochemical purity (>95%). [18F]AV1451, 
[11C](R)-PK11195 and [11C]PiB were produced using the GE PETtrace cyclotron, a 
16 MeV proton and 8 MeV deuteron accelerator. The production of [18F]AV1451 was 
based on the synthetic methods developed by Avid Radiopharmaceuticals and 
modified to use the GE TracerLab FX-FN synthesizer at WBIC. [11C](R)-PK11195 
were prepared using the ‘Disposable’ synthesis system or GE TRACER laboratory 
FX-C module. [11C]PiB was prepared using the GE TRACER laboratory FX-C module. 
All PET radiotracers information is displayed in Table 10.  
 
[18F]AV1451 
[18F]AV1451 radioligand was selected to evaluate the density of tau 
deposits. 370MBq of [18F]AV1451 was injected intravenously over 30 seconds at 
the onset of a 90 minutes scan, with emission data subsequently reconstructed 
into 58 contiguous time frame (18x5, 6x15, 10x30, 7x60, 4x150 and 13x300 
seconds) images for kinetic analysis with the simplified reference tissue model.  
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[11C](R)-PK11195 
[11C](R)-PK11195 radioligand aimed to measure the density of activated 
microglia as an indication of neuroinflammation. 500MBq [11C](R)-PK11195 was 
injected intravenously over 30 seconds at the onset of a 75 minutes scan, with 
emission data subsequently reconstructed into 55 contiguous time frame (18x5, 
6x15, 10x30, 7x60, 4x150 and 10x300 seconds) images for kinetic analysis with 
the blood volume corrected simplified reference tissue model.  
 
 [11C]PiB 
[11C]PiB PET specifically binds fibrillar amyloid-beta plaques. It indicates the 
presence of AD pathology, and increases the likelihood that participants with MCI 
at baseline will clinically convert to AD over time (Okello et al., 2009). 550MBq of 
[11C]PiB were injected as a bolus followed by PET imaging from 40-70 minutes 
post-injection, providing imaging data suitable for subsequent standardised uptake 
value ratio (SUVR) analysis.  
 
PET radiotracer 
type 
[18F]AV1451 [11C](R)-PK11195 [11C]PiB 
Radioligand specific 
activity at the end 
of synthesis 
(GBq/μmol) 
> 216 > 85 > 150 
PET radioligand 
injection dose 
(MBq) 
370 500 550 
PET duration 
(minutes) 
90 75 45 
Frame images 58 55 1 
Cohorts PSP, AD, MCI and 
healthy control 
PSP, AD, MCI and 
healthy control 
MCI 
Measurement Tau pathology Activated microglia Amyloid-β deposits 
Table 10: NIMROD PET radiotracers and study groups.   
Abbreviations: PET, Positron Emission Tomography; GBq, Gigabecquerel; MBq, Megabecquerel; PSP, Progressive 
Supranuclear Palsy; AD, Alzheimer’s disease; MCI, Mild Cognitive Impairment.  
 
 
More than one PET scan was required in patient groups to allow direct  
comparison between tau, amyloid, and inflammation. Two healthy control groups 
were recruited in order for them to prevent excessive radiation exposure; therefore 
one group took a [18F]AV1451 PET session and the other healthy cohort attended  
[11C](R)-PK11195 PET scan instead.   
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2.3.2.4. Positron emission tomography data pre-processing  
Each PET emission frame was reconstructed using the PROMIS 3-
dimensional filtered back projection algorithm into a 128 x 128 matrix 157mm 
trans-axial field of view, with a trans-axial Hann filter cut-off at the Nyquist 
frequency (Kinahan and Rogers, 1989). Corrections were applied for random 
movements, dead time, normalization, scatter, attenuation, and sensitivity.  
Each emission image series was realigned using SPM8 to correct for patient 
motion during data acquisition (www.fil.ion.ucl.ac.uk/spm/software/spm8) and 
create a mean image. In cases of very large movement (>10mm in translation or 
>10 degrees of rotation; this applied for 10% of the cases) the SPM co-registration 
function was used. Every dynamic frame after 1 minute post-injection was co-
registered to the first minute frame. This process was repeated until the motion 
was corrected. The mean aligned PET image was rigidly co-registered to the MRI 
T1-weighted image using SPM8 and the inverse transformation applied to the 
modified Hammers atlas to put it in native PET space. Kinetic modelling was then 
performed on the motion-corrected time series in the cases of [18F]AV1451 and 
[11C](R)-PK11195. Reference regions were required for the kinetic modelling 
analysis.  
For [18F]AV1451, the reference region was defined in the superior grey-
matter of the cerebellum using a 90% grey-matter threshold on the grey-matter 
probability map produced by SPM8 smoothed to PET resolution. The superior 
cerebellum was used as reference region as it is considered to have little or no tau 
pathology in either PSP or AD/MCI+ (Dickson et al., 2010; Okello et al., 2009; 
Schöll et al., 2016; Schwarz et al., 2016; Williams et al., 2007). This was confirmed 
in our post mortem cases (see section 4.5.2.3.).  
 
It is difficult to identify suitable reference region for [11C](R)-PK11195; 
therefore, supervised cluster analysis was used to determine the reference tissue 
time-activity curve (Yaqub et al., 2012). Supervised cluster analysis was designed 
to extract pure grey matter signal. Yaqub and colleagues (2012) demonstrated 
that the supervised cluster analysis with 4 kinetic classes (grey, white, blood and 
high specific binding (HSB)) performs better than 6 kinetic classes (grey, white, 
bone, soft tissue, blood and HSB). In order to extract the reference time activity 
curve (TAC), each voxel TAC of the scan was analyzed using the set of predefined 
kinetic classes to find the scaling coefficient of each kinetic class, so that the total 
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TAC is equal to the sum of these scaled kinetic classes. A non-negative least 
squares algorithm (Turkheimer et al, 2007) was used for finding the scaling 
coefficients. Scaling coefficients of each kinetic class were stored in coefficient 
maps showing their spatial distribution. Finally, to extract the reference tissue TAC, 
the coefficient map from the (normal) grey-matter kinetic class was used to 
calculate the weighted average, as follows: 
 
𝐶𝑡
𝑟𝑒𝑓(𝑡) =  (
∑ 𝑤𝑖
𝑔𝑟𝑒𝑦
× 𝐶𝑡
𝑣𝑜𝑥𝑒𝑙(𝑡)𝑁𝑖=1
∑ 𝑤𝑖
𝑔𝑟𝑒𝑦𝑁
𝑖=1
) 
 
where, N is the number of voxels, 𝐶𝑡
𝑟𝑒𝑓
 the resulting reference tissue TAC, 𝑤𝑖
𝑔𝑟𝑒𝑦
 
the grey scaling coefficient and 𝐶𝑡
𝑣𝑜𝑥𝑒𝑙 the voxel TAC. 
 
 
[18F]AV1451 and [11C](R)-PK11195 BPND was determined for each Hammers 
atlas ROI using a basis function implementation of the simplified reference tissue 
model (SRTM) operating upon the dynamic Hammers atlas and reference tissue 
ROI data, both with and without CSF correction (Gunn et al., 1997). CSF partial 
volumes were calculated by division with the mean ROI probability (normalized to 
1) of grey and white matter segments, each smoothed to PET resolution. To test 
whether correction for CSF affected the main results, we repeated all the 
[18F]AV1451 and [11C](R)-PK11195 PET analyses using data not corrected for CSF 
(see chapter 4, sections 4.4.1.5. and 4.5.1.2., and chapter 5, sections 5.4.1.5. 
and 5.5.1.2).   
 
[11C]PiB data were quantified using standardized uptake value ratio (SUVR) 
by dividing the static image by mean radioactivity concentration of the reference 
tissue region defined by >90% of the superior cerebellum. [11C]PiB data were 
treated as dichotomous measures (i.e., positive or negative MCI) and considered 
MCI positive if the average SUVR value across the cortical ROIs was > 1.52 
(Hatashita and Yamasaki, 2013). 
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2.3.3. Neuropathology 
2.3.3.1. Human brain tissue samples preparation 
Post mortem brain tissue from three subjects (one PSP case, one AD patient 
and one control with similar age) from the Cambridge Brain Bank (CBB) was 
included in this study. The phosphor screen autoradiographic and 
immunohistochemical analyses were conducted in different cases from those 
included in the [18F]AV1451 and [11C](R)-PK11195 PET in vivo studies. Tissue 
collection was approved by the local institutional review board. Neuropathological 
diagnoses were performed according to standardised protocols, on 15 blocked 
regions of cortex and subcortical regions. For this study, additional blocks of frozen 
brain tissue were obtained from the frontal cortex, anterior hippocampus, midbrain 
and substantia nigra, and basal ganglia (globus pallidus and putamen). 20μm thick 
sections were cut in a cryostat (Leica CM30505 S Research Cryostat) mounted on 
Thermo Scientific superfrost plus slides and used for [18F]AV1451 and [11C](R)-
PK11195 PET phosphor screen autoradiographies. In terms of 
immunohistochemistry work, phosphorylated-tau immunoreactivity (AT8) and 
tinctorial stain for neuromelanin (Masson-Hamperl stain) were applied in the 
[18F]AV1451 project, while microglia immunoreactivity (HLA-DR antibody) was 
used in [11C](R)-PK11195 PET instead.  
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Chapter 3 
Cognition in progressive supranuclear 
palsy and Alzheimer’s disease/MCI+ 
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3.1. Introduction 
Progressive supranuclear palsy (PSP) and Alzheimer’s disease (AD) are both 
progressive disorders, in the context of aging. The cognitive profiles of PSP and 
AD have been reviewed previously, including executive, memory, language, 
behavioural, and emotional symptoms and signs (Bak et al., 2010; Blennow et al., 
2006; Gerstenecker et al., 2013; Ghosh et al., 2009; Hodges et al., 1990; Levy et 
al., 1996; Litvan et al., 1996; Mathuranath et al., 2000; Milberg & Albert, 1989; 
Moreira et al., 2017; Perry & Hodges, 1999; Pillon et al., 1986; Radakovic et al., 
2017; Reisberg et al., 1987; Robbins et al., 2010; Rosser & Hodges, 1994; 
Sahakian, 1990; Satler et al., 2017; Spalletta et al., 2010; Steele et al., 1964). In 
this chapter, I will examine the executive function, memory, and behaviour of 
patients in the NIMROD study, and how they relate to other measures of disease 
severity in PSP and AD/MCI+, ahead of chapters 4 and 5’s analysis of the 
pathological substrates for cognitive and motor decline.    
 
It is important to point out that some of these cognitive domains may be 
influenced by mood, anxiety or by sleep disruption. The relationship between 
depression and dementia is complex. There is substantial evidence supporting that 
depression is a common symptom in PSP, although rates vary among studies 
(Menza et al., 1995; Millar et al., 2006; Schrag et al., 2010). Depression is also 
one of the most frequent affective symptoms in subjects with AD. For example, 
Lyketsos estimated in his study that 20% of persons with AD suffered from 
dysphoria whereas 20% percent suffered from irritability, another likely 
manifestation of depression (Lyketsos et al., 2002). Neuropsychiatric symptoms 
such as anxiety and irritability are less common in patients with PSP (Aarsland et 
al., 2001; Litvan et al., 1996). In contrast, the majority of AD patients report 
anxiety signs (Apostolova & Cummings, 2008; Spalletta et al., 2010) including 
worried appearance, fear of being left alone, tension, restlessness, and fidgeting.  
 
Disrupted sleep and alertness are increasingly being recognized as common 
behavioural symptoms in neurodegenerative disorders that negatively affect the 
quality of life and safety of patient. They may suffer with initiating and maintaining 
sleep (Di Trapani et al., 1991) or with other disorders such as central apnoea 
(Walsh et al., 2017) and rapid eye movement (REM) (Lee, 1991). Another sleeping 
abnormalities include the difficulty with sleep/wake regulation that can lead to 
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profound sleep deprivation (De Bruine et al., 1996). Abnormalities in sleep 
architecture and insomnia are more frequently described in PSP than in the other 
neurodegenerative disorders (Abbott & Videnovic, 2014). Sleep disturbances, in 
particular, subjective insomnia and daytime sleepiness, have been described in 
60% of PSP baseline assessments (Arena et al., 2015). It takes longer for PSP 
patients to fall asleep, and they wake more frequently during the night, resulting 
in a shorter time asleep. Nevertheless, patients with AD often have nocturnally 
disrupted sleep. Bliwise’s naturalistic study (1990) showed that sleep patterns 
might present as agitation during the night-time hours, and excessive daytime 
napping.  His results also suggested decreased REM sleep in proportion to the 
extent of their dementia (Bliwise et al., 1990).  
 
3.1.1. Executive function 
Executive function is a term that covers a range of the cognitive processes 
including planning, attentional set-shifting, inhibition, and fluency. Executive 
function is often impaired with PSP (Gerstenecker et al., 2013; O’Keeffe et al., 
2007), despite the emphasis on motor deficits in the clinical diagnostic criteria of 
PSP (Höglinger et al., 2017). Patients who develop PSP may have early and 
prominent impairments in executive functions. This is commonly attributed to early 
changes in frontal lobe structure and frontostriatal connections (Gerstenecker et 
al., 2013; Hodges & Miller, 2001; Sitek et al., 2015). However, Ghosh and his 
colleagues (2013) found little deterioration over 12 to 18 months after diagnosis, 
suggesting that executive cognitive decline is an early feature of PSP (Ghosh et 
al., 2013). In contrast, patients with AD/MCI+ present milder executive 
dysfunction, at least during the early stages (Torralva et al., 2009).   
 
3.1.1.1. Planning 
Difficulties in planning tasks and organization occur in 50% to 80% of PSP 
(Millar et al., 2006). Robbins and colleagues (1994) undertook an early study of 
executive function in PSP, using the Cambridge Neuropsychological Test 
Automated Battery (CANTAB), including Stockings of Cambridge Task (SoC), 
analogous to the Tower of London task (ToL; Shallice, 1982). PSP patients had 
slowing of cognitive processes, increased initial thinking times and poor ability to 
solve problems at the first attempt (Robbins et al., 1994). AD patients are also 
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impaired in planning ahead and executing predetermined plans (Franceschi et al., 
2007; Hughes et al., 1982; Satler et al., 2017). The difficulties encountered when 
taking the ToL test were not restricted to the number of required movements, and 
in contrast to PSP, reducing the number of moves did not improve AD patient 
performance.  
 
3.1.1.2. Set-shifting 
Set-shifting refers to the ability to shift attention between one aspect of a 
task or environment and another. Although simple tests of attention and 
orientation are typically normal in PSP patients, attention set-shifting is 
considerably reduced (Dubois et al., 2000; Robbins et al., 1994). Set-shifting is 
impaired in the Trail Making Test (TMT; Arnett & Labovitz, 1995) and Wisconsin 
Card Sort Test (WCST; Berg, 1948) with fewer categories sorted and more 
perseverative errors in PSP (Monza et al., 1998; Pillon et al., 1991). Although 
amnestic deficits are emphasized in AD, attentional control capacities including 
set-shifting are impaired (Amieva et al., 2004; Belleville et al., 2003; Bondi et al., 
2002; Parasuraman & Haxby, 1993; Perry & Hodges, 1999). Amieva’s and Bondi’s 
studies have reported that patients with AD are impaired in TMT and WCST tasks. 
In particular, they found a larger number of perseverative errors in AD subjects 
than in controls.  
 
3.1.1.3. Inhibition 
Inhibition and inhibitory control are core executive functions. The definitions 
of inhibition may vary depending on whether the conceptual framework in which 
inhibitory processes are described such as selective attention (Neill, 1977), visual 
attention (Posner & Snyder, 1975), working memory (Zacks & Hasher, 1994) or 
language (Gernsbacher & Faust, 1991), with inhibitory processes acting on 
thoughts, verbal responses, visual processing, sounds, actions, etc. PSP and AD 
both impair inhibitory mechanisms. Inhibitory deficits are evident in PSP, with 
motor recklessness (e.g. inappropriately fast or reactive standing, with high risk 
of falls), food cramming even during coughing or choking. Their response inhibition 
is impaired and may lead to impulsivity, which can occur even in the presence of 
profound akinesia and rigidity (Burrell et al., 2014; Wedderburn et al., 2008). For 
example, Zhang and colleagues’ study (2016) examined the mechanisms of PSP 
cognitive impairments underlying disinhibition, using saccadic Go/No-Go task. 
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Their striking results revealed that PSP patients were strongly biased towards 
making a response and yet were severely impaired at accumulating the necessary 
evidence to commit to that response. In opposition to this, Amieva’s team (2004) 
investigated the effects of mild AD on the same Go/No-Go task, but no impairment 
was found.  
 
A clinical bedside test used to elicit a failure of motor inhibition is the 
‘applause sign’: if patients are asked to clap three times, they perseverate and 
continue clapping (Dubois et al., 2005). This study concluded that this simple test 
of motor control is able to differentiate PSP from frontal or striatofrontal 
degenerative diseases such as FTD or PD (Dubois et al., 2005). The current reports 
using the ‘applause sign’ in AD are inconclusive. In Luzzi’s study (2011), PSP and 
AD groups presented the ‘applause sign’ differing significantly from normal 
subjects. In contrast, Isella and colleagues (2013) concluded that DLB and CBS 
cohorts had a significantly more frequent ‘applause sign’, while AD and controls 
did not show any differences. Another popular screening tests in the differential 
diagnosis of bradykinetic rigid syndromes is the Frontal Assessment Battery (FAB; 
Dubois et al., 2000) at the bedside (Brown et al., 2010; Paviour et al., 2005). 
Paviour’s study (2005) demonstrated that letter fluency and motor series best 
differentiated between the PSP and MSA groups. Additionally, this study showed 
that lexical fluency and motor series subscores from FAB correctly classified 70% 
of the PSP, MSA and PD patients. The performance of AD patients in the FAB is 
better than FTD disorders (Iavarone et al., 2004), but their scores are still lower 
that healthy controls (Oguro et al., 2006).  
 
The findings of previous studies using Hayling (Ghosh et al., 2013) and 
Stroop assessments in PSP (Pillon et al., 1995) had lower performance compared 
with controls. The same results were also found when both verbal inhibitory tasks 
were administered in AD, as demonstrated being impaired in relation with healthy 
elderly controls (Belleville et al., 2006).  
 
3.1.1.4. Fluency 
Disorders of language are part of the symptomatology of many dementias.  
Different dementias may differ on tests of language production, such as phonemic 
and categorical/semantic fluencies (Rosser & Hodges, 1994). The common use of 
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both phonemic (letter) and semantic (category) fluency tasks in part stems from 
their face validity as tests of verbal ability and executive control (Ettenhofer et al., 
2006). Participants need to retrieve words from their ‘mental lexicon’, to focus on 
the task, to select apply certain constraints and avoid repetition. These require 
executive control (Fisk & Sharp, 2004). Deficits in either verbal ability or executive 
control may manifest themselves in poor performance in the fluency tasks (Shao 
et al., 2014). Where other parts of the examination can indicate verbal skills, the 
fluency tasks can be used as an index of executive function.  
 
Verbal fluency, for both phonological and semantic categories, is severely 
impaired in PSP (Brown et al., 2010; O’Keeffe et al., 2007; Pillon et al., 1991; 
Rittman et al., 2013; Soliveri et al., 1999). In controls, phonemic fluency is more 
difficult than semantic fluency (Rosser & Hodges, 1994). This relative pattern of 
performance is exaggerated in PSP, although PSP subjects were significantly 
impaired on both fluency tasks. Phonemic fluency alone provides accurate 
discrimination between PSP and controls or PD (Rittman et al., 2013), and is 
severely affected by the time of diagnosis.  Patients with PSP may only be able to 
produce three or four words beginning with ‘P’ (Ghosh et al., 2013; Rittman et al., 
2013). Intriguingly, the few p-words that are produced may not start 
phonologically with “/p/”, and may also be low frequency words with initial sounds 
“/t/” or “/s/” (e.g. ptarmigan, psychiatrist) in contrast to typically high frequency 
words produced by controls and AD.   
 
Patients with AD perform poorly on category fluency tasks (e.g. animals), 
but are less impaired at letter fluency, performing at near normal levels on this 
task (Cerhan et al., 2002; Henry et al., 2004; Monsch et al., 1992). Traditionally, 
emphasis has been placed on episodic memory deficits, but recent research 
indicates that some MCI patients show subtle, non-amnestic cognitive difficulties. 
Changes in aspects of executive function, such as verbal fluency, have been 
observed in people years before the clinical diagnosis of AD (Bäckman et al., 
2005). For instance, Saxton and her colleagues included verbal fluency tasks in 
research on neuropsychological performance approximately 1.5 to 5 years prior to 
the onset of AD. Results indicated that decline in category (semantic) fluency was 
one of the predictors of subsequent conversion to AD in older adults (Saxton et 
al., 2004). Another study found that amnestic MCI participants produced 
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significantly fewer words on category, but not phonemic fluency when compared 
to healthy controls, though overall performance on both tasks fell within normal 
limits clinically (Murphy et al., 2006).  
 
3.1.2. Memory 
Often memory is understood as an informational processing system in which 
information is encoded, stored, and retrieved. Although once thought to be a 
simple concept, memory is now considered to be a collection of mental abilities 
that use different systems and components within the brain. Therefore, I will 
explain next these types of memories in brief. 
 
3.1.2.1. Episodic memory 
 The term episodic memory refers to the capacity to recollect specific events 
and episodes from our lives. It is a form of mental time travel that is considered 
to be unique in humans (Tulving, 2002 & 2012). Disturbances to this type of 
memory system are among the earliest signs and symptoms of AD (Blennow et 
al., 2006; Cahn et al., 1995; Egerházi et al., 2007; Milberg & Albert, 1989), 
reflecting the involvement of the hippocampal formation (Fox et al., 1998). It is 
also one of the key symptoms that is prominent pre-clinically (Bäckman et al., 
2004) in the disease, such disruptions may result in difficulty remembering 
significant past events, such a recent visit to the doctor or trip to the cinema. In 
contrast, the pattern of episodic memory of PSP patients differs from that of AD 
patients. While episodic memory is severely affected early in the course of AD, it 
appears to be relatively spared in PSP (Van der Hurk & Hodges, 1995), although 
approximately one third patients could manifest impairments of episodic memory 
(Bak et al., 2005; Brown et al., 2010).  
 
3.1.2.2. Recall vs recognition 
Poor delayed recall and recognition memory is a well-established pattern in 
the AD literature, although recall is considered to become impaired earlier on in 
the course of the disease (Small et al., 2003). Early studies in AD that used word 
list learning tasks such as those from the Consortium to Establish a Registry for 
Alzheimer Disease (CERAD) (Welsh et al., 1992) showed that AD patients rapidly 
forget information over time and are equally impaired (relative to age-matched 
controls) on recognition and free recall components of the tasks. This pattern of 
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performance is considered to reflect deficits in storage caused by deficient 
consolidation of new memory traces rather than ineffective retrieval of new 
information (Weintraub et al., 2012). In addition, previous evidence indicates 
impaired delayed recall scores in word-list learning tasks such as the Rey Auditory 
Verbal Learning Test (RAVLT; Rey, 1958) are perhaps the most accurate measures 
when used to accurately predict diagnostic conversion from MCI to AD (Estévez-
González et al., 2003; Griffith et al., 2006; Maruff et al., 2004).  
 
PSP patients have prominent recall deficits and forgetfulness with relative 
preservation of short-term and implicit memory processes, in contrast to AD where 
patients develop aphasia and apraxia (Litvan et al., 1989). Pillon and colleagues 
(1994) revealed that PSP patients had impaired memory deficits characterized by 
reduced immediate memory span, consistent with the notion that the cognitive 
deficits in PSP were due to involvement of frontal-striatal systems.  
 
3.1.2.3. Autobiographical 
Autobiographical memory refers to episodic memories of an individual, 
which are characterized by a sense of subjective time and autonoetic 
awareness (Tulving, 1972), and entailed by feelings of emotional re-
experience (Markowitsch, 2003).  Because of the interaction of episodic and 
semantic memory and the uniqueness to humans, autobiographical memory is 
considered to be crucial for the continuity of the self and the development of 
personal identity (Conway, 2005). Conway described the importance of 
autobiographical memory to the maintenance of the self: “autobiographical 
knowledge constrains what the self is, has been, and can be”. These processes are 
typically disturbed in patients with AD (Seidl et al., 2011). Berna’s study (2012) 
revealed that a significant impairment of episodic autobiographical memory 
performance was associated with MCI, but not with normal aging. Mild 
autobiographical memory impairment was also observed in PSP, but without a 
temporal gradient for the recall of autobiographical or personal semantic 
information (Zarei et al., 2010).  
 
3.1.2.4. Semantic knowledge 
 Semantic memory refers to memory for words, concepts, rules and abstract 
ideas which are not specific to time or place. Unlike episodic memories, semantic 
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memories are independent of ourselves and of time and of our recollective 
experience (Tulving, 2002; Overman & Becker, 2009).  
 
Patients with AD show mild impairment on a range of semantic memory 
tests, including word-picture matching, category fluency, picture naming, picture 
sorting, and generation of verbal definitions (Bentham et al., 1997), which may 
occur several years prior to diagnosis (Tippett et al., 2007; Verma & Howard, 
2012). A loss of semantic knowledge in AD may make it difficult for patients to 
establish connections to their semantic knowledge base during encoding (Garrard 
& Carroll, 2006). The loss is however, much milder than in Semantic Dementia 
(semantic variant primary progressive aphasia). In contrast, patients with PSP 
perform well on semantic memory tests if they are given sufficient time to 
complete them (Albert et al., 1974; Podoll et al., 1991).  
 
3.1.2.5. Motor learning 
Procedural memory refers to the ability to learn behavioral and cognitive 
skills and algorithms that are used at an unconscious level (Budson & Price, 2005). 
For example, patients may lose the ability to perform automatic, skilled 
movements, such as writing, riding a bike or playing a musical instrument that 
healthy people take for granted. It is thought that procedural memories are 
retained in AD for a long time. In fact, it has been proposed that patients with AD 
could not only acquire, but also retain, long-lasting procedural memories (Kawai 
et al., 2002) and the retention of this type of memory has been used to help 
rehabilitate cognitive deficits in patients with AD (Woodberry et al., 2015). In 
contrast, PSP patients have shown impairments in this type of memory because of 
a disruption to basal ganglia circuits (Boeve et al., 2003; Magherini & Litvan, 
2005).  
 
3.1.3. Behaviour 
Behaviour refers to the way that somebody interacts with environment and 
people around them. Behavioural change is common in PSP and AD, but with 
different patterns that reflect the underlying cognitive processes. Patients with PSP 
show the highest prevalence of behavioural symptoms, with high rates of apathy, 
impulsivity, stereotypic behaviours, disinhibition, and abnormal eating (Bak et al., 
2010; Golbe & Ohman-Strickland, 2007; Aarsland et al., 2001). In contrast, 
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common symptoms in AD include delusions, irritability, agitation, anxiety and 
depression (Burns et al., 1990; Nagahama et al., 2006).  
 
3.1.3.1. Social and emotional cognition 
Social cognition entails a complex set of processes including representation 
of the self, the perception of social groups (e.g. race and gender stereotypes), and 
the ability to make inferences about the knowledge, beliefs and desires of the self 
and of others (‘theory of mind’) (Fiske & Taylor, 1991). Social cognition tasks 
engage the anterior rostral medial frontal cortex (arMFC) (Bush et al., 2000; Frith 
& Frith, 1999). The posterior rostral MFC (prMFC) is involved in action monitoring 
and the updating of the predicted value of actions, whereas the orbital MFC (oMFC) 
is involved in monitoring reward and punishment, and in the updating of the 
predicted value of outcomes (Kahnt et al., 2012; Amodio & Frith, 2006; Perkins et 
al., 2013). Impaired social and emotion cognition are now recognized to be part 
of the cognitive syndrome of PSP provoking difficulties with relationships in the 
family, and communication problems (Ghosh et al., 2009; Ghosh et al., 2013; 
O’Keeffe et al., 2007). Ghosh’s studies confirms that patients with PSP have 
significant impairments in multiple tests of social cognition. They showed, by 
comparing pictures versus sounds of emotionally distinctive cues, that is not a 
result of impaired face perception but an integral part of the cognitive dysfunction 
associated with PSP. Their findings concluded that emotion recognition is affected, 
preventing them what another person is thinking or feeling.  
 
Deficits in recognizing others’ emotions are also reported in AD (Cadieux & 
Greve, 1997), and in its prodromal stage MCI, (Teng et al., 2007). Martinez and 
her colleagues (2018) found that patients with AD or PD have a decreased ability 
to detect emotions compared to their caregivers, although caregivers failed to 
recognize patients’ emotion recognition deficits due to the caregiver burden and 
depression.  
 
3.1.3.2. Motivation and reward 
Motivation refers to the amount of work than an animal or person is willing 
to commit for a given level of reward. Apathy can be defined as a disorder of 
motivation, and loss of ‘interest’ in goal-directed activities (Levy et al., 1998; 
Robert et al., 2002). Apathy can be profound in PSP, and is a feature in the 
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diagnostic criteria (Höglinger et al., 2017). It affects over 80% of patients, as 
indicated by carer ratings of motivation such as Cambridge Behavioural Inventory-
Revised (CBI-R) (Bak et al., 2010), and clinical ratings including Dementia Rating 
Scale (DRS) and Frontal Assessment Battery (FAB) (Brown et al., 2010). It is often 
one of the earliest features, even if not recognized as such before diagnosis. 
Indeed, apathy may be misdiagnosed as depression, leading to the delay in 
diagnosis of PSP. Apathy is also a common neuropsychiatric symptom in patients 
with AD (Nobis & Husain, 2018; Zhao et al., 2016), with prevalence rates ranging 
from 55% –80% (Spalletta et al., 2010). It has been reported to cause rapid 
cognitive and functional decline towards AD dementia in MCI patients (Dujardin et 
al., 2009; Vicini Chilovi et al., 2009). Recent work in both healthy people and AD 
confirms the emerging view that apathy is not a single construct but a 
multidimensional disorder that can also include distinct social as well as emotional 
deficits (Ang et al., 2017; Radakovic et al., 2017).  
 
PSP is often accompanied by impulsivity, despite paradoxically the presence 
of apathy. Both apathy and impulsivity are multidimensional concepts (Levy & 
Dubois, 2006; Nombela et al., 2014), and the processes of motivation, reward and 
decision-making are some of the cognitive contributory features (Levy & Dubois, 
2006; Zhang et al., 2016). Gambling reflects choice impulsivity. It is often 
assessed using gambling tasks such as the Cambridge Gambling Task (CGT; Zois 
et al., 2014), and Iowa Gambling Task (IGT; Bechara et al., 1994). Unlike other 
gambling tasks, the CGT examines decision making, without confounds of learning 
and working memory, by clearly presenting all information needed to make a 
decision throughout the task. Patients with frontal lobe lesions place high bets in 
both ascending and descending conditions, reflecting risky behaviours (Manes et 
al., 2002). Despite the inclusion of disinhibition in the criteria for PSP and bvFTD, 
pathological gambling is uncommon in FTLD syndromes (Manes et al., 2002), in 
contrast to PD (Marques et al., 2018; Voon et al., 2011).  
 
 
3.2. Aims 
The aims of this chapter are: 
I. to determine the behavioural and neuropsychological profiles of patients 
with PSP and AD/MCI+ in the NIMROD study and, 
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II. to relate cognitive and behavioural deficits in my cohort to disease severity 
(PSP-RS and CDR), and functional decline (CBI-R and NPI).  
 
To meet these aims the objectives were: 
I. to summarise the variables and set them in the context of existing literature, 
II. to present group wise summary statistics and, 
III. to describe parametric and non-parametric correlations among key 
variables.  
 
 
3.3. NIMROD assessments 
 The neuropsychological and disease severity evaluations are described in detail 
in Chapter 2, which are classified in terms of global cognition, executive-domain 
based tests, carer-reported questionnaires, mood scale measurements, and 
indirect sleep disturbances rating. See section 2.3.1. for details.  
 
 
3.4. Material and methods 
3.4.1. Participants  
 The current study was conducted within the context of the ‘Neuroimaging of 
Inflammation in Memory and Other Disorders project (NIMROD, see Chapter 2) 
(Bevan-Jones et al., 2017).  
For the purpose of the substudy present in this chapter, we recruited 20 
patients with probable PSP by the 1996 MDS criteria (representing a ‘classical 
phenotype’ which is sometimes referred to as Richardson’s syndrome, PSP-RS); 
nine patients meeting diagnostic criteria for probable AD (McKhann et al., 2011), 
and six patients with MCI+ were recruited. All PSP patients also meet 2017 revised 
criteria for probable PSP-RS (Höglinger et al., 2017; Litvan et al., 1996). Thirteen 
age- and sex-matched healthy controls with no history of major psychiatric or 
neurological illnesses, head injury or any other significant medical comorbidity 
were also included to allow group-wise comparisons with the clinical cohorts.  
3.4.2. Statistical analysis 
Statistical analyses were performed in SPSS software (V23.0; 
https://www.ibm.com/uk-en/marketplace/spss-statistics/purchase). I compared 
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the patient groups with the healthy controls, and the performance of PSP versus 
AD/MCI+ patients.  
The demographic and neuropsychological data were compared using 
ANCOVA with Bonferroni correction for post hoc tests. Education was considered 
as covariate in comparisons between patient and controls groups. Continuous 
rating scales were checked for normality, and subjected to either parametric or 
nonparametric tests as appropriate. Discrete variables (e.g. sex) were compared 
by Chi-Square. For neuropsychological measures, I corrected for multiple 
comparisons within each type of tests (see Tables 14, 15, 16 and 19).  
 
 
3.5. Results 
3.5.1. Demographics 
Demographic information is shown in Table 11. There were no significant 
differences between patient groups and healthy controls in terms of age or sex. 
Participants with PSP had fewer years of formal education than those with AD/MCI+ 
and HC, but AD/MCI+ and HC groups did not differ in years of education. 
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 PSP 
(N = 20) 
AD/MCI+ 
(N = 15) 
HC 
(N = 13) 
ANOVA (F) or 
Chi-Square (χ2) 
or t-Test (t) 
df,dferror p 
value 
Pairwise 
comparison 1 
PSP 
vs. 
AD/MCI+ 
Pairwise 
comparison 2 
PSP 
vs. 
HC 
Pairwise 
comparison 3 
AD/MCI+ 
vs. 
HC 
Age 
mean 
(SD) 
 
70.40 
(±5.84) 
 
72.94 
(±8.96) 
 
68.18 
(±7.67) 
 
1.44 
 
(2,42) 
 
ns 
 
ns 
 
ns 
 
ns 
Gender 
M/F 
 
12/8 
 
9/6 
 
6/7 
 
0.73 
 
(2,42) 
 
ns 
 
ns 
 
ns 
 
ns 
Education 
mean 
(SD) 
 
11.95 
(±1.82) 
 
14.27 
(±3.41) 
 
15.85 
(±1.99) 
 
10.35 
 
(2,42) 
 
<0.00001 
 
ns 
 
<0.00001 
 
ns 
Symptom 
Duration* 
mean 
(SD) 
 
 
7.40 
(±3.74) 
 
 
5.69 
(±2.19) 
 
 
na 
 
 
2.44 
 
 
(1,33) 
 
 
ns 
 
 
na 
 
 
na 
 
 
na 
Table 11: Demographic profile of patient groups and healthy controls. 
p-values indicate significance and state the equivalent threshold for significance after Bonferroni correction for multiple comparisons (p=0.05/4=0.0125). 
Abbreviations: ns = not significant; SD, Standard Deviation; na, not applicable; df, degrees of freedom; PSP, Progressive Supranuclear Palsy; AD, Alzheimer’s D isease; MCI+, 
Mild Cognitive Impairment with amyloid-positive; HC, Healthy Control; M, Male; F, Female.  
*As we recognise the ‘disease’ pathology starts many years before symptoms.  
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3.5.2. Disease severity 
Tables 12 and 13 provide the mean and standard deviation (SD) of the total 
scores and subscores for each disease severity assessments (Progressive 
Supranuclear Palsy-Rating Scale in PSP and Clinical Dementia Rating in AD).  
 
 Mean SD 
PSP-RS 
Max = 100 
43.65 ±15.44 
History 
Max = 24 
9.35 ±4.55 
Mental 
Max = 16  
3.55 ±2.87 
Bulbar 
Max = 8 
2.85 ±2.11 
 Supranuclear ocular motor 
Max = 16 
9.75 ±3.12 
Limb motor 
Max = 16 
4.50 ±2.70 
Gait and midline 
Max = 20 
13.45 ±4.12 
Table 12: Progressive Supranuclear Palsy–Rating Scale (PSP-RS) total score  
and subscores of PSP group. 
Abbreviations: PSP-RS, Progressive Supranuclear Palsy-Rating Scale; SD, Standard Deviation.  
 
 
 Mean SD 
CDR  
Max = 36 
13.53 
 
±4.79 
Memory 
Max = 6 
2.60 
 
±0.73 
Orientation 
Max = 6 
1.80 
 
±0.67 
Judgement and problem solving 
Max = 6 
2.87 ±1.45 
Community affairs 
Max = 6 
2.27 
 
±0.96 
Home and hobbies 
Max = 6 
2.47 
 
±1.18 
Personal care 
Max = 6 
1.53 
 
±0.64 
Table 13: Clinical Dementia Rating (CDR) total score and subscores of AD/MCI+ group. 
Abbreviations: CDR, Clinical Dementia Rating; SD, Standard Deviation. 
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3.5.3. Neuropsychology 
Descriptive data for global cognition, measured by the Addenbrooke’s 
Cognitive Examination-Revised (ACE-R) and Mini-mental State Examination 
(MMSE) are shown in Table 14. As expected, there was a significant main effect of 
group for cognitive measures, driven by reduced ACE-R and MMSE scores in PSP 
and AD/MCI+ patients relative to healthy controls. Participants with AD/MCI+ had 
lower score in memory than those with PSP and HC, but PSP and HC groups did 
not differ in this dimension. PSP group exhibited a poorer performance on verbal 
fluency including both letter and category fluency assessments in relation with 
healthy controls. AD/MCI+ also performed worse than the control group on verbal 
fluency, although only in the category fluency task.  
 
The results of the executive domain-based evaluation, using the INECO 
Frontal Screening (IFS) is presented in Table 15. A between-group comparison 
showed a significant effect of diagnosis on the total score of the IFS. There were 
also significant differences for conflicting instructions, Go-No Go, backward digit 
span, spatial working memory, proverb interpretation, and verbal response 
inhibition. PSP patients did not show any differences than AD/MCI+ on the IFS total 
score and in any of the eight IFS subtests. However, PSP and AD/MCI+ patients 
revealed a lower performance than healthy controls in terms of the overall IFS 
score. PSP group executed significantly worst in both backward digit span and 
proverbs subtests in comparison with the control group. Instead, AD/MCI+ group 
presented lower performance on almost each IFS subtasks such as conflicting 
instructions, Go-No go, backward digit span, spatial working memory, proverb 
interpretation, and verbal response inhibition (Table 15).  
 
The results of the Trail Making Test (TMT) are detailed in Tables 16. The 
TMT results showed a significant effect of diagnosis in the three groups in terms 
of both time and error scores but only in the Trails A. PSP patients exhibited higher 
number of errors than healthy controls and AD/MCI+ (Table 16). Regrettably, the 
study sample obtained in the Stockings of Cambridge (SOC) was too little to report 
any results. This was a consequence of fatigue and long testing sessions. As a 
matter of fact, only nine patients with PSP, four participants with AD/MCI+ and 13 
healthy controls were able to complete the full battery of neuropsychological tests. 
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 PSP  = 20 
mean  
(SD) 
AD/MCI+ = 15 
mean  
(SD) 
HC = 13 
mean  
(SD) 
ANOVA  
(F) 
df,dferror p  
value 
 
Pairwise 
comparison 1 
PSP 
vs.  
AD/MCI+ 
Pairwise 
comparison 2 
PSP 
vs. 
HC 
Pairwise 
 comparison 3 
AD/MCI+ 
 vs. 
HC 
ACE-R 
Max = 100 
79.65 
(±16.29) 
71.67 
(±14.37) 
95.54  
(±3.15) 
9.31 (2,44) <0.00001 ns ns <0.00001 
MMSE 
Max = 30 
26.40 
(±4.66) 
23.87 
(±3.96) 
29.31  
(±0.75) 
6.45 (2,44) 0.0002 
 
ns ns 0.0004 
Attention & 
Orientation 
Max = 18 
16.25 
(±2.75) 
15.87 
(±2.94) 
18.00 
(±0.00) 
1.97 (2,44) ns ns ns ns 
Memory 
Max = 26 
21.05 
(±4.46) 
12.33 
(±4.86) 
24.46 
 (±2.22) 
35.36 (2,44) <0.00001 <0.00001 ns <0.00001 
Fluency  
Scaled score  
Max = 14 
6.55 
(±3.47) 
7.67 
(±3.67) 
12.23  
(±1.53) 
7.79 (2,44)  0.00009 ns 0.0002 0.0004 
Phonemic 
 fluency 
Words 
6.55  
(±4.62) 
11.40  
(±5.77) 
15.38 
 (±4.99) 
5.88 (2,44) 0.00045 ns 0.0004 ns 
Semantic 
fluency  
Words 
10.90 
(±4.78) 
10.40 
(±4.62) 
22.85 
 (±4.35) 
23.52 (2,44) <0.00001 ns <0.00001 <0.00001 
Language 
Max = 26 
23.20 
(±4.50) 
22.53  
(±3.27) 
25.08  
(±0.95) 
1.33 (2,44) ns ns ns ns 
Visuospatial 
Max = 16 
12.35 
(±4.06) 
13.27 
 (±3.39) 
15.69 
 (±0.48) 
2.33 (2,44) ns ns ns ns 
Pentagon 
copying 
Max = 1 
0.70 
(±0.47) 
0.67 
(±0.48) 
1.00 
(±0.00) 
1.89 (2,44) ns ns ns ns 
Clock 
drawing 
Max = 5 
3.35  
(±1.89) 
3.87 
(±1.18) 
4.92  
(±0.27) 
2.57 (2,44) ns ns ns ns 
Table 14: Addenbrooke’s Cognitive Examination-Revised (ACE-R) and Mini-mental State Examination (MMSE) scores and ACE-R subscores 
of patient groups and healthy controls. 
p-values indicate significance and state the equivalent threshold for significance after Bonferroni correction for multiple comparisons (p=0.05/11=0.0045).  
Abbreviations: ns = not significant; SD, Standard Deviation; df, degrees of freedom; ACE-R, Addenbrooke’s Cognitive Examination-Revised; MMSE, Mini-Mental State 
Examination; PSP, Progressive Supranuclear Palsy; AD, Alzheimer’s D isease; MCI+, Mild Cognitive Impairment with amyloid-positive; HC, Healthy Control. Education was 
included as covariate of no interest in the statistical models.  
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Table 15: INECO Frontal Screening (IFS) scores and subscores of patient groups and healthy controls.                         
p-values indicate significance and state the equivalent threshold for significance after Bonferroni correction for multiple comparisons (p=0.05/9=0.0055).  
Abbreviations: ns = not significant; SD, Standard Deviation; df, degrees of freedom; IFS, INECO Frontal Screening; PSP, Progressive Supranuclear Palsy; AD, Alzheimer’s 
Disease; MCI+, Mild Cognitive Impairment with amyloid-positive; HC, Healthy Control; VWM, Verbal Working Memory; SWM, Spatial Working Memory. Education was included 
as covariate of no interest in the statistical models. 
 
 
 PSP  = 18 
mean 
(SD) 
AD/MCI+ = 15 
mean 
(SD) 
HC = 13 
mean 
(SD) 
ANOVA 
(F) 
df,dferror p  
value 
Pairwise 
comparison 1 
PSP 
vs. 
AD/MCI+ 
Pairwise 
comparison 2 
PSP 
vs. 
HC 
Pairwise 
comparison 3 
AD/MCI+ 
vs. 
HC 
IFS  
Max = 30 
15.63 
(±4.45) 
13.53 
(±6.05) 
24.34 
(±3.36) 
15.10 (2,42) <0.00001 ns 0.0004 <0.00001 
Motor 
sequencing 
Max = 3 
1.47 
(±0.96) 
1.33  
(±0.89) 
2.07 
(±0.95) 
1.89 (2,42) ns ns ns ns 
Conflicting 
instructions 
Max = 3 
1.66  
(±0.97) 
1.53  
(±1.45) 
2.92 
(±0.27) 
5.16 (2,42) 0.0011 ns ns 0.0008 
Go-No go 
Max = 3 
1.55 
 (±0.85) 
1.46 
(±0.91) 
2.53 
(±0.66) 
4.65 (2,42) 0.0016 ns ns 0.0014 
Backward digit 
span 
Max = 6 
3.10 
 (±1.24) 
3.13  
(±1.12) 
4.76 
(±1.30) 
5.62 (2,42) 0.0007 ns 0.0038 0.0007 
VWM 
Max = 2 
1.47 
(±0.90) 
1.26  
(±0.96) 
2.00 
(±0.00) 
2.69 (2,42) ns ns ns ns 
SWM 
Max = 4 
1.83  
(±0.78) 
1.20  
(±0.67) 
2.30 
(±1.25) 
4.88 (2,42) 0.0013 ns ns 0.0017 
Proverb 
interpretation 
Max = 3 
0.89  
(±1.07) 
0.93  
(±1.01) 
2.42 
(±0.64) 
6.62 (2,42) 0.0003 ns 0.0041 0.0003 
Verbal 
response 
inhibition 
Max = 6 
3.47 
 (±2.01) 
2.66  
(±2.38) 
5.30 
(±0.75) 
5.71 (2,42) 0.0006 ns ns 0.0005 
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 PSP  = 9 
mean 
(SD) 
AD/MCI+ = 9 
mean 
(SD) 
HC = 13 
mean 
(SD) 
ANOVA  
(F) 
df,dferror p 
value 
Pairwise 
comparison 1 
PSP 
vs. 
AD/MCI+ 
Pairwise 
comparison 2 
PSP 
vs. 
HC 
Pairwise 
comparison 3 
AD/MCI+ 
vs. 
HC 
Trails A  
Time 
71.67 
(±45.06) 
47.00 
(±20.45) 
31.38 
(±6.69) 
4.17 (2,27) 0.0067 ns 0.0057 ns 
Trails A  
Errors 
0.56 
(±0.52) 
0.00 
(±0.00) 
0.00 
(±0.00) 
6.79 (2,27) 0.001 0.003 0.0015 ns 
Trails B 
Time 
204.44 
(±187.43) 
145.67 
(±83.47) 
64.62 
(±13.78) 
2.50 (2,27) ns ns ns ns 
Trails B 
Errors 
0.56 
(±0.72) 
1.00 
(±1.50) 
0.08 
(±0.27) 
3.02 (2,27) ns ns ns ns 
Table 16: Trail Making Test (TMT) scores of patient groups and healthy controls. 
p-values indicate significance and state the equivalent threshold for significance after Bonferroni correction for multiple comparisons (p=0.05/4=0.0125).  
Abbreviations: ns = not significant; SD, Standard Deviation; df, degrees of freedom; TMT, Trail Making Test; PSP, Progressive Supranuclear Palsy; AD, Alzheimer’s D isease; 
MCI+, Mild Cognitive Impairment with amyloid-positive; HC, Healthy Control. Education was included as covariate of no interest in the statistical models. 
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3.5.4. Carer-reported impairments 
The results of the informant-based questionnaires, Cambridge Behavioural 
CBI-R (CBI-R) and Neuropsychiatric Inventory (NPI) for each patient group are 
shown in Tables 17 and 18. There were no significant differences between PSP and 
AD/MCI+ patients in terms of the CBI-R total score; however, AD/MCI+ group had 
higher scores in memory and orientation than those with PSP. In contrast, patients 
with PSP differed in self-care and eating habits domains.  
 
 PSP  = 20 
mean 
(SD) 
AD/MCI+ = 15 
mean 
(SD) 
t - test df p  
value 
CBI-R 
Max = 180 
51.40 
(±33.24) 
43.20 
(±26.43) 
0.78 33 ns 
Memory and 
orientation 
Max = 32 
8.55 
(±6.78) 
15.73 
(±6.13) 
-3.23 33 0.003 
Everyday 
skills 
Max = 20 
8.95 
(±6.55) 
5.80 
(±5.32) 
1.52 33 ns 
Self-care 
Max = 16 
7.10 
(±5.28) 
0.80 
(±1.26) 
5.14 21.84 < 0.0001 
Abnormal 
behaviour 
Max = 24 
4.35 
(±5.00) 
2.33 
(±3.30) 
1.35 33 ns 
Mood 
Max = 16 
3.80 
(±2.76) 
2.67 
(±2.69) 
1.21 33 ns 
Beliefs 
Max = 12 
1.10 
(±1.94) 
0.47 
(±1.06) 
1.13 33 ns 
Eating habits 
Max = 16 
4.35 
(±3.76) 
1.87 
(±2.16) 
2.28 33 0.029 
Sleep 
disturbances 
Max = 8 
4.10 
(±2.12) 
2.87 
(±2.47) 
1.58 33 ns 
Stereotypic 
and motor 
behaviour 
Max = 16 
3.00 
(±3.32) 
3.53 
(±3.99) 
-0.43 33 ns 
Motivation 
Max = 20 
6.10 
(±4.56) 
6.73 
(±6.13) 
-0.35 33 ns 
Table 17: Cambridge Behavioural CBI-R total score and subscores of patient groups.  
Abbreviations: ns = not significant at p > 0.05; SD, Standard Deviation; df, degrees of freedom; CBI-R, 
Cambridge Behavioural Inventory-Revised; PSP, Progressive Supranuclear Palsy; AD, Alzheimer’s Disease; MCI+, 
Mild Cognitive Impairment with amyloid-positive. Education was not included as a covariate.  
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The findings in the NPI assessment between patient groups only differed in 
the night behaviour feature, being this higher in the PSP cohort in comparison with 
patients with AD/MCI+.  
 
 PSP  = 20 
mean 
(SD) 
AD/MCI+ = 15 
mean 
(SD) 
t - test df p 
 value 
NPI 
Max = 156 
19.90 
(±15.28) 
13.93 
(±14.63) 
1.16 33 ns 
Delusions 
Max = 12 
0.35 
(±1.56) 
0.53 
(±2.06) 
-0.29 33 ns 
Hallucinations 
Max = 12 
0.65 
(±1.63) 
0.27 
(±1.03) 
0.79 33 ns 
Agitation 
Max = 12 
2.05 
(±2.92) 
1.73 
(±3.03) 
0.31 33 ns 
Depression 
Max = 12 
2.30 
(±2.94) 
1.93 
(±2.54) 
0.38 33 ns 
Anxiety 
Max = 12 
1.55 
(±2.7) 
1.53 
(±2.32) 
0.01 33 ns 
Euphoria 
Max = 12 
0.40 
(±1.27) 
0.33 
(±1.29) 
0.15 33 ns 
Apathy 
Max = 12 
2.15 
(±3.61) 
3.47 
(±3.85) 
-1.03 33 ns 
Disinhibition 
Max = 12 
1.85 
(±3.13) 
0.33 
(±1.29) 
1.95 26.71 ns 
Irritation 
Max = 12 
0.85 
(±1.78) 
1.20 
(±2.39) 
-0.49 33 ns 
Abnormal motor 
behaviour 
Max = 12 
1.00 
(±3.09) 
0.73 
(±2.15) 
0.28 33 ns 
Night behaviour 
Max = 12 
3.35 
(±3.96) 
0.27 
(±1.03) 
3.33 22.34 0.003 
Eating 
abnormalities 
Max = 12 
3.53 
(±4.15) 
1.40 
(±2.41) 
1.86 29.70 ns 
Stereotype 
Max = 12 
0.30 
(±1.12) 
0.20 
(±0.77) 
0.29 33 ns 
Table 18: Neuropsychiatric Inventory (NPI) total score and subscores of patient groups. 
Abbreviations: ns = not significant at p > 0.05; SD, Standard Deviation; df, degrees of freedom; NPI, 
Neuropsychiatry Inventory; PSP, Progressive Supranuclear Palsy; AD, Alzheimer’s Disease; MCI+, Mild Cognitive 
Impairment with amyloid-positive.  
 
 
3.5.5. Mood  
Table 19 presents the results of the mood evaluation test, Hospital Anxiety 
and Depression Scale (HADS). There were no significant differences between 
patient groups and healthy controls in terms of anxiety. Participants with PSP had 
greater score in depression than those with AD/MCI+ and HC, but AD/MCI+ and HC 
groups did not differ in this variable.
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 PSP  = 20 
mean 
(SD) 
AD/MCI+ = 15 
mean 
(SD) 
HC = 13 
mean 
(SD) 
ANOVA  
(F) 
df,dferror p 
 value 
Pairwise 
comparison 1 
PSP 
vs. 
AD/MCI+ 
Pairwise 
comparison 2 
PSP 
vs. 
HC 
Pairwise 
comparison 3 
AD/MCI+ 
vs. 
HC 
Anxiety 
Max = 21 
4.25 
(±2.95) 
4.53 
(±3.29) 
4.38 
(±3.54) 
0.03 (2,45) ns ns ns ns 
Depression 
Max = 21 
5.90 
(±2.90) 
2.20 
(±2.11) 
3.31 
(±3.96) 
6.95 (2,45) 0.001 0.001 ns ns 
Table 19: Hospital Anxiety and Depression Scale (HADS) scores of patient groups and healthy controls.  
p-values indicate significance and state the equivalent threshold for significance after Bonferroni correction for multiple comparisons (p=0.05/2=0.025).  
Abbreviations: ns = not significant; SD, Standard Deviation; df, degrees of freedom; HADS, Hospital Anxiety and Depression Scale; PSP, Progressive Supranuclear Palsy; 
AD, Alzheimer’s Disease; MCI+, Mild Cognitive Impairment with amyloid-positive; HC, Healthy Control. Education was not included as a covariate.
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3.5.6. Relationships among global cognitive function and age 
Figures 7 and 8 present the outcomes whether global cognition related to 
age in each clinical group. In the PSP group, there was a significant negative 
correlation between global cognitive function, as assessed via the ACE-R total 
score, and age. In contrast, the AD/MCI+ group did not show a significant 
correlation between the ACE-R score and age. 
 
 
 
 
Figure 8: Relationship 
between global 
cognitive function 
(ACE-R) and age in 
the AD/MCI+ group. 
Scatter-plot with fit line 
showing significant partial 
correlation controlling for 
years of education and 
HADS depression 
(r = 0.340, p = 0.256) 
between age (X-axis) and 
ACE-R score (Y-axis) in the 
AD/MCI+ subjects (red 
dots). Abbreviations: HADS; 
Hospital Anxiety and 
Depression Scale; ACE-R, 
Addenbrooke’s Cognitive 
Examination-Revised; AD, 
Alzheimer’s Disease; MCI+, 
Mild Cognitive Impairment 
with amyloid-positive. 
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Figure 7: Relationship 
between global 
cognitive function 
(ACE-R) and age in the 
PSP group. 
Scatter-plot with fit line 
showing significant partial 
correlation controlling for 
years of education and HADS 
depression  
(r = -0.471, p = 0.049) 
between age (X-axis) and 
ACE-R score (Y-axis) in the 
PSP subjects (blue dots). 
Abbreviations: HADS; 
Hospital Anxiety and 
Depression Scale; ACE-R, 
Addenbrooke’s Cognitive 
Examination-Revised; PSP, 
Progressive Supranuclear 
Palsy. 
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3.5.7. Relationships between global cognitive function and disease 
severity 
Correlations in terms of global cognition and disease severity, measured by 
the PSP-RS and CDR in the PSP and AD/MCI+, respectively are displayed in Figures 
9 and 10. There was a significant negative correlation between the ACE-R overall 
score and PSP-RS. However, not significant correlation was found between ACE-R 
total score and disease severity (CDR).   
 
Figure 9: Relationship 
between global 
cognitive function 
(ACE-R) and disease 
severity (PSP-RS) in 
the PSP group. 
Scatter-plot with fit line 
showing significant partial 
correlation controlling for 
years of education and 
HADS depression  
(r = -0.765, p = 0.000) 
between PSP-RS measure 
(X-axis) and ACE-R score 
(Y-axis) in the PSP subjects 
(blue dots). Abbreviations: 
HADS; Hospital Anxiety and 
Depression Scale; PSP-RS, 
Progressive Supranuclear 
Palsy-Rating Scale; ACE-R, 
Addenbrooke’s Cognitive 
Examination-Revised; PSP, 
Progressive Supranuclear 
Palsy.  
 
Figure 10: Relationship 
between global 
cognitive function 
(ACE-R) and disease 
severity (CDR) in the 
AD/MCI+ group.   
Scatter-plot with fit line 
showing significant partial 
correlation controlling for 
years of education and HADS 
depression (r = 3.40, 
p = 2.56) between CDR 
measure (X-axis) and ACE-R 
score (Y-axis) in the 
AD/MCI+ subjects (red 
dots). Abbreviations: HADS; 
Hospital Anxiety and 
Depression Scale; CDR, 
Clinical Dementia Rating; 
ACE-R, Addenbrooke’s 
Cognitive Examination-
Revised; AD, Alzheimer’s 
Disease; MCI+, Mild 
Cognitive Impairment with 
amyloid-positive. 
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3.5.8. Relationships between executive domain-based function and 
disease severity 
Figures 11 and 12 present the correlations whether executive domain-based 
function, evaluated by the INECO Frontal Screening (IFS), related to disease 
severity in each patient group. In the PSP group, there was a significant negative 
correlation between IFS total score and disease severity, as assessed via PSP-RS. 
AD/MCI+ group did also show a significant negative correlation between IFS total 
result and CDR as a disease severity assessment.  
 
Figure 11: Relationship 
between the domain-
based assessment 
(IFS) and disease 
severity scale (PSP-
RS) in the PSP group. 
Scatter-plot with fit line 
showing significant partial 
correlation controlling for 
years of education and HADS 
depression (r = -0.530,        
p = 0.035) between PSP-RS 
measure (X-axis) and IFS 
score (Y-axis) in the PSP 
subjects (blue dots). 
Abbreviations: HADS; 
Hospital Anxiety and 
Depression Scale; PSP-RS, 
Progressive Supranuclear 
Palsy-Rating Scale; IFS, 
INECO Frontal Screening; 
PSP, Progressive 
Supranuclear Palsy. 
 
Figure 12: 
Relationship between 
the domain-based 
assessment (IFS) and 
disease severity scale 
(CDR) in the AD/MCI+ 
group. 
Scatter-plot with fit line 
showing significant partial 
correlation controlling for 
years of education and 
HADS depression 
(r = -0.610, p = 0.027) 
between CDR measure (X-
axis) and IFS score (Y-axis) 
in the AD/MCI+ subjects (red 
dots). Abbreviations: HADS; 
Hospital Anxiety and 
Depression scale; CDR, 
Clinical Dementia Rating; 
IFS, INECO Frontal 
Screening; AD, Alzheimer’s 
Disease; MCI+, Mild 
Cognitive Impairment with 
amyloid-positive. 
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3.5.9. Relationships between carer-reported assessment and 
disease severity 
The results of the relationship in terms of carer-reported assessment 
measured by the Cambridge Behavioural Inventory-Revised (CBI-R) and disease 
severity in the clinical groups are displayed in Figures 13 and 14. There was a 
significant positive correlation between the CBI-R overall score and PSP-RS in the 
PSP cohort. Also, a significant positive correlation was found in the AD/MCI+ group 
between the ACE-R total score and disease severity (CDR).   
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Figure 13: Relationship 
between the carer-
reported assessment 
(CBI-R) and disease 
severity scale (PSP-RS) 
in the PSP group. 
Scatter-plot with fit line 
showing significant Pearson’s 
correlation (r = 0.474,  
p = 0.035) between PSP-RS 
measure (X-axis) and CBI-R 
score (Y-axis) in the PSP 
subjects (blue dots). 
Abbreviations: CBI-R; 
Cambridge Behavioural 
Inventory-Revised; PSP-RS, 
Progressive Supranuclear 
Palsy-Rating Scale; PSP, 
Progressive Supranuclear 
Palsy. 
 
Figure 14: Relationship 
between carer-
reported assessment 
(CBI-R) and disease 
severity scale (CDR) in 
the AD/MCI+ group. 
Scatter-plot with fit line 
showing significant Pearson’s 
correlation (r = 0.690,  
p = 0.004) between CDR 
measure (X-axis) and CBI-R 
score (Y-axis) in the 
AD/MCI+ subjects (red 
dots). Abbreviations: CDR, 
Clinical Dementia Rating; 
CBI-R, Cambridge 
Behavioural Inventory-
Revised; AD, Alzheimer’s 
Disease; MCI+, Mild 
Cognitive Impairment with 
amyloid-positive. 
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3.6. Discussion 
Both patient groups had significant levels of cognitive and behavioural 
deficits, which were broadly in line with the reports from other studies in the 
literature. In terms of global cognitive screening test scores (ACE-R/MMSE), PSP 
patients did not differ from AD/MCI+. While this suggests that those global scales 
may not be helpful for discriminating patients, it is an advantage for subsequent 
analysis that the groups were matched in terms of global cognitive dysfunction.  
 
The differentiation between PSP and AD/MCI+ lies in subscales of cognition. 
For example, in memory subscores: the most pronounced deficit in patients with 
AD/MCI+ was memory, which is typically impaired early in the course of the disease 
(Blennow et al., 2006; Lindau et al., 2000; Pillon et al., 1991). Memory 
performance of the PSP patients did not differ from the healthy control group. 
Burrell and colleagues (2014) have proposed that patients with PSP can perform 
well on memory tests if they are given sufficient time to complete the test, 
especially when slow speed of processing (bradyphrenia) is characteristic of PSP. 
However, memory recall and recognition in ACER are not timed tests, and slow 
information processing per se cannot be assumed to be the cause of impairment.  
 
 Healthy controls recalled fewer words on letter fluency than on category 
fluency, a finding consistent with other studies (Hodges et al., 1990; Monsch et 
al., 1992). This effect was exaggerated in the PSP group, showing severe 
impairment on letter fluency. This decline in letter fluency should not be 
interpreted entirely due to bradykinesia or bradyphrenia, as fluency requires very 
little motor function and word production tails off long before the end of the 60-
second test interval (Rittman et al., 2013). For AD/MCI+, the fluency pattern was 
different. Patients with AD/MCI+ performed better on letter fluency than PSP 
subjects. Thus, AD/MCI+ cohort displays a reversal of the normal pattern of 
performance. Although the letter and category fluency task are superficially 
similar, they differ in important ways in their task demands. Letter fluency must 
be performed without reference to meaning, and the spread of activation within 
the phonological lexicon may proceed less rapidly than at the semantic level 
(Rosser & Hodges, 1994). By contrast, the category fluency task resembles 
everyday production tasks, such as making a shopping list, so that healthy 
participants can exploit existing links between related concepts to retrieve 
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responses (Shao et al., 2014). In addition, even though it has been recognized 
that PSP patients have reduced letter fluency (Bak et al., 2005; Pillon et al., 1995), 
whereas the AD/MCI+ deficit is greater for categorical/semantic rather than 
phonemic (Milberg & Albert, 1989; Rosser & Hodges, 1994), the number of correct 
exemplars on semantic fluency task produced by both patient groups is similar. In 
line with my results, clinical studies have found that patients with AD/MCI+ has 
been observed to be relatively more impaired in the category than the letter 
fluency tasks, consistent with impaired access to semantic information (Laws et 
al., 2010; Magaud et al., 2010; Meijer et al., 2011). By contrast, PSP patients were 
significantly more impaired on both types of verbal fluency task compared with 
controls. PSP can impair both phonological and semantic categories (Bensimon et 
al., 2008; Brown et al., 2010; O’Keeffe et al., 2007; Pillon et al., 1991; Rittman et 
al., 2013; Soliveri et al., 1999), but patients with AD/MCI+ are most severely 
impaired in semantic fluency.  
It is also necessary to comment on how the differential pattern of both letter 
and category fluency deficits in PSP and AD might relate to the underlying brain 
networks involved. Performance on both tasks depends upon frontostriatal circuits 
that control aspects of executive function and working memory (Rosser & Hodges, 
1994). In the case of initial letter fluency, the phonologically based word store is 
clearly critical, whereas category fluency depends on the intactness of semantic 
memory (Hodges et al., 1992; Martin & Fedio, 1983; Butters et al., 1987). There 
is a considerable body of evidence that frontostriatal deficits, of the type found in 
patients with PSP, result in equally severe impairment on letter and category 
fluency tasks (Grafman et al., 1990; Soliveri et al., 2000). By contrast, disorders 
that cause breakdown in the organisation of semantic memory, such as AD, 
resulted in more pronounced impairment on category fluency due to temporal lobe 
based deficits (Bak et al., 2005).  
 
Surprisingly, the IFS total score and its executive subdomains did not 
discriminate between the patient groups. PSP patients showed a significant lower 
performance than the healthy control group on working memory tests, and proverb 
interpretation, consistent with the early and prominent impairments in executive 
function described in PSP (Gerstenecker et al., 2013; Grafman et al., 1990). The 
IFS total and subscores were reduced in AD/MCI+ versus healthy controls groups, 
even though the differences from PSP were not significant. This suggests an 
121 
intermediate deficit in PSP, without statistical significance from either controls of 
AD/MCI+.  
 
The CBI-R total score was similar in both patient groups. Nevertheless, the 
PSP profile encompassed behavioural deficits with impairment in the self-care 
subsection while AD impaired memory and attention. Self-care difficulties in this 
group may reflect motor disability, but could also result from organisational and 
executive impairments that affect instrumental activities of daily living. These 
results were in keeping with those previously reported (McCrone et al., 2011; 
Nagahama et al., 2006). Bozeat and collaborators (2000) suggested that eating 
behaviours distinguished between frontotemporal dementia (FTD) and AD. My 
results suggest that stereotypical eating habits differentiates also PSP from 
AD/MCI+. AD/MCI+ patients were more severely impaired on memory and 
orientation items than PSP. These findings agree with the general trend found in 
previous studies that have confirmed that AD/MCI+ is characterised by profound 
impairment in episodic memory (Buckner, 2005; Lindau et al., 2000; Mathuranath 
et al., 2000; Morris, 1993; Wedderburn et al., 2008).  
 
The feature of neuropsychiatric symptoms, measured by the NPI, showed 
quite a similar pattern in both disorders. Consistent with previous studies and a 
priori expectations, sleep disturbances were most pronounced in the PSP group in 
comparison with patients with AD/MCI+. This result confirms Abbot’s and 
Videnovic’s views that weaker night time and daytime rhythms may result 
increased sleep during the day and decreased sleep at night (Abbott & Videnovic, 
2014; Videnovic et al., 2014). Interestingly, PSP’s carers did not score higher in 
terms of their relatives eating habits on NPI, however it was significantly different 
using the CBI-R. This discrepancy may occur as the NPI questions are more 
towards the exploration of eating changes rather than eating habits. For example, 
the NPI asks about changes in food preference and features that may result from 
changes in appetite such as weight gain, whereas the CBI-R is more focused on 
particular aspects of eating behaviour such as table manners or rigidity of food 
preferences. Studies using the NPI have found apathy (77% – 91% of cases) and 
disinhibition (35% – 56% of cases) to be common behavioural features in PSP 
subjects (Aarsland et al., 2001; Levy et al., 1996; Litvan et al., 1996; Litvan et 
al., 1998). However, neither behaviour were detected by NPI in the current PSP 
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group.  A potential explanation may be again that NPI, as the CBI-R, are carer-
reported assessments; therefore they are susceptible to recall bias. Alternatively, 
the PSP study group is not typical of PSP: a selection bias towards more motivated 
patients may have arisen in view of the commitment needed to engage with the 
demanding multimodal assessment protocol of NIMROD. 
 
The neuropsychiatric profile in patients with PSP differs in some key domains 
from the AD/MCI+ group, but both patients groups have much in common in their 
differences from controls. The present results confirm that PSP should be 
considered as not only a movement disorder, but also a disorder with a wide range 
of neuropsychiatric symptoms. 
There were not strong endorsements for depression or anxiety within the 
study groups. This result agrees with Menza (1995), Livan (1996), and Aarsland 
(2001), who found that features of depression and anxiety were uncommon in 
PSP, despite the lack of agreement in the literature about depression in PSP (Millar 
et al., 2006). In contrast to the literature about depression being one of the most 
frequent behavioral symptoms in AD (Engedal et al., 2011; Levy et al., 1996; Olin 
et al., 2002; Shin et al., 2005), depression was not prominent in our AD/MCI+ 
group. This discrepancy may reflect the range of instruments used – and the ease 
with which physical symptoms of sleep, weight, appetite  may move a patient 
towards the threshold for ‘depression’ in some clinical rating scales (e.g. BDI-II), 
even though their occurrence in the patient group is not due to depression but 
other disease specific factors. This confounds the use of thresholded ratings scales 
in the assessment of depression prevalence. However, we must also acknowledge 
that our patients may not have been typical, if there was a selection bias to more 
motived and engaged patients for such a demanding study protocol.  
 
In this study, we sought to identify the relationships between cognitive 
deficits, functional decline, and disease severity. Disease severity was judged 
using the PSP-RS and CDR, respectively. In the present study, the ACE-R total 
scores showed a positive strong correlation with the PSP-RS and CDR scores. A 
similar correlation between the ACE-R total scores and the CDR and PSP-RS scores 
were demonstrated in a previous studies (Mioshi et al., 2006; Passamonti et al., 
2018). The domain-based evaluation (IFS) related to disease severity in each 
clinical group, with a large effect in both disorders. Last but not least, there were 
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a strong negative correlation between functional decline and disease severity in 
PSP and AD/MCI+. 
 
There are a number of limitations to be considered. First, the current sample 
was relatively small, and may not be representative of the larger patient 
populations. Participants needed to agree to participate in several hours of testing 
including to attend at least to two neuroimaging sessions, score >24 on the MMSE 
be able to provide informed consent, and not have other central nervous system 
disorders. This likely yields a select, and perhaps milder, group of patients, and, 
therefore, results might not generalize to all patients.  
Second, as it has been demonstrated by pathological confirmation, PSP can 
be divided into several phenotypes that are difficult to differentiate during life 
(Hassan et al., 2012; Williams et al., 2005). Consequently, to provide a more 
complete description of behavioral abnormalities in PSP, future studies should 
classify patients according to their subtype as the methodology for distinguishing 
between subtypes improve. However, our patients were selected as PSP-RS, not 
other variant phenotypes of PSP. 
 
A further limitation in this chapter is the lack of education matching across 
the three cohorts. Shorter education was reported by patients with PSP relative to 
other groups (Table 11). One interpretation of this difference is that healthy control 
cohorts over-represent people from higher socio-economic groups and with longer 
education; however, low education and its effects on health may also be a risk 
factor for the development of PSP (Litvan et al., 2016). Another explanation can 
be the wider population base for PSP versus more selected Cambridge-based 
patients with AD and healthy controls.  
 
Fourth, cognitive assessment could take several hours to complete. This can 
be challenging for patients and result in fatigue and loss of concentration. These 
factors add to measurement error and may be a reason for patients to performance 
worst or ultimately, abort the testing procedure. We opted to curtail testing where 
appropriate, resulting in incomplete data on some scales (e.g. TMT and OCS).  
 
Fifth, low scores may arise for different reasons in the patient groups, 
particularly in the PSP cohort. For example, it is possible that apraxia or other 
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features of a movement disorder impaired task performance differentially between 
groups, especially where graphical skills are required for assessment of cognition 
e.g. ACER visuospatial skills.  
 
Finally, significant differences between the rating of mental measures by 
individuals with dementia and the reports of their caregivers are well documented 
(Farias et al., 2005; Leicht et al., 2010; Schulz et al., 2013). Consequently, the 
CBI-R and NPI scores might be biased and be partially attributed to caregiver 
burden and stress, and they should not be seen as exclusively objective measures 
of function (Lansdall et al., 2017).  
 
In summary, I examined the cognitive features including the executive 
function, memory and behaviour, and motor impairments of patients in the 
NIMROD study, and how they relate to other measures of disease severity in PSP 
and AD/MCI+. I have then distinguished the typical features of each disease which 
reflect the classical phenotype. 
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Chapter 4 
Imaging tau in progressive supranuclear 
palsy and Alzheimer’s disease 
 
Material in this chapter has been published as:  
 
Passamonti, L.*, Vázquez Rodríguez, P.*, Hong, Y. T., Allinson, K. S., Williamson, 
D., Borchert, R. J., Sami, S., Cope, T. E., Bevan-Jones, W. R., Jones, P. S., Arnold, 
R., Surendranathan, A., Mak, E., Su, L., Fryer, T. D., Aigbirhio, F. I., O’Brien, J. T. 
& Rowe, J. B. (2017). [18F]AV1451 positron emission tomography in Alzheimer’s 
disease and progressive supranuclear palsy. Brain, 140(3), 781-791. doi: 
10.1093/brain/aww340 
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4.1. Introduction 
Progressive supranuclear palsy (PSP) and Alzheimer’s disease (AD) are both 
associated with abnormal accumulation of misfolded and aggregated tau protein. 
In patients with PSP and in analogous murine models, intra-neuronal and 
astrocytic aggregates of pathological tau isoforms (in the form of straight 
filaments) characterize and promote neurodegeneration (Clavaguera et al., 2013). 
In AD, oligomeric and aggregated neurofibrillary tau tangles are a major 
determinant of synaptic/cell dysfunction and death (Ballatore et al., 2007; De 
Calignon et al., 2012; Goedert et al., 1988), notwithstanding the importance of β-
amyloid in its ‘toxic alliance’ with pathological tau (Bloom, 2014). The intensity 
and distribution of tau in AD also correlates with the clinical syndrome and severity 
and has been considered as one of the primary factors in the neuropathological 
staging of AD (Braak et al., 2006; Murray et al., 2014; Ossenkoppele et al., 2015). 
To be able to quantify the burden and distribution of tau pathology in living 
patients, or those at high risk of developing tau-related disorders, would be a 
major step forward in the development of disease modifying therapies targeting 
the tau protein.  
 
Radioligands have recently been developed for positron emission 
tomography (PET) to measure in vivo binding to aggregated tau, including PBB3 
(Maruyama et al., 2013), a series of ‘THK’ compounds (Okamura et al., 2013), and 
[18F]AV1451 (Chien et al., 2013; Xia et al., 2013). In autoradiographic studies with 
post mortem human brain tissues, the radiotracer [18F]AV1451 colocalizes 
selectively with hyperphosphorylated tau over β-amyloid plaques (Marquié et al., 
2015). NIMROD chose to use [18F]AV1451, which has most extensive evidence 
internationally so far. Subsequently, the severity of displacement of THK5351 by 
selegiline (acting on MAO-B), and lack of large scale data with PBB3, have left 
[18F]AV1451 the lead compound despite its controversies, while second generation 
ligands are developed and validated.  
In patients with MCI and AD, there is higher [18F]AV1451 non-displaceable 
binding potential (BPND), a measure of specific binding, in frontal, parietal, and 
temporal cortices relative to age-matched healthy controls (Okello et al., 2009). 
Progressively increasing regional [18F]AV1451 binding in AD has also been 
associated with Braak staging of neurofibrillary tau pathology (Schöll et al., 2016; 
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Schwarz et al., 2016), while [18F]AV1451 PET binding patterns mirror the clinical 
and neuroanatomical variability in the AD spectrum (Ossenkoppele et al., 2016). 
Specifically, patients with the amnestic presentation of AD showed the highest 
[18F]AV1451 uptake in medial temporal lobe regions including the hippocampus, 
while patients with the logopenic variant of AD displayed increased left hemispheric 
[18F]AV1451 binding, particularly in posterior temporoparietal areas implicated in 
linguistic processes (Ossenkoppele et al., 2016). Performance on domain-specific 
neuropsychological tests was also associated with increased [18F]AV1451 uptake 
in brain regions involved in episodic memory, visuospatial skills, and language 
production or comprehension (Ossenkoppele et al., 2016).  
Nevertheless, critical issues remain unresolved, and in particular the value 
of [18F]AV1451 in differentiating distinct tauopathies as well as the specificity of 
binding to tau as verified through pathological correlation. Neuropathological data 
with autoradiography have suggested that the [18F]AV1451 tracer displays strong 
binding to paired helical filaments characteristic of AD (e.g., intra- and extra-
neuronal neurofibrillary tangles and dystrophic neurites), but it does not bind so 
specifically to the straight tau filaments that are more typical of PSP and non-AD 
disease tauopathies (e.g., CBD) (Marquié et al., 2015). However, it has recently 
been found that [18F]AV1451 binds to regions of pathology (i.e., frontal and 
temporal cortices) in a patient with a MAPT gene mutation leading to straight tau 
filaments and non-AD dementia (Bevan Jones et al., 2016). It has also been 
proposed that the [18F]AV1451 tracer displays off-target binding, specifically to 
neuromelanin-containing cells. This was supported by evidence in patients with 
PD, in vivo, in the midbrain; and post mortem, in retinal and brain tissues in 
porcine and rodent models (Hansen et al., 2016). 
 
4.2. Aims 
Here, we assessed the magnitude and patterns of [18F]AV1451 binding in 
two very different neurodegenerative diseases, PSP and AD/MCI+, characterized 
by distinct anatomical distributions of pathology and distinct molecular 
pathologies. The value of comparing these two groups does not lie in their 
differential diagnosis, which is clear on clinical grounds and amyloid-β based 
biomarkers, but in testing the ligand’s binding against well-established 
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clinicopathological correlations and distinct distributions of tau pathology.  
Overall, the aims of the work in this chapter were:  
I. To identify the patterns of [18F]AV1451 PET binding in patients with PSP, 
relative to patients with AD/MCI+ as well as sex- and age-matched healthy 
controls. 
II. To assess whether regional [18F]AV1451 PET binding could distinguish 
between PSP and AD/MCI+ groups.  
III. To test whether [18F]AV1451 PET binding relates to different measures of 
clinical severity in PSP and AD/MCI+ cohorts. 
IV.  In view of the suggested effect of off-target binding, we also examined 
[18F]AV1451 uptake in relation to AT8 immunohistochemistry of 
hyperphosphorylated tau protein and tinctorial stain for neuromelanin, in 
post mortem sections from patients with PSP, AD, and a similarly aged 
healthy control from the Cambridge Brain Bank (CBB).  
 
4.3. Hypotheses 
The principal hypotheses were that: 
I. Patients with PSP would display increased [18F]AV1451 PET binding 
especially in the midbrain and basal ganglia, with likely additional binding 
in frontal cortex (including the motor areas) and supramarginal gyrus, a set 
of subcortical and cortical regions that have been shown to display tau 
pathology in PSP (Dickson et al., 2007; Schofield et al., 2005; Smith et al., 
2017). Patients with AD and those with MCI and PET scans positive for 
amyloid-β would show increased [18F]AV1451 binding in the cortical and 
subcortical areas associated with AD pathology, including the medial 
temporal lobe as well as frontal, parietal, and temporal cortices (Serrano-
Pozo et al., 2011).  
II. PSP and AD/MCI+ patients would be distinguishable on the basis of the 
regional [18F]AV1451 PET binding levels, particularly in the hippocampus 
and midbrain, two key subcortical regions that show distinct 
neuropathological changes in AD/MCI+ and PSP, respectively.  
III. [18F]AV1451 PET binding would be associated with disease severity in both 
PSP and AD/MCI+ groups, using disease specific measures of severity.  
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IV. [18F]AV1451 binding in PSP and AD post mortem brains would mirror the 
expected brain regions as in the in vivo PET study, and not be accounted 
for by off-target binding to neuromelanin.  
 
 
4.4. Materials and methods 
4.4.1. Neuroimaging  
4.4.4.1. Participants 
The current study was conducted within the context of the ‘Neuroimaging of 
Inflammation in MemoRy and Other Disorders’ project (NIMROD, see also Chapter 
2) (Bevan-Jones et al., 2017).  
For the purpose of the substudy present in this chapter, we recruited 19 
patients with probable PSP by the 1996 MDS criteria (representing a ‘classical 
phenotype’ which is sometimes referred to as Richardson’s syndrome, PSP-RS); 
nine patients meeting diagnostic criteria for probable AD (McKhann et al., 2011), 
and six patients with MCI+ were recruited. All PSP patients also meet 2017 revised 
criteria for probable PSP-RS (Höglinger et al., 2017; Litvan et al., 1996). Thirteen 
age- and sex-matched healthy controls with no history of major psychiatric or 
neurological illnesses, head injury or any other significant medical comorbidity 
were also included to allow group-wise comparisons with the clinical cohorts. 
4.4.1.2. Clinical and cognitive assessments 
All clinical measures, and cognitive and care-reported assessments that 
patient groups and healthy controls carry out though the NIMROD study are also 
explained in chapter 2, section 2.3.1. To test the hypotheses above (section 4.3) 
we focus on measures set out in Table 20. 
 
Test name Format Measured variable Cohort 
PSP-RS Assessment tool 
completed by clinician 
Disease severity PSP 
ACE-R 
 
Structured test 
administered by 
researcher 
Disease severity PSP, AD/MCI+ 
and HC 
Table 20: Clinical and neuropsychological assessments for patient groups and healthy 
controls. 
Abbreviations: PSPR-RS, Progressive Supranuclear Palsy-Rating Scale; ACE-R, Addenbrooke’s Cognitive 
Examination-Revised; PSP, Progressive Supranuclear Palsy; AD, Alzheimer’s Disease; MCI+, Mild Cognitive 
Impairment with positive β-amyloid; HC, Healthy Control. 
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4.4.1.3. Magnetic Resonance Imaging data  
In brief, all participants underwent an MRI session acquired on a 3 Tesla 
(3T) using a magnetization-prepared rapid acquisition gradient-echo (MPRAGE) 
T1-weighted sequence. The T1-weighted images were used to facilitate tissue class 
segmentation and to allow inverse normalisation of template space regions of 
interest (ROIs) defined by modified Hammers atlas (Hammers et al., 2003) to 
subject MRI space. Each T1 image was non-rigidly registered to the ICBM2009a 
template brain using ANTS (http://www.picsl.upenn.edu/ANTS/) and the inverse 
transform was applied to the modified Hammers atlas (resliced from MNI152 to 
ICBM2009a space) to bring the ROIs to subject MRI space. 
 
For further details of MRI data acquisition and pre-processing, see chapter 
2, sections 2.3.2.1. and 2.3.2.2. 
 
4.4.1.4. Positron Emission Tomography data  
 In summary, all PET scanning was performed either at the WBIC or 
Addenbrooke’s hospital. [18F]AV1451 radioligand was selected to evaluate the 
density of tau deposits. 370MBq of [18F]AV1451 was injected intravenously over 
30 seconds at the onset of a 90 minutes scan.  
Each PET emission frame was reconstructed and corrections were applied. 
Each emission image series was realigned using SPM8 to correct for patient motion 
during data acquisition and create a mean image. The mean aligned PET image 
was rigidly co-registered to the MRI T1-weighted image using SPM8 and the 
inverse transformation applied to the modified Hammers atlas to put it in native 
PET space. Kinetic modelling was then performed on the motion-corrected time 
series in the cases of [18F]AV1451. The reference region was defined in the superior 
grey-matter of the cerebellum using a 90% grey-matter threshold on the grey-
matter probability map produced by SPM8 smoothed to PET resolution. The 
dentate nucleus was subtracted from the cerebellar reference region as is a 
common feature in PSP (Ishizawa et al., 2000). The findings in section 4.5.2.3. 
corroborated the use of the superior cerebellum as reference region in the PET 
analyses.  
 
For further details of PET data acquisition and pre-processing, see chapter 
2, sections 2.3.2.3. and 2.3.2.4.  
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4.4.1.5. [18F]AV1451 BPND  statistical analyses 
To compare [18F]AV1451 binding across groups (PSP, AD/MCI+, and healthy 
controls), individual ROI BPND values for [18F]AV1451 were used in a repeated-
measures general linear model (GLM) to test for the main effect of ROI, main effect 
of group, and group x ROI interaction. Age and education were included as 
covariates of no interest. For the PSP and AD/MCI+ groups, we tested for 
correlations between regional [18F]AV1451 BPND and disease severity using the 
Progressive Supranuclear Palsy Rating Scale (PSP-RS) for PSP patients and the 
Addenbrooke’s Cognitive Examination-Revised (ACE-R) scores for AD/MCI+ 
patients with Pearson’s correlation (with partial correlations accounting for age and 
education). All analyses were repeated using [18F]AV1451 BPND values that were 
not corrected for CSF partial volume effects.  
 
To assess the ability of [18F]AV1451 BPND to distinguish PSP patients from 
AD/MCI+ cases, subject-specific [18F]AV1451 data in a set of ROIs were input as 
key features in a support vector machine (SVM), a multivariate supervised 
statistical learning method suitable for neuroimaging modalities (Cortes and 
Vapnik, 1995). A reduced group of ROIs considered as the most characteristic ROIs 
affected by tau pathology in PSP and AD/MCI+ was selected (i.e., basal ganglia 
and midbrain for PSP and superior/inferior temporal cortex, lateral occipital cortex, 
inferior parietal cortex, and hippocampus for AD/MCI+); noting that the ROIs 
included in the SVM were identical for both groups. This extended the whole-brain 
hierarchical cluster analysis described in section 4.5.1.4. The accuracy of each ROI 
to discriminate between the PSP and AD/MCI+ groups was computed using an SVM 
classifier with a K means cross-validation (K = 5) scheme with a linear kernel and 
standard cost parameter of 1.  
 
4.4.2. Neuropathology 
The human brain tissue preparation is set out in Chapter 2, section 2.3.3.1.  
The post mortem brain tissue used in this study came from three subjects: 
one PSP case, one AD case and one control. The PSP patient (NP16-69) was a 79 
year old female who died from pneumonia. The AD case (NP16-264) was a 74 year 
old lady diagnosed with Braak stage VI, and according to her death certificate she 
died from AD. The control brain tissue (NP16-202) derived from a male of 73 years 
who died due to rectal colon cancer. 
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4.4.2.1. [18F]AV1451 Phosphor screen autoradiography 
[18F]AV1451 phosphor screen autoradiography was performed following a 
previously published protocol by Marquiè and collaborators (Marquié et al., 2015). 
In brief, 20μm thick frozen brain sections were fixed in 100% methanol at room 
temperature for 20 minutes and then transferred to a bath containing high specific 
activity [18F]AV1451 in 10mM phosphate-buffered saline (PBS) with a radioactivity 
concentration of approximately 20μCi/ml. Adjacent brain slices were placed in a 
bath that was identical in all aspects except that unlabelled AV1451 was added to 
yield 1μM chemical concentration, a blocking condition sufficient to saturate 
essentially all available specific binding sites of tau. After incubation for 60 
minutes, racks of slides were removed from the respective radioactive solutions 
and briefly incubated in a series of wash baths to remove unbound radiotracer. 
Wash solutions and incubation times were: 10mM PBS for 1 minute, 70% 
ethanol/30% PBS for 2 minutes, 30% ethanol/70% PBS for 1 minute, and lastly 
100% 10mM PBS for 1 minute. Racks were removed from the final wash solution, 
and slides were allowed to air dry before transfer to a storage phosphor screen 
(GE healthcare) that had been photo-bleached immediately prior by exposure on 
a white light box for a minimum of 15 minutes. The slides were enclosed in an 
aluminium film cassette and set away from sources of radioactivity for the duration 
of the overnight exposure period. The cassette was opened and the slides were 
removed from the exposed screen, which was mounted on the digital imaging 
system (CR 35 BIO, Durr medical). Scanning of screens was controlled by Aida 
Image Analyser v.4.27 using 600 dpi resolution (approximately 42μm sampling 
interval). Digital images were saved at full resolution and pixel depth. Images from 
adjacent brain slices incubated in the unblocked (high specific activity [18F]AV1451 
only) and blocking ([18F]AV1451 plus 1μm unlabelled AV1451) conditions were 
compared to estimate total and nonspecific binding of [18F]AV1451.  
 
4.4.2.2. Immunohistochemistry 
I. AT8 immunohistochemistry of hyperphosphorylated tau protein 
Sections were incubated in 10mM PBS/0.1% Triton X-100 buffer (Sigma, 
UK) twice for 5 minutes. Bovine serum albumin (0.7mls 5% w/v dissolved in buffer, 
Sigma, UK) was applied to each section and left for 1 hour. After washing twice in 
buffer, 0.7 ml of the primary antibody to tau (mouse monoclonal AT8, 1:1000 
dilution) was applied to each section and incubated overnight at 4°C. The following 
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day, after washing the sections twice in PBS, 0.7ml of the secondary antibody 
(Alexa Flour 555, 1:1000 dilution) was applied to each section for 1 hour. Samples 
were washed, dried and coverslipped with Floursave (Calbiochem, UK). Prior to 
microscopy, sections were stored at 4°C in the dark. Microscopy analysis (Leica 
DM 6000B) was filtered to detect fluorescence from the antibody (555nm, red) and 
non-specific fluorescence (488nm, green). 
 
II. Masson Hamperl staining method for the demonstration of 
neuromelanin  
The tinctorial or silver stain for neuromelanin, in post mortem sections from 
patients with PSP, AD, and a similarly aged healthy control was investigated 
following the Masson Hamperl staining method (Masson, 1923) followed by image 
analysis. The captured images were processed with a Sigma Scan Pro image 
analysis software (Jandel Scientific, San Rafael, CA) by conversion to gray-scale 
images and detection of the immunolabel by its pixel intensity. In brief, frozen 
sections were dried for 20 minutes (Lamb E18.31), then placed in ultra-pure water 
for 30 seconds before incubated in silver solution at 60°. After 15 minutes, sections 
were rinsed in ultra-pure water. Sections were returned to the silver solution for 
further staining between 3 to 5 minutes as required. After rinsing in ultra-pure 
water, sections were fixed with 5% sodium thiosulphate. Sections were then 
counterstained with 0.1% nuclear fast red solution for 5 minutes, rinsed with 
water, then dehydrated in denatured alcohol (100% IDA) for 15 seconds, twice. 
After two changes of xylene, 15 seconds each, slides were cover slipped.  
 
 
4.5. Results 
4.5.1. Neuroimaging  
4.5.1.1. Demographics and cognitive variables of patients and healthy 
controls in the [18F]AV1451 BPND in vivo study 
Descriptive data for demographic and cognitive details are shown in Table 
21. There were no statistically significant differences between patient and healthy 
control groups in terms of age or sex. Age and education were included as 
covariates of no interest in the statistical models assessing the main effect of group 
and group x ROI interaction. As expected, there was a significant main effect of 
134 
group for cognitive measures, driven by reduced MMSE and ACE-R scores in PSP 
and AD/MCI+ patients relative to healthy controls.  
 
 PSP 
(N=19) 
AD/MCI+ 
(N=15) 
HC 
(N=13) 
ANOVA (F) or 
Chi-Square (χ2) 
df p value 
Age 
mean 
(SD) 
69.5 
(±5.8) 
71.6 
(±8.7) 
67.2 
(±7.3) 
1.2 2 ns 
Gender 
M/F 
11/8 9/6 6/7 0.6 2 ns 
Education 
mean 
(SD) 
11.9 
(±1.8) 
14.3 
(±3.3) 
15.8 
(±1.9) 
10.2 2 0.0003 
MMSE 
mean 
(SD) 
26.1 
(±4.5) 
25.5 
(±2.8) 
29.3 
(±0.7) 
4.9 2 0.012 
ACE-R 
mean 
(SD) 
78.7 
(±15.8) 
75.9 
(±11.0) 
95.5 
(± 3.0) 
10.3 2 0.0002 
PSP-RS 
mean 
(SD) 
43.6 
(±15.8) 
- - - - - 
Table 21: Demographics and cognitive variables of study participants.  
Abbreviations: PSP, Progressive Supranuclear Palsy; AD, Alzheimer’s Disease; MCI+, Mild Cognitive Impairment 
with positive β-amyloid; HC, Healthy Control; df, degrees of freedom; SD, Standard Deviation; M, Male; F, 
Female; MMSE, Mini-Mental State Examination; ACE-R, Addenbrooke’s Cognitive Examination-Revised; PSPR-RS, 
Progressive Supranuclear Palsy-Rating Scale; ns = not significant at p > 0.05. 
 
 
4.5.1.2. [18F]AV1451 BPND in relation to clinical diagnosis 
The mean [18F]AV1451 BPND PET map in each group (Figure 15) and 
quantitative ROI analyses  (Figure 16), indicated high [18F]AV1451 uptake in the 
basal ganglia in all groups including controls. In the repeated-measures ANOVA of 
regional binding, we found a significant main effect of group (F2, 41 = 17.5, p = 
0.00001) and a ROI x group interaction (F2, 68  = 7.5, p < 0.00001), although there 
was no main effect of ROIs (F2, 34  = 0.8, p = 0.8) (Figure 16). The group and 
interaction effects were driven in part by greater [18F]AV1451 BPND in the AD/MCI+ 
group relative to the PSP and healthy control groups, in cortical and subcortical 
ROIs including frontal, parietal, lateral temporal, and occipital cortices as well as 
the hippocampus and other medial temporal lobe ROIs (post hoc t-tests, t’s > 2.2, 
p’s < 0.04) (Figures 16, 18 and 19). The PSP group, relative to the AD/MCI+ group, 
showed increased [18F]AV1451 BPND in the midbrain (t = 2.1, p < 0.04); while, 
relative to healthy controls, PSP patients showed increased [18F]AV1451 BPND 
uptake in the putamen, pallidum, thalamus, midbrain and dentate nucleus of the 
cerebellum (t’s > 2.7, p < 0.02) (Figures 16 and 17).  
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Figure 15: Voxel-wise BPND maps for [18F]AV1451 for patients and healthy controls. 
Note the [18F]AV1451 binding in the basal ganglia in all groups, albeit higher in AD and PSP patients. Patients 
with AD also showed increased [18F]AV1451 binding in medial temporal lobe regions and widespread neocortical 
areas, relative to controls and PSP patients, while PSP patients had increased high [18F]AV1451 binding to the 
midbrain, relative to patients with AD and control subjects. 
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  Figure 16: Mean (±SD) [18F]AV1451 BPND in each region of interest for the patient groups and healthy controls. 
  This figure shows the bar plots represent the mean values (± SE) of the [18F]AV1451 BPND in each region of interest for the participant groups:  
  AD/MCI+, PSP, and HCs. The [18F]AV1451 BPND data reported here are corrected for CSF partial volume effects. Post hoc t tests: *p < 0.05,  
  **p < 0.01, ***p < 0.005. Abbreviations: AD, Alzheimer Disease; MCI+, Mild Cognitive Impairment with positive β-amyloid; PSP, Progressive 
  Supranuclear Palsy; HC, Healthy Control; BPND, Non-displaceable Binding Potential. 
AD>PSP** 
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Repeating the analyses using [18F]AV1451 BPND values that were not 
corrected for CSF partial volume effects yielded similar results (F2, 36  = 1.1, p = 
0.2, for the main effect of ROIs; F2, 41  = 16.7, p < 0.00001 for the main effect of 
group; and F2, 72  = 6.3, p < 0.00001 for the group x ROI interaction).  
 
We then tested whether regional [18F]AV1451 BPND related to disease 
severity. In the PSP group, we found no significant correlation between 
[18F]AV1451 BPND in any ROI and disease severity, as assessed via the PSP-RS (p’s 
> 0.16). Similarly, in the AD/MCI+ group, there was no significant correlation 
between ACE-R score and [18F]AV1451 BPND in any ROI (p’s > 0.14). Repeating 
the correlation analyses when using the [18F]AV1451 BPND values that were not 
corrected for CSF volume yielded similar non-significant results (p’s > 0.1).  
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Figure 17: Scatter plot for subcortical regions to show the range of [18F]AV1451 BPND values in patients with PSP.  
Each dot represents one patient, coloured by individual. Abbreviations: BPND, Non-displaceable Binding Potential; PSP, Progressive 
Supranuclear Palsy.  
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Figure 18: Scatter plot for cortical regions to show the range of [18F]AV1451 BPND values in patients with AD/MCI+.  
Each dot represents one patient, coloured by individual. Abbreviations: BPND, Non-displaceable Binding Potential; AD, Alzheimer’s Disease; 
MCI+, Mild Cognitive Impairment.  
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Figure 1918: Scatter plot for subcortical regions to show the range of [18F]AV1451 BPND values in patients with AD/MCI+.  
Each dot represents one patient, coloured by individual. Abbreviations: BPND, Non-displaceable Binding Potential; AD, Alzheimer’s Disease; MCI+, Mild Cognitive 
Impairment.  
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4.5.1.3. Classification of cases by [18F]AV1451 BPND 
The support vector machine analysis using [18F]AV1451 BPND values in a 
subset of ROIs was able to separate the AD/MCI+ patients from PSP cases with a 
classification accuracy of 94.1%. The accuracy for the other pairwise comparisons 
is as follows: PSP vs. healthy controls = 90.6%; AD/MCI+ vs. healthy controls = 
85.7%. The ability of a SVM to separate groups can be readily appreciated from 
the bivariate plot of hippocampal and midbrain BPND (Figure 20). Although neither 
region individually support accurate differentiation of AD from PSP, the 
combination of data across two regions leads to clear separate on groups.  
 
 
 
 
 
 
Figure 20: Bivariate plot of [18F]AV1451 BPND values in hippocampus and midbrain, in 
patient groups and healthy controls. 
This figure shows the individual [18F]AV1451 BPND values in the hippocampus (X-axis) and midbrain (Y-axis) in 
patients with Alzheimer’s Disease/Mild Cognitive Amyloid positive patients (red dots), Progressive Supranuclear 
Palsy (blue dots) and Healthy controls (green dots). Abbreviations: BPND, Non-displaceable Binding Potential; AD, 
Alzheimer’s Disease; MCI+, Mild Cognitive Impairment; PSP, Progressive Supranuclear Palsy.  
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4.5.1.4. Hierarchical clustering analyses 
To test whether the distribution of [18F]AV1451 BPND differed across groups, 
we used hierarchical clustering according to the similarity of their region-wise 
[18F]AV1451 binding, collapsed across hemispheres. The similarities driving this 
classification can be visualised using multi-dimensional scaling (Figure 21). The 
accuracy for pair-wise comparisons using hierarchical cluster analyses is as 
follows: PSP vs. healthy controls = 84.4%; AD/MCI+ vs. PSP = 88.2%; AD/MCI+ 
vs. healthy controls = 82%.  
 
 
 
  
Figure 21: Two dimensional scaling of [18F]AV1451 BPND distribution across groups. 
This figure represents the three study groups: Healthy controls (blue dots); Progressive Supranuclear Palsy 
patients (green dots); Alzheimer’s Disease/Mild Cognitive Amyloid Positive patients (red dots). 
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4.5.2. Neuropathology 
A summary of the phosphor screen autoradiography results, AT8 
immunohistochemistry data and neuromelanin staining in post mortem AD, PSP 
and healthy control brain cases is shown in Figure 22. 
 
Figure 22: 
[18F]AV1451 BPND 
Phosphor screen 
autoradiography and 
immunohistochemistry 
for patient and healthy 
control cases. 
The figure 22 aligns the 
[18F]AV1451 
autoradiographic binding in 
key regions of interest in an 
Alzheimer’s disease (AD) 
case, a patient with 
progressive supranuclear 
palsy (PSP), and a control of 
similar age. 
Immunohistochemistry data 
assessing 
hyperphosphorylated tau 
(AT8, red) and 
neuromelanin staining (dark 
brown) are also shown for 
the same cases and regions 
of interest. Note that the 
yellow stains do not 
represent antibodies but 
rather represent non-
specific protein 
immunofluorescence 
There is [18F]AV1451 BPND in 
the hippocampus and, to a 
lesser extent, in the frontal 
cortex in AD. In contrast, 
[18F]AV1451 BPND to the 
midbrain slices was not 
specific to PSP but was also 
detected in the AD and 
control cases, who showed 
little or no tau pathology in 
the midbrain. Despite the in 
vivo [18F]AV1451 BPND to the 
basal ganglia in all groups 
(including controls), post 
mortem [18F]AV1451 BPND to 
the basal ganglia was sparse 
and non-specific in these 
three cases. Note the 
absence of neuromelanin-
containing cells in the basal 
ganglia and cortical regions. 
The magnification of the 
autoradiography was x1, 
while immunohistochemistry 
pictures (AT8) and 
neuromelanin staining were 
taken under a ×20 
objective.  
 
 
Figure 19: Post 
mortem 
immunohistochemist
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4.5.2.1. [18F]AV1451 Phosphor screen autoradiography 
The autoradiography phosphor screen analyses in the AD brain tissue 
samples revealed that the anterior hippocampus had the highest and most specific 
binding of the [18F]AV1451 radiotracer. [18F]AV1451 binding was also found in the 
frontal cortex in the AD case, although to a lesser extent than in the hippocampal 
slice. In contrast, sparse and non-specific [18F]AV1451 binding was found in the 
AD basal ganglia tissue. The PSP and healthy control tissues showed overall sparse 
and nonspecific [18F]AV1451 binding, including anterior hippocampus, midbrain, 
basal ganglia and frontal cortex.  
 
4.5.2.2. Immunohistochemistry  
Abundant hyperphosphorylated tau protein was detected in the anterior 
hippocampus of the AD case, while small and punctate tau staining was found in 
the midbrain and frontal cortex of the same patient, which is overall consistent 
with the results of the phosphor screen autoradiography. Although 
hyperphosphorylated tau was found in the frontal cortex in the AD case, its 
relatively low density could be due to a slow cortical disease progression in this 
particular patient. The PSP tissue displayed high concentration of 
hyperphosphorylated tau in the midbrain and basal ganglia, while the AD brain 
displayed little AT8 staining in the same ROI. As expected, the healthy control 
brain did not show AT8 immunoreactivity in any of the ROIs examined.  
 
Neuromelanin-containing cells were only observed in the midbrain in all post 
mortem cases. Of note, no neuromelanin-containing cells were found in the basal 
ganglia in either the AD, PSP or control case, which is in contrast to the strong in 
vivo [18F]AV1451 BPND of this radiotracer to the same ROI.  
 
4.5.2.3. Tau immunohistochemistry (AT8) in the superior cerebellum 
Only very sparse and punctate tau staining was found in the superior 
cerebellum of the PSP case (Figure 23-A), while no tau pathology was seen in the 
AD and control case (see respectively Figures 23-B and 23-C). This is overall 
consistent with the hypothesis that the superior cerebellum displays little or no 
tauopathy compared to other brain areas in either PSP and AD (Dickson et al., 
2007; Okello et al., 2009; Schöll et al., 2016; Schwarz et al., 2016; Williams et 
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al., 2007). These findings also corroborated the use of the superior cerebellum as 
reference regions in the PET analyses (see section 4.4.1.4.).  
 
 
 
4.6. Discussion 
The principal result of our study is that PET imaging with the radiotracer 
[18F]AV1451 revealed distinct patterns of binding in the primary tauopathy of PSP, 
in comparison to AD and its prodromal state of MCI+. The relatively large size of 
our PET study confirmed the high accuracy of discrimination between the clinical 
groups using [18F]AV1451 BPND data, indeed by visual inspection (see section 
4.5.1.2.; Figures 15-19), and with a simple support vector machine (see section 
4.5.1.3.; Figure 20). However, despite this heuristic potential of [18F]AV1451 as a 
tau biomarker, caution in the interpretation of its binding targets is indicated by 
the neuropathological and autoradiographic data (see section 4.5.2.; Figure 22). 
In particular, while [18F]AV1451 strongly bound to AD-related tau pathology, non-
specific binding of the same tracer can be found in PSP patients and healthy 
controls (Marquié et al., 2015). Nevertheless, our post mortem data suggest that 
off-target binding to neuromelanin is not a sufficient explanation of the BPND for 
[18F]AV1451 at least in the context of PSP, and in some critical regions. For 
instance, we found in vivo significant [18F]AV1451 uptake in the basal ganglia (in 
all groups including healthy controls) in the absence of post mortem neuromelanin-
containing cells. This indicates that neuromelanin is not the principal target of off-
target binding for [18F]AV1451, but there may be other off-target binding sites 
which have as yet not been identified, including non-tau targets in disorders 
associated with predominantly TDP43 pathology (Bevan-Jones et al., 2016).  
Figure 23: Post mortem immunohistochemistry of hyperphosphorylated tau in the 
superior cerebellum. 
A. Progressive supranuclear palsy. B. Alzheimer’s disease. C. No neurodegenerative disorders (healthy control). 
Note the small and punctate tau staining in the superior cerebellum of the PSP case and the absence of tau 
pathology in the other cases. The magnification of the immunohistochemistry pictures is x20. 
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For [18F]AV1451 PET to meet its full potential as a biomarker to stratify or 
monitor the effect of disease modifying drugs in future clinical trials, additional 
properties would therefore need to be established. In particular, further work is 
needed to demonstrate changes in [18F]AV1451 PET over time, or in response to 
treatment. A cross-sectional study as this one cannot be used to infer longitudinal 
change, but it can be employed to inform and model a biomarker’s potential. More 
specifically, the relevance of [18F]AV1451 is increased by the demonstration that 
its binding patterns recapitulate in vivo the established post mortem distributions 
of tau pathology in PSP and AD. In addition, [18F]AV1451 PET may have biomarker 
potential for the differential diagnosis of equivocal cases: whilst the distinction 
between PSP and AD can be readily made on clinical grounds, patients with PSP-
parkinsonism clinically resemble PD (Williams et al., 2005).  
 
In contrast to previous results (Johnson et al., 2016; Ossenkoppele et al., 
2016), [18F]AV1451 uptake was not correlated with disease severity in our groups 
(i.e., PSP-RS in PSP patients and severity of cognitive impairment in AD/MCI+ 
patients). Although, Smith et al. (2017) only found positive correlation between 
globus pallidus SUVRs and the PSP-RS values, but not in other regions, including 
the putamen and thalamus (Smith et al., 2017). There are several possible 
explanations for the lack of a correlation in our study, including lack of statistical 
power (type II error) or the use of clinical measures that were not sufficiently 
sensitive to describe the full spectrum of clinical variability in PSP and AD. 
Alternatively, it may be that [18F]AV1451 uptake is inherently limited in staging 
disease severity in PSP and AD, analogous to the PiB tracer in AD (Hatashita  and 
Yamasaki, 2010).  
 
Technical considerations in assessing the [18F]AV1451 binding post mortem 
and in estimating BPND in vivo must also be considered. First, it is possible that in 
the autoradiographic protocol (Marquié et al., 2015), ethanol washing and other 
procedures may have affected the labelling with [18F]AV 1451, especially in the 
basal ganglia. Second, our PET analyses employed correction of ‘partial volume 
effects’, resulting from the CSF volume within each region. This mitigates the 
potential influence of brain volume loss seen in PSP and AD/MCI+. Nevertheless, 
using uncorrected PET data yielded qualitatively similar results in terms of the 
main effect of group and group x ROI interaction, which suggests that we avoided 
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‘over-correcting’ the BPND values based on cortical and subcortical atrophy, and 
the consequent inferential error from CSF volume and its correction.  
 
Interestingly, the regions with the most significant group differences in 
[18F]AV1451 BPND in PSP and AD in vivo were those predicted from prior post 
mortem studies for each disease. More specifically, PSP was associated with a 
pattern of increased [18F]AV1451 BPND in the basal ganglia, midbrain and dentate 
nucleus of the cerebellum, consistent with the pathophysiology of the disease 
(Hauw et al., 1994; Litvan et al., 1996). Conversely, the clinical syndromes of AD 
and biomarker positive MCI were associated with increased [18F]AV1451 BPND in 
widely distributed subcortical and cortical areas that have been consistently 
implicated in the pathogenesis and progression of AD (e.g., hippocampus, 
amygdala as well as frontal, parietal, temporal, and occipital cortices) (Braak et 
al., 2006; Braak and Braak, 1995). Together, these data demonstrated that the 
[18F]AV1451 ligand recapitulates in vivo the typical neuropathological changes 
seen in PSP and AD, although it cannot be assumed that the cellular and/or 
molecular targets of [18F]AV1451 binding are the same in both disorders.  
 
[18F]AV1451 BPND in selected regions of interest also distinguished PSP cases 
from AD/MCI+ patients with an accuracy of 94%, which suggests the potential of 
this radiotracer to discriminate in vivo amongst different tauopathies despite the 
relatively weak signal. The value of this analysis is not as a diagnostic biomarker, 
as clinical features readily distinguish the groups, but rather represents an early 
step in the process of validating [18F]AV1451 PET as a biomarker for tauopathies. 
Multicentre replication with larger samples and broader diagnostic spectra would 
nonetheless be necessary, including for example, patients with frontotemporal 
dementia, corticobasal syndrome, or pre-symptomatic individuals with high risk of 
developing tau-related neurodegenerative disorders (e.g., carrying specific gene 
mutations).  
Finally, we note that our data are specific to [18F]AV1451 and do not 
necessarily generalize to other radioligands. Further work is required to determine 
the specificity of [18F]AV1451 and other candidate ligands’ binding to the different 
isoforms of tau protein, their differential modes of modification (e.g., 
phosphorylation, acetylation) and aggregation (e.g., oligomeric states). These 
issues are of high relevance for this and other studies because: i) PSP pathology 
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is mainly a 4R isoform tauopathy, while AD is characterized by balanced 3R/4R 
isoforms (Buée & Delacourte, 1999; Espinoza et al., 2008), and ii) the toxicity of 
tau aggregates may be driven by oligomers rather than tangles.  
 
In conclusion, we suggest that [18F]AV1451 is a useful PET ligand for in vivo 
studies in clinical populations with non-AD primary tauopathies such as PSP, 
despite the potential contribution of non-specific or “off-target” binding, and AD 
pathology. The brain regions with increased [18F]AV1451 binding were those 
predicted from the well-established patterns of neurodegeneration in both 
diseases, and are in keeping with the cognitive and motor features classically seen 
in PSP and AD/MCI+ clinical syndromes. Together, our current findings support the 
further use of [18F]AV1451 PET in vivo and in vitro to evaluate tau pathology in 
studies of dementia and neurodegeneration.  
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Chapter 5 
Neuroinflammation in progressive 
supranuclear palsy and Alzheimer’s 
disease 
 
Material in this chapter has been published as:  
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5.1. Introduction 
Neurodegenerative disorders are due to long-lasting pathological processes 
associated with the deposition of abnormal toxic protein aggregates in the brain 
and the activation of a cascade of aberrant biochemical, metabolic, functional and 
structural changes (Pievani et al., 2014; Brettschneider et al., 2015). Recent 
literature has focused on the role of neuroinflammatory processes in 
neurodegeneration. In particular, it has been intensely investigated whether 
neuroinflammation occurs as a primary or secondary event in the course of 
neurodegenerative disorders, possibly exerting either beneficial/regenerative or 
detrimental effects (Heneka et al., 2014; Du et al., 2017; Pasqualetti et al., 2015). 
The characteristics of the neuroinflammation response largely depend on the 
specific features of the trigger insult, including duration and magnitude, which can 
drive either a neuro-regenerative protective function or a neurotoxic action 
(Rivest, 2009).  
 
Many studies focusing on the glial cells involved in the inflammatory 
responses of the brain, namely microglia and astroglia, have over the years 
pointed out the dynamic and changing behaviour of these cells, accompanied by 
different morphologies and activation forms. A significant amount of literature 
points to a key role for activated microglia and astroglia in neurodegenerative 
disorders. Presence of activated microglia cells has been demonstrated in PSP, AD, 
PD, and Huntington’s disease (HD) (Anderson et al., 2007; Cagnin et al., 2001; 
Edison et al., 2013; Edison et al., 2008; Fan et al., 2015; Fernández-Botrán et al., 
2011; Gerhard et al., 2006a; Gerhard et al., 2006b; Kropholler et al., 2007; 
Schuitemaker et al., 2013; Wiley et al., 2009), thus suggesting a biochemical link 
between the accumulating toxic proteins and microglia activation in 
neurodegenerative diseases. Comparably, astrocytes play an important role in 
neurodegenerative disorders with exacerbating effects when they are activated or 
reactive (Perry et al., 2010). Several approaches have over time revealed different 
facets of microglial phenotypic diversity, and advanced genetic analyses, in recent 
years, have added new insights into microglial heterogeneity, opening novel 
scenarios that researchers have just started to explore. 
 
Clinical studies have shown that microglial activation, a proxy of 
neuroinflammation, is present even at the early stages not only in AD and PD, but 
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also in other neurodegenerative conditions such as frontotemporal dementias 
(FTD) (Stefaniak & O’Brien, 2015; Miyoshi et al., 2010; Lant et al., 2014). 
Similarly, reactive astrocytosis is an early phenomenon in the progression of AD 
(Santillo et al., 2011; Carter et al., 2012). The possible detrimental role of 
microglia activation in neurodegenerative disorders and its influence during the 
different disease phases remain largely unexplored. 
Variations in several genes putatively involved in inflammation and immune 
responses have been suggested as risk factors of late onset AD on the basis of a 
genome-wide association study (GWAS) such as SORL1 (sortilin-related receptor) 
and TREM2 (triggering receptor expressed on myeloid cells 2) (Guerreiro et al., 
2013; Jonsson et al., 2013; Rogaeva et al., 2007). Conversely, inflammatory 
genes have not been reported as risk factors of PSP (Sanchez-Contreras et al., 
2018). 
 
The currently available PET molecular imaging techniques allow the 
measurement of neuroinflammation through imaging of both astrocytes and 
microglia activation (Jacobs et al., 2012). The great majority of research has 
focused on PET imaging of microglia activation, and many radioligands have been 
synthetized, the great majority of which target the over-expression of the 18-kDa 
translocator protein (TSPO). TSPO is an outer mitochondrial membrane protein, 
expressed mostly by microglia and, to a lesser extent, by astrocytes (Venneti et 
al., 2006; Liu et al., 2014). Its levels in the central nervous system in healthy 
conditions are generally low, whereas their over-expression in the disease state 
has been well documented (Liu et al., 2014). Among the others, [11C](R)-PK11195 
is the first PET marker of in vivo microglial activation (Chauveau et al., 2008) and 
has been widely adopted in multiple neurodegenerative conditions, including PSP 
and AD (Cagnin et al., 2001; Edison et al., 2013; Edison et al., 2008; Fan et al., 
2015; Gerhard et al., 2006a; Gerhard et al., 2006b). Understanding whether and 
how microglia are reacting within a disease course may provide important insights 
into disease pathogenesis and have remarkable implications for future clinical 
trials; although one needs to bear in mind that microglial activation represents 
only part of the complex cascade of events in neuroinflammation (Agostinho et al., 
2010).  
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PET radiotracer development for neuroinflammation beyond TSPO, for 
imaging neurodegenerative diseases (and other neurological disorders), is an 
active area of research with several emerging targets and tracers under various 
stages of preclinical and clinical research studies underway. Today, PET imaging 
of neuroinflammation is not yet regarded as an in vivo biomarker for clinical 
diagnosis or to evaluate disease progression, but it may help to test novel 
therapeutic agents targeting glial cells (Hamby & Sofroniew, 2010). A number of 
novel tracers for microglial activation have already been developed (Tronel et al., 
2017) but hardly any PET tracers are used to investigate in vivo astrocyte 
activation.  
There is a current interest in developing more astrocyte tracers. For 
example, Tyancke and colleagues (2018) have recently successfully evaluated 
[11C]BU99008 as a specific and selective in vivo PET radioligand for the 
imidazoline2 binding site (I2BS) in humans.  
 
 
5.2. Aims 
I aimed assessed the magnitude and patterns of [11C](R)-PK11195 binding 
in two very different neurodegenerative entities, PSP and AD/MCI+, characterized 
by distinct anatomical distributions of pathology. The value of this comparison does 
not lie in the differential diagnosis between these clinically diverse entities but 
rather in establishing the distribution and relevance of neuroinflammation in two 
distinct tauopathies. Overall, the aims of the work in this chapter were:  
I. To assess neuroinflammation in typical patients with PSP, relative to 
patients with AD/MCI+ and sex- and age-matched healthy controls.  
II. To assess if neuroinflammation relates to clinical severity in PSP and 
AD/MCI+ cohorts, using disease specific measures of severity.  
III. To explore if neuroinflammation is observed in post mortem tissue from 
patients with PSP and AD.  
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5.3. Hypotheses 
The principal hypotheses were that:  
I. PSP patients would show enhanced [11C](R)-PK11195 binding in regions 
critically implicated in PSP pathogenesis, including the basal ganglia and 
midbrain (Williams et al., 2007). AD/MCI+ patients would displayed 
increased [11C](R)-PK11195 binding in cortical and subcortical areas 
associated with hallmarks of AD pathology, including the medial 
temporal lobe, parietal, and temporal cortices (Braak et al., 2006).  
II. [11C](R)-PK11195 binding would be associated with disease severity in 
both PSP and AD/MCI+ groups. 
III. [11C](R)-PK11195 binding in PSP and AD post mortem brains would 
mirror the expected brain regions as in the in vivo PET study. 
 
 
5.4. Materials and methods 
5.4.1. Neuroimaging  
5.4.1.1 Participants 
The current project was conducted within the context of the ‘Neuroimaging 
of Inflammation in MemoRy and Other Disorders study (NIMROD, see Chapter 2) 
(Bevan-Jones et al., 2017). The sub-study included 16 PSP patients with probable 
PSP by the 1996 MDS criteria (representing a ‘classical phenotype’, which is 
sometimes referred to as Richardson’s syndrome, PSP-RS. All patients also meet 
2017 revised criteria for probable PSP-RS (Höglinger et al., 2017; Litvan et al., 
1996); nine patients meeting diagnostic criteria for probable AD (McKhann et al., 
2011) (typical amnestic phenotype, without biomarkers), and seven amnestic 
MCI+ patients (PiB PET biomarker positive). Thirteen age-, sex-, and education-
matched healthy controls with no history of major psychiatric or neurological 
illnesses, head injury or any other significant medical comorbidity were also 
recruited. All participants did not have any acute infectious or chronic systemic 
inflammatory disorder (e.g., lupus, rheumatoid arthritis, Crohn’s disease, 
polymyalgia rheumatica).  
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5.4.1.2. Clinical and cognitive assessments 
The relevant NIMROD tests to test the current hypothesis are displayed in 
Table 22. 
Test name Format Measured variable Cohort 
PSP-RS Assessment tool 
completed by study 
clinician 
Disease severity PSP 
RAVLT Researcher administered 
test of learning, recall and 
repetition of semantically 
unrelated words 
Disease severity AD/MCI+ 
ACE-R 
 
Structured test 
administered by 
researcher 
Attention and orientation, 
memory, fluency, language 
and visuospatial domains 
PSP, 
AD/MCI+ 
and HC 
Table 22: Clinical and neuropsychological assessments for patient groups and healthy 
controls. 
Abbreviations: PSPR-RS, Progressive Supranuclear Palsy-Rating Scale; RAVLT, Rey Auditory and Verbal Learning 
Test; ACE-R, Addenbrooke’s Cognitive Examination-Revised; PSP, Progressive Supranuclear Palsy; AD, 
Alzheimer’s Disease; MCI+, Mild Cognitive Impairment with positive β-amyloid; HC, Healthy Control. 
 
5.4.1.3. Magnetic Resonance Imaging data  
In brief, all participants underwent an MRI session acquired on a 3 Tesla 
(3T) using a magnetization-prepared rapid acquisition gradient-echo (MPRAGE) 
T1-weighted sequence. The T1-weighted images were used to facilitate tissue class 
segmentation and to allow inverse normalisation of template space regions of 
interest (ROIs) defined by modified Hammers atlas (Hammers et al., 2003) to 
subject MRI space. Each T1 image was non-rigidly registered to the ICBM2009a 
template brain using ANTS (http://www.picsl.upenn.edu/ANTS/) and the inverse 
transform was applied to the modified Hammers atlas (resliced from MNI152 to 
ICBM2009a space) to bring the ROIs to subject MRI space. 
 
For further details of MRI data acquisition and pre-processing, see chapter 
2, sections 2.3.2.1. and 2.3.2.2. 
 
5.4.1.4. Positron Emission Tomography data  
In summary, all PET scanning was performed at the WBIC or Addenbrooke’s 
hospital. [11C](R)-PK11195 radioligand aimed to measure the density of activated 
microglia as an indication of neuroinflammation. 500MBq [11C](R)-PK11195 was 
injected intravenously over 30 seconds at the onset of a 75 minutes scan.  
Each PET emission frame was reconstructed and corrections were applied. 
Each emission image series was realigned using SPM8 to correct for patient motion 
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during data acquisition and create a mean image. The mean aligned PET image 
was rigidly co-registered to the MRI T1-weighted image using SPM8 and the 
inverse transformation applied to the modified Hammers atlas to put it in native 
PET space. In the absence of a standard reference region for [11C](R)-PK11195; a 
supervised cluster analysis was used to determine the reference tissue time-
activity curve (Yaqub et al., 2012).  
 
In the published paper, we chose not to purpose a voxel-wise approach 
because the PK signal can be noisy (even with negative values in some voxels, 
especially in white matter and in ventricles). Smoothing such data would be 
required for the application of Gaussian Random Field (GRF) theory to voxel-wise 
statistic maps. But smoothing across grey matter, white matter and ventricles 
signals might introduce artefacts, making interpretation of the more results 
difficult. The published data therefore focussed on a ROI analysis that readily 
permits adjustment of the data for spill-in and spill-out of PET signal.  However, in 
this thesis, I also present the voxel-wise data, to complement the ROI analysis.  
 
The methods are summarised in the next section, but for further details of 
PET data acquisition and pre-processing, see chapter 2, sections 2.3.2.3 and 
2.3.2.4. 
 
5.4.1.5. Regional [11C](R)-PK11195 BPND statistical analyses 
To compare [11C](R)-PK11195 binding across groups (PSP, AD/MCI+ and 
healthy controls), individual ROI BPND values for [11C](R)-PK11195 were used in a 
repeated-measures GLM to test for the main effect of ROI, main effect of group, 
and group × ROI interaction. Age and sex were included as covariates of no 
interest. For the AD/MCI+ and PSP group, we also tested Pearson’s correlations 
between regional [11C](R)-PK11195 BPND and disease severity using the PSP-RS 
for PSP patients and the RAVLT scores for AD/MCI+ patients. All analyses were 
repeated using [11C](R)-PK11195 BPND values that were not corrected for CSF 
partial volume effects. 
 
5.4.1.6. Whole brain [11C](R)-PK11195 BPND statistical analyses 
Whole brain voxel-wise analysis was performed on the BP maps. Images 
were processed in SPM12 (http://www.fil.ion.ucl.ac.uk/spm/software/spm12/) 
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and in-house scripts. The T1-weighted images were segmented into six tissue 
classes and matched together using the DARTEL pipeline. The study specific 
template image was then affine registered to MNI space, so as to present results 
in standardised stereotactic coordinates, using the combined normalisation 
transform parameters for each participant’s images. The mean images from each 
PET session were registered to each participant’s T1-weighted image. The native 
space BP map was then transformed into MNI spaces using the DARTEL flow field 
and template-to-MNI transform. In addition, partial volume corrected BP maps 
were created using the Meltzer method (Meltzer et al., 1996) to adjust for CSF, 
and the Muller-Gartner method (Muller-Gartner et al., 1992) to adjust grey matter 
for white matter fraction. The maps were smoothed by an isotropic Gaussian 
Kernel of 8mm. Statistical analysis was performed in SPM12, using an ANOVA 
design with a single factor of three levels, one for each group. 
 
5.4.2. Neuropathology 
The human brain tissue preparation is described in Chapter 2, part 2.3.3.1. 
The post mortem brain tissue used in this study came from three subjects: one 
PSP case, one AD case and one control. The PSP patient (NP16-42) was a 79 year 
old female who died from sepsis. The AD case (NP16-00151) was an 88 year old 
male diagnosed with Braak stage VI, and according to his death certificate he died 
from AD. The control brain tissue (NP16-00258) derived from a female of 49 years 
who died due to anorexia nervosa.  
 
5.4.2.1. [11C](R)-PK11195 Phosphor screen autoradiography 
[11C](R)-PK11195 phosphor screen autoradiography was performed 
following a previously published protocol by Johnström and colleagues (2012). In 
brief, frozen brain sections were thawed and immersed in 10mM PBS/0.1% v/v 
Triton X100 for 2 minutes. After repeating the wash for 2 minutes, 0.2 MBq/ml of 
[11C](R)-PK11195 was added and sections were incubated for 1 hour. Sections 
were washed twice in PBS/tween buffer for 2 minutes, rinsed in water and allowed 
to dry before transfer to a storage phosphor screen (GE healthcare) that had been 
photo-bleached prior by exposure. The slides and phosphor screen were enclosed 
in an aluminium film cassette for 3 hours. The slides were mounted on a digital 
imaging system (CR 35 BIO, Durr medical). Scanning of screens was controlled by 
Aida Image Analyser v.4.27 using 600 dpi resolution (approximately 42μm 
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sampling interval). Digital images were saved at full resolution and pixel depth, 
and images analysed using Aida imaging software. 
 
5.4.2.2. Immunohistochemistry 
The microglial burden was investigated in frozen tissue samples provided by 
the Cambridge Brain Bank. My colleagues Olly Green and Robert Fincham 
conducted this work using the 3 step Avidin-Biotin Complex (ABC) method (Vector 
Laboratories Ltd 2017), based on immunohistochemical staining of activated 
microglia with a monoclonal anti-human HLA-DR (Dako UK, M0775, HLA-
DP,DQ,DR Clone CR3/43). Microglial burden is expressed as the LN3 %-area. After 
fixation of frozen sections in industrial methylated spirits for 10 minutes, sections 
were incubated with PBS (Oxoid BR001G) for 10 minutes. To reduce nonspecific 
antibody binding, samples were incubated in 20% normal rabbit serum (NRS) 
blocker for 20 minutes. Sections were then incubated in primary antibody HLA-DR 
(Dako UK, M0775) at a dilution of 1:500 in PBS for 1 hour then rinsed in PBS for 
10 minutes. Sections were then incubated in biotinylated rabbit anti-mouse 
secondary antibody (RAMB) (Dako UK, E0345). The secondary antibody was used 
at a dilution of 1:200 made up in a solution of 10% Normal Human Serum (NHS) 
(Sigma H4522). Sections were incubated in the secondary antibody for 30 minutes, 
before being rinsed with PBS for 10 minutes. Sections were then incubated in a 
tertiary solution of Avidin Biotin Complex solution (Vector Laboratories PK6100) 
for 30 minutes. Sections were rinsed in PBS, before incubating in 3,3’-
Diaminobenzidine (DAB) solution for 4 minutes (Vector Laboratories SK4100). 
After DAB staining slides were rinsed in water. Slides were then counterstained in 
Harris’ Haematoxylin (Cellpath RBA-4205-009) for 15 seconds, and then rinsed in 
water for 5 minutes. Sections were differentiated in 1% acid alcohol and then left 
for 5 minutes to blue in water. The final step was to dehydrate, clear and mount. 
Microglia were manually counted in selected high magnification fields (x40) fields 
using an Olympus BX53 light microscope and Lumenera Infinity 2 camera. Regions 
of interest were selected within each brain region studied (middle frontal gyrus, 
hippocampus, substantia nigra, basal ganglia, and dentate nucleus). Only 
amoeboid microglia were counted and not ramified cells (with thanks to Dr Kieren 
Allinson).  
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5.5. Results 
5.5.1. Neuroimaging 
5.5.1.1. Demographics and cognition 
Descriptive data for demographic and cognitive details are shown in Table 
23. The patient and healthy control groups were matched in terms of age, sex, 
and education. Nevertheless, to account for any possible residual confounding 
effect associated with variability in demographic measures, age and sex were 
included as covariates of no interest in the general linear models of the main effect 
of ROI, the main effect of group, and the group × ROI interaction. As expected, 
there was a significant main effect of group for cognitive measures, driven by 
reduced MMSE and ACE-R scores in PSP and AD/MCI+ patients relative to healthy 
controls. Episodic memory, as assessed via the RAVLT (delayed recall), was 
significantly impaired in AD/MCI+ patients, relative to controls.
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 PSP 
(N= 16) 
AD/MCI+  
(N=16) 
HC 
(N= 13) 
Group difference 
Age 
mean 
(SD) 
68.4 
(±5.7) 
68.7 
(±8.6) 
68.0 
(±5.3) 
ns (per each post hoc t-test group comparison 
Gender 
M/F 
10/6 9/7 5/8 ns (per each post hoc t-test group comparison 
Education 
mean 
(SD) 
12.2 
(±1.9) 
13.8 
(±3.1) 
14.1 
(±2.7) 
ns (per each post hoc t-test group comparison 
MMSE 
mean 
(SD) 
27.4 
(±1.9) 
25.4 
(±3.0) 
28.7 
(±1.0) 
F = 7.60, p = 0.002 
(HC’s > AD***, HC’s > PSP*, PSP > AD*) 
ACE-R 
mean 
(SD) 
82.3 
(±10.0) 
77.5 
(±11.0) 
91.3 
(±5.3) 
F = 7.58, p = 0.002 
(HC’s > AD***, HC’s > PSP**) 
RAVLT 
mean 
(SD) 
- 1.3 
(±1.4) 
9.7 
(±3.2) 
t = 8.93, p < 0.0001 
(HC’s > AD***) 
PSP-RS 
mean 
(SD) 
40.8 
(±15.0) 
- - - 
Table 23: Demographics and cognitive variables of study participants.  
Abbreviations: PSP, Progressive Supranuclear Palsy; AD, Alzheimer’s Disease; MCI+, Mild Cognitive Impairment with positive β-amyloid; HC, Healthy 
Control; SD, Standard Deviation; M, Male; F, Female; MMSE, Mini-Mental State Examination; ACE-R, Addenbrooke’s Cognitive Examination-Revised; 
RAVLT, Rey Auditory Verbal Learning Test; ns, not significant at p < 0.05 (uncorrected) by ANOVA, post hoc t-test or chi-squared as appropriate. 
Post-hoc independent samples t-tests (*p < 0.05, **p < 0.01, ***p < 0.005).   
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5.5.1.2. Regional [11C](R)-PK11195 BPND in relation to clinical diagnosis 
In the repeated-measures analysis of regional binding, we found a 
significant main effect of ROI (F2, 36 = 3.8, p < 0.001), main effect of group (F2, 36 
= 5.7, p < 0.006), and a group × ROI interaction (F2, 70 = 2.6, p < 0.001) (Figure 
24). The group and interaction effects were driven in part by higher [11C](R)-
PK11195 BPND values in the AD/MCI+ group relative to both the PSP and healthy 
control groups, in cortical and subcortical ROIs including occipital, parietal, and 
temporal cortices, as well as in the hippocampus, amygdala, and other medial 
temporal lobe ROIs (Figures 24, 26 and 27). The PSP group, relative to healthy 
controls, showed increased [11C](R)-PK11195 BPND in the thalamus, putamen, and 
pallidum (Figures 24 and 25). 
 
Repeating these analyses using ROI [11C](R)-PK11195 BPND values that were 
not corrected for CSF partial volume effects yielded similar results (F2, 36 = 2.2, p 
< 0.0001, for the main effect of ROIs; F2, 36=6.1, p < 0.006 for the main effect of 
group; and F2, 70=2.0, p < 0.0001 for the group × ROI interaction).
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Figure 24: [11C](R)-
PK11195 BPND in 
each region of 
interest for the 
patient groups and 
healthy controls. 
This figure shows the bar 
plots represent the mean 
values (± SE) of the [11C] 
(R)-PK11195 BPND in 
each region of interest 
for the participant 
groups: AD/MCI+, PSP, 
and HCs. The [11C](R)-
PK11195 BPND data 
reported here are 
corrected for CSF partial 
volume effects. Post hoc 
t tests: *p < 0.05, **p < 
0.01, ***p < 0.005. 
Abbreviations: AD, 
Alzheimer Disease; MCI+, 
Mild Cognitive 
impairment with positive 
β-amyloid; PSP, 
Progressive Supranuclear 
Palsy; HC, Healthy 
Control; BPND, Non-
displaceable Binding 
Potential. 
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Figure 25: Scatter plot for subcortical regions to show the range of [11C](R)-PK11195 BPND values in patients with PSP.  
Each dot represents one patient, coloured by individual. Abbreviations: BPND, Non-displaceable Binding Potential; PSP, Progressive Supranuclear Palsy.  
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Figure 26: Scatter plot for cortical regions to show the range of [11C](R)-PK11195 BPND values in patients with AD/MCI+.  
Each dot represents one patient, coloured by individual. Abbreviations: BPND, Non-displaceable Binding Potential; AD, Alzheimer’s Disease; MCI+, Mild Cognitive 
Impairment.  
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Figure 207: Scatter plot for subcortical regions to show the range of [11C](R)-PK11195 BPND values in patients with AD/MCI+.  
Each dot represents one patient, coloured by individual. Abbreviations: BPND, Non-displaceable Binding Potential; AD, Alzheimer’s Disease; MCI+, Mild Cognitive Impairment.  
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5.5.1.3. Regional [11C](R)-PK11195 BPND associated with disease severity 
We then tested whether regional [11C](R)-PK11195 BPND related to disease 
severity in each clinical group. In the AD/MCI+ group, there was a significant 
negative correlation between the RAVLT scores (delayed recall at 30 minutes) and 
[11C](R)-PK11195 BPND in the pre-cuneus (Figure 28-A). In the PSP group, we 
found a significant positive correlation between [11C](R)-PK11195 BPND in the 
pallidum, midbrain, and pons and disease severity, as assessed via the PSP-RS 
(Figures 28-B, C and D).  
 
 
 
 
 
 
 
 
 
Figure 28: Correlations between disease severity assessments and patient groups. 
A. Correlation between [11C](R)-PK11195 BPND values in the precuneus (X-axis) and RAVLT scores (Y-axis) in 
patients with AD/MCI+ (red dots). B–D. Correlation between [11C](R)-PK11195 BPND values in the pallidum, 
midbrain, and pons (x-axes) and PSP-RS (y-axes) in patients with PSP.  
Abbreviations: AD, Alzheimer Disease; MCI+, Mild Cognitive Impairment with positive β-amyloid; PSP, 
Progressive Supranuclear Palsy; BPND, Non-displaceable Binding Potential; RAVLT, Rey Auditory Verbal Learning 
Test; PSP-RS, Progressive Supranuclear Palsy-Rating Scale.  
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5.5.1.4. Whole brain voxel-wise [11C](R)-PK11195 BPND 
Figure 29 illustrates the voxel wise maps for [11C](R)-PK11195 BPND. While 
broad patterns can be discerned in the distribution of BPND estimates, the spatial 
noise can also be seen, as a relatively ‘speckled’ appearance of the BPND. For group 
wise comparisons, the individual data were therefore smoothed, and presented as 
an array of axial slices in Figures 30 to 32.  
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C 
AD PSP Control 
Figure 29: Examples of coronal, transverse and sagittal sections of voxel-wise BPND 
maps for [11C](R)-PK11195 co-registered to the individual MRI. Note the [11C](R)-
PK11195 binding in the basal ganglia in all groups, albeit higher in the PSP patient (B). 
Patient with AD (A) also showed increased [11C](R)-PK11195 binding in medial 
temporal lobe regions and widespread neocortical areas, relative to PSP patient and 
control (B and C), while in the PSP case (B) had increased high [11C](R)-PK11195 
binding to the midbrain, relative to the AD patient and the  control subject (A and C). 
The colour bars denote BP values.  
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Voxel-wise BPND contrast for AD/MCI+ greater than controls is shown in 
Figure 30. Two uncorrected peaks were found bilaterally in the anterior medial-
temporal lobe which are indicated by the yellow arrows. This result corresponds to 
the amygdalo-hippocampal differences seen in Figure 24, but the group effect 
appears to be anatomically restricted. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Significant voxels from voxel-wise analysis of [11C](R)-PK11195 BPND maps for 
AD/MCI+ greater than controls (uncorrected height threshold p<0.001). Voxels overlaid on 
axial and sagittal slices of the group-average T1-weighted image in standard MNI space. The 
colour bars denote t-values. Arrows indicate significant clusters. 
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Voxel-wise BPND contrast for PSP greater than controls (p<0.05 FWE cluster-
wise) is shown in Figure 31, overlaid on axial and sagittal slices of the group-
average T1-weighted image in standard MNI space. This voxel-wise result 
recapitulates the midbrain differences seen in Figure 24, but at this FWE cluster 
corrected threshold, the group effect appears to be anatomically restricted and 
does not identify striatal or thalamic differences. The cerebellar voxel wise effects 
are also not observed in the cerebellar regional contrast.  
 
 
 
 
 
 
 
 
 
Figure 31: Significant clusters from voxel-wise analysis of [11C](R)-PK11195 BPND maps for 
PSP greater than controls (p<0.05 FWE, following an initial uncorrected height threshold 
p<0.001). Clusters overlaid on axial and sagittal slices of the group-average T1-weighted 
image in standard MNI space. The colour bars denote t-values. 
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Voxel-wise BPND contrast for AD/MCI+ greater than PSP (p<0.05 FEW 
cluster-wise) is shown in Figure 32, overlaid on axial and sagittal slices of the 
group-average T1-weighted image in standard MNI space. This voxel-wise result 
highlights the regional differences in neuroinflammation in AD/MCI+ versus PSP, 
in the temporal lobe, extending posteriorly to occipital cortex.  
 
 
5.5.2. Neuropathology 
5.5.2.1. [11C](R)-PK11195 Phosphor screen autoradiography  
A summary of the phosphor screen autoradiography results in post mortem 
AD, PSP and control brain cases are shown in Figure 33. 
 
The autoradiography phosphor screen analyses in the AD brain tissue 
samples revealed that in the white matter of the middle frontal gyrus and 
cerebellum had the highest and most specific binding of the [11C](R)-PK11195 in 
this group. [11C](R)-PK11195 binding was also found in the hippocampus. In 
contrast, sparse [11C](R)-PK11195 binding was found in the AD basal ganglia 
(globus pallidus and putamen) and midbrain slices.  
Figure 32: Significant clusters from voxel-wise analysis of [11C](R)-PK11195 BPND maps 
for AD/MCI+ greater than PSP (p<0.05 FEW, following an initial uncorrected height 
threshold p<0.001). Clusters overlaid on axial and sagittal slices of the group-average T1-
weighted image in standard MNI space. The colour bars denote t-values. 
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The highest [11C](R)-PK11195 BPND in PSP was also detected in the frontal 
cortex and cerebellum like the AD case, but there was an important [11C](R)-
PK11195 uptake in the midbrain.  The PSP case showed lower [11C](R)-PK11195 
BPND in the basal ganglia, and non-specific uptake was found in the hippocampus.  
The control post mortem phosphor autoradiography showed the highest and 
most specific binding of the [11C](R)-PK11195 uptake  in the basal ganglia. 
[11C](R)-PK11195 binding was also found in the midbrain and the dentate of the 
cerebellum, although sparse and non-specific [11C](R)-PK11195 uptake was 
detected in the middle frontal gyrus and hippocampus.  
 
 
5.5.2.2. Immunohistochemistry  
A summary of the HLA-DR immunohistochemistry data in post mortem AD, 
PSP and healthy control brain cases is shown in Figure 34. 
 
Microglia were manually counted in selected high magnification fields (x40) 
Figure 33: [11C](R)-PK11195 BPND Phosphor screen autoradiography for patient and 
healthy control cases.  
The Figure 33 aligns the [11C](R)-PK11195 BPND autoradiographic binding in key regions of interest in an 
Alzheimer’s disease (AD) case, a patient with progressive supranuclear palsy (PSP), and a control of similar age. 
In the AD case, there was [11C](R)-PK11195 BPND in the frontal cortex, hippocampus and cerebellum. In contrast, 
sparse [11C](R)-PK11195 binding was found in the AD basal ganglia (globus pallidus and putamen) and midbrain 
slices. The PSP tissue showed higher [11C](R)-PK11195 binding in the frontal cortex, midbrain and cerebellum, 
and in a lower degree in the basal ganglia. In contrast, non-specific [11C](R)-PK11195 uptake was found in the 
hippocampus in the PSP case. The control case showed substantial [11C](R)-PK11195 uptake within the basal 
ganglia, midbrain and cerebellum, and to a lesser extent, in the frontal and hippocampus slices. Abbreviations: 
AD, Alzheimer’s Disease; PSP, Progressive Supranuclear Palsy; HC, Healthy Control. The magnification of the 
autoradiography was x1. 
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fields using an Olympus BX53 light microscope and Lumenera Infinity 2 camera. 
The regions of interest were selected within each brain region studied: middle 
frontal gyrus, hippocampus, substantia nigra (midbrain), basal ganglia (globus 
pallidum and putamen), and cerebellar dentate nucleus. Only amoeboid microglia 
were only counted and not ramified cells (Table 24). 
 
 Alzheimer’s 
Disease  
Progressive 
Supranuclear 
Palsy 
Healthy 
Control 
Middle frontal cortex 11 0 7 
Hippocampus 11 0 0 
Substantia nigra 
(Midbrain) 
13 15 4 
Basal ganglia 0 16 0 
Dentate nucleus 4 14 2 
Table 24: Number of amoeboid microglial cells.  
 
Abundant activated microglia were identified, particularly in the white 
matter in the middle frontal gyrus and hippocampus in the AD case, while less 
activated microglia staining was found in the cerebellar dentate nucleus. The AD 
brain tissue did not show microglial activation in the globus pallidus and putamen 
(basal ganglia).  
The PSP tissue displayed high concentration of activated microglia in the 
basal ganglia, substantia nigra in the midbrain, and the cerebellum. In contrast, 
PSP brain sample did not show HLA-DR immunoreactivity in the middle frontal 
cortex neither hippocampus, while the AD brain displayed HLA-DR staining in those 
same ROI’s.  
The control brain tissue did not show any activation of the microglia in the 
hippocampus either in the basal ganglia. Instead, amoeboid microglial cells were 
common in the middle frontal gyrus, and in a lower degree in the substantia nigra 
and cerebellar dentate nucleus.  
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Figure 214: Microglia activation immunohistochemistry (HLA-DR) for patient and healthy 
control cases. 
The Figure 34 aligns the HLA-DR staining in key regions of interest in an Alzheimer’s disease (AD) case, a patient 
with progressive supranuclear palsy (PSP), and a control of similar age. Activated microglia was mainly identified 
in the middle frontal gyrus, hippocampus and substantia nigra in the AD case. The AD brain tissue did not show 
microglial activation in the basal ganglia. HLA-DR staining in PSP tissue was detected in the basal ganglia, 
midbrain and the cerebellar dentate nucleus. In contrast, PSP brain sample did not show HLA-DR 
immunoreactivity in the middle frontal cortex neither hippocampus. The control case showed activated microglia 
staining in the middle frontal cortex and to a lesser extent in the midbrain and cerebellar dentate nucleus but did 
not show any activation of the microglia in the hippocampus either in the basal ganglia.  Abbreviations: AD, 
Alzheimer’s Disease; PSP, Progressive Supranuclear Palsy; HC, Healthy Control. Immunohistochemistry pictures 
(HLA-DR) staining were taken under a ×20 objective. 
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5.6. Discussion 
The brain regions with the most marked abnormalities of [11C](R)-PK11195 
PET BPND in PSP and AD/MCI+ were those predicted from the established 
distribution of neurodegeneration of each disease. Specifically, PSP patients had 
evidence of enhanced neuroinflammation in the thalamus, pallidum, and putamen, 
a group of subcortical regions that have been implicated in the pathophysiology of 
PSP (Hauw et al., 1994; Litvan et al., 1996). The increased [11C](R)-PK11195 
binding in the basal ganglia in PSP is also consistent with preliminary findings 
reported in a study with four PSP patients (Gerhard et al., 2006). Conversely, 
amnestic AD/MCI+ patients had evidence of increased neuroinflammation in the 
medial temporal lobe as well as parietal and lateral temporal cortices (Braak et al., 
2006; Ossenkoppele et al., 2015; Schöll et al., 2016; Schwarz et al., 2016).  
 
Our data demonstrate that the density and distribution of activated 
microglia in living patients with PSP and AD/MCI+ mirror the typical 
neuropathological changes characteristic of each disorder. This could result from a 
causal link between neuroinflammation and neurodegeneration, although the 
association might also derive from the process of neurodegeneration itself. A cross-
sectional and non-interventional study such as this one cannot alone provide the 
direction of causality. Nevertheless, the disease-specific anatomical distributions 
of activated microglia in PSP and AD/MCI+ suggest a regional association rather 
than a side effect of a global increased [11C](R)-PK11195 binding in response to a 
general inflammatory insult. 
 
Our PET data are also in keeping with previous post mortem findings 
(Fernández-Botrán et al., 2011) which demonstrated that microglia burden (as 
assessed via LN3-immuno-staining) showed a disease-specific topological 
relationship with the pathological hallmarks of PSP and AD (Fernández-Botrán et 
al., 2011). More specifically, the previous post mortem study (Fernández-Botrán 
et al., 2011) found that the microglia density was greater in the substantia nigra 
of PSP cases relative to AD patients and healthy controls, while AD patients had 
significantly higher microglia density in the parietal cortices when compared to PSP 
cases and healthy controls (Fernández-Botrán et al., 2011). Together with our 
findings, these data suggest that microglia activation exists with the pathogenic 
processes underlying PSP and AD could contribute to the process of on-going 
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neurodegeneration (Fernández-Botrán et al., 2011). If so, this would warrant the 
further investigation of immune-therapeutic strategies to modulate 
neuroinflammation in PSP and AD, although evidence from earlier anti-
inflammatory trials in AD remains controversial (Lyketsos et al., 2007; Martin et 
al., 2008); and no such clinical trials have been conducted in PSP.  
In contrast, [11C](R)-PK11195 binding in post mortem phosphor screen 
autoradiography and immunohistochemical analyses were less consistent with 
[11C](R)-PK11195 PET imaging in vivo seen in these diseases and controls.  
 
There are several potential reasons why the thalamic and midbrain [11C](R)-
PK11195 binding signal was high across all groups. It may be due to the relatively 
old age of the donors (Kumar et al., 2012; Cagnin et al., 2001). In a study of 
normal adults aged 32 to 80 years, Cagnin and colleagues (2001) found that 
regional [11C](R)-PK11195 did not significantly change with age, except in the 
thalamus, which showed an age-dependent increase. The thalamus is connected 
to widespread cortical regions. Similarly, the midbrain is reciprocally connected to 
several brain regions, primarily the thalamus and basal ganglia, and has one of 
the highest densities of microglia, particularly in the substantia nigra (Lawson et 
al., 1990). Therefore, subtle inflammation or injury in other regions may induce 
amplified microglial responses in the highly connected ‘relays’ of thalamus and 
midbrain. Another possible cause is the proximity of the thalamus to several white 
matter tracts which are highly lipophilic (Catalano et al., 1996). Given the lipophilic 
nature of [11C](R)-PK11195, there can be high non-specific binding that 
contributes to the background levels in TSPO-PET imaging in this area (Chen & 
Guilarte, 2008; Petit-Taboue et al., 1991). This would not explain the high 
[11C](R)-PK11195 binding in the cerebellum in the AD case, but we do not know 
the mechanism of death of the AD donor: one might speculate about comorbid 
sepsis in agonal hours as a contributor to cerebellar inflammation.  
Dementia is also a common neurological condition associated with traumatic 
brain injury (TBI) (Smith et al., 2013), and survivors may deteriorate years after 
their injury (Whitnall et al., 2006). Neuroinflammation in the form of glial 
activation triggered by the TBI can persist for many years, and might contribute 
to the PET signal in some of the patients in the current study. For instance, 
Ramlackhansingh and collaborators (2011) showed that [11C](R)-PK11195 uptake 
was detected in the thalamus up to 17 years after TBI. Scott’s study (2015) 
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showed for the first time in vivo that the degrees of thalamic microglial activation 
and thalamo-cortical white matter tract damage are closely related. Glia become 
activated at sites of injury (Thiel et al., 2010; Maxwell et al., 2006) but also at 
distant sites (Johnson et al., 2013), including subcortical nuclei like the thalamus 
(Maxwell et al., 2006).  
Our data also confirmed the hypothesis that [11C](R)-PK11195 binding 
correlates with disease severity in both PSP and AD/MCI+; more specifically, with 
PSP severity as measured via the PSP-RS in PSP and severity of episodic memory 
impairment as assessed via the RAVLT in AD/MCI+. Again, these effects were not 
global correlations, but adhered to the functional anatomy of cognitive and motor 
symptoms in PSP and AD (i.e., pallidum, midbrain, and pons in relation to PSP-RS 
in PSP as well as the cuneus/pre-cuneus in relation to episodic memory deficits in 
AD). 
 
Overall, the use of [11C](R)-PK11195 PET could provide useful information 
to stratify patients in future clinical trials or to track the effects of treatments 
targeting neuroinflammation in neurodegenerative disorders like PSP and 
AD/MCI+. However, to fully meet its potential towards these directions, additional 
properties are necessary to show for this biomarker of neuroinflammation. 
Specifically, although recent longitudinal studies in AD have demonstrated that 
changes in [11C](R)-PK11195 binding may be associated with disease progression 
(Kreisl et al., 2016; Schuitemaker et al., 2007), such a correlation has not been 
established in PSP. Neuroinflammation might be stable in symptomatic stages of 
PSP, as suggested by a pilot study of two PSP patients (Gerhard et al., 2006).  
 
Perhaps more importantly, it remains to be determined whether the putative 
effects of anti-inflammatory therapies can reduce the elevated [11C](R)-PK11195 
binding in PSP and AD/MCI+, consequently, could help slowing the progression of 
these disorders. This would also enable mediation analysis to test the causality 
between immune-reactivity and disease progression in dementia and related 
disorders. Furthermore, we suggest that multi-tracer PET studies will be useful to 
formally assess how neuroinflammation relates to other important molecular 
aspects in dementia and related disorders including, for example, studying how 
neuroinflammation is associated with amyloid load in AD (Fan et al., 2015) as well 
as with tau burden in AD and PSP. A cross-sectional and single-tracer study like 
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the present one is not able to address such interesting and open questions, 
although it represents the necessary first step towards achieving this goal. 
 
Technical considerations regarding the [11C](R)-PK11195 BPND PET methods 
should also be considered. In particular, our main regional PET analyses used 
partial volume correction for CSF, which controlled for differences in CSF signal 
contamination within each region and across the different diagnostic groups (i.e., 
PSP, AD/MCI+, and healthy control groups). Although this approach is important 
to reduce the potential influence of brain volume loss seen in PSP and AD/MCI+, 
this MRI-guided method is subject to error due to one imperfect registration of PET 
and MR images, together with errors in segmentation and point spread function 
modelling. However, we note that using uncorrected PET data yielded similar 
results in terms of the main effect of ROI, main effect of group, and group × ROI 
interaction, which provides substantiation of the CSF-corrected results. The 
supervised cluster method for estimating [11C](R)-PK11195 BPND could also have 
introduced an under-estimation bias, as the reference tissue may have still 
included specific binding of the radioligand. In any case, this may have only 
reduced the effect sizes without altering the risk of reporting false positive results. 
 
We also highlight that our data are specific to [11C](R)-PK11195 and may 
not generalize to second-generation TSPO ligands (e.g., PBR28) or alternative 
tracers of neuroinflammation over and above those that bind to TSPO (e.g., COX-
1, MPO, macrophage infiltration) (Hamelin et al., 2016; Suridjan et al., 2015; 
Yokokura et al., 2016). Further studies should assess the utility of such novel 
markers for in vivo imaging of neuroinflammation, bearing in mind that the binding 
of second-generation TSPO tracers like PBR28 can be affected by genetic variations 
(i.e., the rs6971 TSPO polymorphism) (Owen et al., 2012). 
 
In conclusion, we have provided clear evidence that [11C](R)-PK11195 is a 
sensitive PET ligand for in vivo and in post mortem studies of neuroinflammation 
in clinical populations with non-AD tauopathy, PSP-Richardson’s syndrome, as well 
as in AD and its prodromal stage of amnestic MCI. The brain regions that showed 
increased [11C](R)-PK11195 binding were those predicted from the well-
established pattern of regional cortical and subcortical neurodegeneration in each 
disease. Our data support the further use of [11C](R)-PK11195 PET to study 
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microglial activation in neurodegenerative disorders and in clinical trials that aim 
to modulate neuroinflammation in neurodegenerative disease. 
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Chapter 6 
General discussion  
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6.1. Review and interpretation  
The aim of this thesis was to advance the understanding of tau pathology 
and neuroinflammation, in PSP and AD/MCI+, through in vivo brain imaging and 
post mortem neuropathological investigations. I recruited two distinct patient 
cohorts and defined them first in terms of their neuropsychological profiles and 
disease severity. This confirmed the differentiating clinical features, including 
executive function, memory, behaviour and motor function, and standardized 
ratings of global disease severity (i.e. Clinical Dementia Rating and PSP Rating 
Scale). The cognitive profiles were in accord with larger published series. I then 
tested in vivo, whether the classical phenotypes of PSP and AD/MCI+ were 
associated with changes in two neuropathological processes, tau aggregation with 
tangle formation (AV1451 PET) and inflammation in the form of microglia 
activation (PK11195 PET). Post mortem analyses provided validation of the in vivo 
methods.  
 
The radiotracer [18F]AV1451 was used as an index of tau aggregation across 
the whole brain including cortical and subcortical brain regions. The differences in 
the distribution of tau pathology between PSP and AD/MCI+, and the difference in 
ultrastructure of the tau aggregates, underpinned my predictions of regionally 
specific binding, for example the midbrain and hippocampus, in patients with PSP 
and AD/MCI+, respectively.  
 
Comparing PSP with controls, there was increased [18F]AV1451 BPND in the 
basal ganglia, midbrain and dentate nucleus of the cerebellum. This approximates 
the well-characterized distribution of pathology in PSP found in post mortem 
studies (Dickson et al., 2007; Hauw et al., 1994). However, I could not establish 
any correlation with disease severity. There are several possible explanations for 
this lack of correlation.  
 
Firstly, it is possible that the ligand is not sensitive enough to the 
progression or variation in severity of the tauopathy of PSP. In keeping with this 
it has previously been shown that it has a high affinity for paired helical filaments 
of tau protein in AD but low or intermediate affinity to straight filaments of tau in 
various non-AD tauopathies (Marquié et al., 2015).  
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Secondly, the progression of pathology in PSP is accompanied by changes 
in several forms of tau, from oligomeric to filamentous to tangle tau: different 
stages or severity levels of PSP might be associated with difference in the relative 
abundance of these different tau species. The relative toxicity of these tau species 
varies, and there is controversy over their role in cell death. There is direct 
evidence for NFT toxicity, for example in some mouse models of tauopathy, 
filaments coincide in the time course of the disease with features such as neuronal 
death and motor deficits (Ishihara et al., 1999). Similar results were also seen in 
one Drosophila model of tauopathy in which tau filament formation was reported 
(Wu et al., 2013). However, the target of AV1451 in PSP pathology may not be 
relevant toxic tau species underlying neurodegeneration (cell death) and thereby 
relate directly to disease stage or severity.  Supporting this evidence from animal 
models suggests that tau-mediated neuronal death can occur even in the absence 
of tangle formation. For instance, in most Drosophila (Kosmidis et al., 2010; 
Williams et al., 2000) expressing human tau display behavioural phenotypes 
indicative of neuronal dysfunction and toxicity without forming tau filaments or 
larger aggregates. Even in mice, brains may contain some form of insoluble tau 
but not NFTs or PHFs, while the animals display motor impairment (Spittaels et 
al., 2000). Such evidence indicates that filaments and NFTS are not necessary for 
tau-induced toxicity. Indeed, many studies suggest that the tau oligomer, is likely 
responsible for cell injury and disease progression. The onset of symptoms in 
animal models following transfection from extracts of human brain tissue (with 
PSP and AD) correlates with elevated levels of tau oligomer (Gerson et al., 2014; 
Maeda et al., 2006; Patterson et al., 2011).  Importantly this oligomeric tau is not 
imaged by AV-1451 potentially accounting for the lack of correlation with disease 
severity.  
 
Thirdly, this study may lack the statistical power (type II error) to test the 
association between PET and clinical severity. However, our power calculations 
suggested acceptable power to detect group differences in binding and this was 
the largest study at the time it was undertaken. Subsequently, larger studies have 
detected associations between binding and disease severity suggesting a lack of 
power may have been a contributory factor in the correlational analyses 
(Ossenkoppele et al., 2016; Schöll et al., 2017).   
 
182 
A further limitation in the identification of the PET correlation with severity 
is inherent limitation with the clinical measures themselves. These may not be 
sufficiently sensitive to describe the spectrum of pathological variability in the 
regions identified by the PET in PSP and AD/MCI+, and they will have variability 
arising from subjective interpretations of the questions.  
 
Finally it is possible that the neurobiology is such that there truly is no cross 
sectional correlation with severity. This is borne out by the longitudinal AV1451 
data. That is to say, there is an increase in binding during earlier phases of disease, 
but later with massive cell death the tau burden falls again. When averaging over 
the patients at different phases in a cross sectional study, the linear correlation 
does not exist.  
 
Taken together, these caveats and the lack of correlation with clinical 
severity suggest that AV1451 binding cannot be interpreted simplistically as a 
measure of progressive disease severity. Further work will be required to address 
these issues if AV1451 is to fulfil a role as a biomarker of tau pathology in PSP.  
 
In my analysis of AD pathology, I considered clinical AD and the prodromal 
state of biomarker positive MCI as one disease entity, with a continuum in terms 
of severity. The diagnosis of AD/MCI+ was associated with greater [18F]AV1451 
BPND compared to controls, in the hippocampus, amygdala as well as frontal, 
parietal, temporal, and occipital cortices. This reflects the regions that are 
characteristic of the AD pathology in post mortem studies. However, once again, 
no correlation with disease severity was found.  
 
The reasons for a lack of correlation in AD/MCI+ may be the same as the 
reasons in PSP, although the ligand typically shows much higher binding to AD-tau 
tangles than PSP, suggesting that power and affinity are less likely to be the 
reasons for a lack of correlation with severity. A biphasic relationship of 
accumulation of tau in surviving cells and then cell loss, may explain the lack of 
overall correlation. Others have shown higher binding in clinical AD than MCI 
(Ossenkoppele et al., 2016) suggesting that there can be an effect of severity, 
even if not strong enough to be identified on our cohort of patients.  
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Despite the potential of [18F]AV1451 as a biomarker of disease, caution in 
the interpretation of its binding targets is suggested by autoradiographic and 
immunohistochemistry data, and differences in binding between different 
tauopathies (Sander et al., 2016). While [18F]AV1451 BPND strongly binds to AD-
related cortical tau pathology in other series, and my cohort (n= 15), non-specific 
binding has been reported in PSP patients (n=20), healthy controls (n=13), and 
disorders that are associated with TDP43 pathology but not tau pathology (e.g. 
semantic dementia, Bevan-Jones et al., 2017). The concept of off-target binding 
has overshadowed the use of AV1451 in the last 2 years. The relevant non-tau 
targets are not definitively known but options include neuromelanin (Marquié et 
al., 2015) and monoamine oxidase B (MAO-B; Harada et al., 2017; Jang et al., 
2018).  
 
The relevance of these off target binding sites may vary between brain 
region and disease. For example, neuromelanin is expected in the substantia nigra 
and locus coeruleus, but not cortex (Hansen et al., 2016). Whilst there is no doubt 
about AV1451 binds avidly to neuromelanin, there is doubt over the relevance of 
this to cortical and basal ganglia signal in patients. Indeed, my post mortem data 
suggest that off-target binding to neuromelanin is not the explanation for 
[18F]AV1451 uptake in basal ganglia or cortex (Chapter 4, section 4.5.2.2). I found 
significant in vivo [18F]AV1451 uptake in the basal ganglia (in all groups including 
healthy controls) in the absence of post mortem neuromelanin-containing cells. 
This indicates that neuromelanin is not the principal target of off-target binding for 
[18F]AV1451. In the basal ganglia, there is expression of MAO-A and this accounted 
for most of the signal of an alternative tau PET ligand called THK5351 (Ng et al., 
2017). Preclinical studies indicate that AV1451 is also displaced by monoamine 
oxidase type A agonists (MAO-A; Vermeiren et al., 2018), although a definitive 
displacement study of human AV1451 binding is awaited. The basal ganglia have 
high levels of MAO (type A), but MAO (albeit type B) is expressed in activated 
microglia. This raises the possibility that AV1451 reflects not just tau in PSP and 
AD, but also the activated microglia, which are the specific target of the TSPO 
ligand PK11195. Preliminary evidence against this artefactual cross-binding of 
AV1451 and PK11195 comes from the combination of both ligands in a carrier of 
a MAPT 10+16 mutation (Bevan-Jones et al., 2016) – in whom there was markedly 
increased PK11195 binding but no excess of AV151 binding. Further off target 
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binding sites, including the target in relation to TDP43 disorders (Bevan-Jones et 
al., 2018; Bevan-Jones et al., 2017) remain to be elucidated.  
 
In Chapter 5, I also reported the assessment of neuroinflammation, 
providing in vivo evidence for microglial activation in both PSP and AD/MCI+ using 
the TSPO ligand [11C](R)-PK11195. In PSP there was greater neuroinflammation 
in the thalamus, pallidum, and putamen. Conversely, amnestic AD/MCI+ patients 
had evidence of increased neuroinflammation in the medial temporal lobe as well 
as parietal and lateral temporal cortices.  
 
In contrast to the degree of AV1451 binding, the [11C](R)-PK11195 BPND 
correlated with disease severity in both PSP and AD/MCI+ groups. I used different 
disease-specific measures of severity, via the PSP-RS and RAVLT, respectively. 
Although these effects were not global correlations, they adhered to the respective 
functional anatomy of cognitive and motor symptoms in PSP and AD/MCI+ in 
published data on tau burden (Ossenkoppele et al., 2018) and atrophy (Frisoni et 
al., 2010; Mak et al., 2017; Price et al., 2004). Moreover, [11C](R)-PK11195 
binding in post mortem phosphor screen autoradiography and 
immunohistochemical analysis of microglial were in agreement in both clinical 
groups and controls.  
 
 
6.2. Future directions  
I propose four main areas to consider for future research in this area.  
 
(I) My data suggest that despite its limitations, the ligand [18F]AV1451 has 
some of the useful properties of a biomarker. It could discriminate two distinct 
tauopathies by quantifying and localizing ‘tau’ in regions typically associated with 
each disease. This may have future applications in terms of developing reliable 
biomarkers for these disorders, and for tracking the effects of anti-tau clinical trials 
using disease-modifying therapies. This is already progressing in the setting of AD 
(Ossenkoppele et al., 2018), where there is greater confidence in the target of the 
ligand.  
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 I also showed the presence of neuroinflammation in distinctive distributions 
for both diseases, and a relationship with disease severity. This is consistent with 
the mechanistic relevance of microglial activation and neuroinflammation to 
disease progression. Despite the epidemiological (Veld et al., 2001; McGeer et al., 
1996), genetic (Malik et al., 2015; Zhang et al., 2015) and PET (Edison et al., 
2008; Esposito et al., 2008) evidence for inflammation in AD, the causal role of 
inflammation in pathogenesis is not yet confirmed.  
 
Neuroinflammation may be associated with PSP and AD as independent, 
causal mediators of disease. But, inflammation might be reactive to pathological 
protein species such as tau oligomers; or to cell death. Further, interventional, 
studies will be needed to resolve these uncertainties. The partially protective effect 
of anti-inflammatories in epidemiological studies hint that inflammation 
accelerates or aggravates the development of AD. However, randomised placebo-
controlled interventional trials are required, to overcome the potential biases in 
epidemiology – such as the confounding effects of the diseases, or risk factors, 
which lie behind the use of anti-inflammatories.  In PSP, there are fewer studies 
establishing the presence of in vivo neuroinflammation, although Gerhard and 
colleagues clearly showed the presence of microglial activation in primary 
tauopathies including PSP in an earlier PET study (Gerhard et al., 2006). 
Epidemiological data on anti-inflammatory use in PSP is lacking, although it is 
noteworthy that the genetic associations from genome-wide associations of PSP 
include loci that are plausible involved in regulating inflammation (Höglinger et al., 
2011).  
 
The relationship between inflammation and disease severity seen here 
motivates further studies focusing on the role of neuroinflammation in vivo in PSP, 
and its relation with tau pathology, cell death and disease progression. This is 
particularly important because microglia activation may prove to be a modifiable 
component to PSP pathology, and a target for disease modifying therapies.  
 
(II). Larger cross-sectional studies are required to look at tau and 
neuroinflammation in PSP and AD/MCI+, along with disease severity and clinical 
features. Studies with increased statistical power from larger cohorts may reveal 
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significant associations with disease severity, or genetic variation between 
individuals.  
In addition, larger cohorts would benefit from a wider range of clinical 
phenotypes in both diseases.  For example, the clinical spectrum of PSP has 
expanded in recent years, to include PSP-PGF, PSP-P, PSP-F (Dickson et al., 2007; 
Höglinger et al., 2017; Ling et al., 2014; Paviour et al., 2007). These other PSP 
clinical syndromes provide the opportunity to test the association between PET 
indices of localized pathology and localized functional anatomical deficits across 
variants. This would mirror advances in AD where the Ossenkoppele study of 
amnestic-AD, PCA-AD and logopenic aphasia-AD was instrumental in showing the 
importance of tau over amyloid for phenotypic expression (Ossenkoppele et al., 
2016).  
 
It would also be a positive step to compare the PSP clinical spectrum with 
other tauopathologies (e.g. CBS), and other diseases like PD/DLB which although 
not primarily tauopathies, are nonetheless modulated by tau haplotype and tau 
expression (Gomperts et al., 2016; Mak et al., 2017).  
 
Given the problems with AV1451 specificity binding outside of AD the 
development of second-generation tau tracers that have higher affinity for 4R or 
straight filamentous tauopathy would be important. PBB3 showed promise in this 
direction, and data are awaited for 18F-RO-98 and 18F-MK6240 (Betthauser et al., 
2018; Pascoal et al., 2018).  
 
(III). Future studies need also to include longitudinal assessment, in order 
to understand the course of tau and neuroinflammatory changes. I have carried 
out [18F]AV1451 follow up on 8 of my 20 PSP patients, analysed in collaboration 
with Dr Luca Passamonti. Preliminary data are presented in the Appendix 1. In 
summary, this pilot analysis suggests a negative correlation between the change 
in [18F]AV1451 BPND and change in disease severity, during the mid-stage 
progression of disease. However, the follow up cases are biased towards mild and 
slow progressing patients as some of the original cross-sectional patients were too 
unwell to be re-scanned or were deceased. Clearly, definitive longitudinal studies 
are required.  
 
187 
In AD longitudinal studies are already underway and there are now several 
that show increasing tau in vivo with disease severity and following Braak staging 
(Jack et al., 2018; Lowe et al., 2018). The value of using [18F]AV1451 PET as 
biomarker of PSP and AD may lie in its ability to track individual differences in 
disease progression rather than changes at the group level. This is beginning to 
become clear in AD but not yet in PSP. Similar studies to those coming out of the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) collaboration, such as those 
of Lowe and Jack above, will be required in PSP.  
 
(IV). Exploring correlations between [18F]AV1451, [11C](R)-PK11195 and  
[11C]PiB binding in this dataset would extend this work. Recent studies have 
highlighted how the same pathology, PSP, can be associated with diverse 
functional phenotypes (Respondek et al., 2014; Hoeglinger et al., 2017). Such 
phenotypic variance may in part arise from the combination of multiple pathogenic 
processes. I have shown that PET can be used to quantify both neuroinflammation 
and tau protein aggregation in PSP and AD. But, the relationship between these 
two processes is not well understood. If highly correlated, one could go on to test 
the temporal order of inflammation before tau aggregation or vice versa, and the 
degree to which inflammation and aggregation are synergistic.  
 
(V). Another important application of tau-PET is to inform models of 
mechanisms of disease. For example, in the past few years, a growing number of 
studies have provided converging evidence for the cell-to-cell transmissibility of 
the diverse disease proteins, including tau protein, as a common mechanism for 
the onset and progression of various neurodegenerative disorders (Frost et al., 
2009; Guo & Lee, 2011). The ‘transmission hypothesis’ for non-prion 
neurodegenerative diseases provides a viable explanation for the stereotypical 
pathology spreading patterns that have long been observed in multiple diseases 
(Brundin et al., 2010; Jucker & Walker, 2011; Lee et al., 2010). Tau-PET allows 
us to test this hypothesis in vivo. For example, areas with high connectivity in AD 
are most vulnerable to occurring tau pathology (Cope et al., 2018). This may be 
due to vulnerability to amplification and aggregation of tau intracellularly, but it 
may also reflect the receipt of pathogenic tau species (Clavaguera et al., 2009, 
2014).  
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6.3. Limitations  
There were limitations in this study, with technological, demographic, and 
neuropathological issues to consider.  
In terms of technological limitations, using different PET scanners during the 
study have due to hardware change and the installations of the new scanner.  This 
introduces another uncontrolled source of variability into the study but was 
unfortunately unavoidable. This only affected a small number of participants 
(n=5).  
Secondly, there is inevitably some variability in the dose of the radioligand 
given to each participant. However, more importantly there was also a minimum 
dose required in order for the scan to proceed.  Therefore any variability is above 
the threshold required for a technically adequate scan and is accounted for in the 
modelling of the PET data.  
 
Thirdly, there may be limitations with regards the reference region used for 
modelling the PET data. For AV1451 we chose the superior cerebellum as a region 
unlike to be affected by PSP or AD pathology making sure to exclude the cerebellar 
dentate, which is affected in PSP. For PK11195 the reference region was 
determined in a data driven fashion using supervised cluster analysis.  
 
In terms of demographic and clinical limitations, we included typical PSP-RS 
and AD participants.  This lack of phenotypic spectrum in both PSP and AD reduces 
the relevance of the study to the real world range of both diseases and also the 
answers to potential mechanistic questions about the relationship between 
pathology, symptoms and severity. 
 
A further issue is bias toward to those with early disease as they could 
complete the study protocol. For example, those with severe motor impairment 
are likely to be scanned (in particular, MRI session were limited by difficulties with 
coil closure due to neck rigidity). In addition, even if AD and MCI+ belong to the 
same spectrum, having severe cognitive and functional impairments made 
enrolment in the study less likely.  Although the study aimed to recruit a broad 
range of severities, the study protocol required a degree of functional and cognitive 
ability that precluded the enrolment of severely affected participants (i.e. those 
with a CDR of 3). Consequently, this bias, and a potential pool of cases derived 
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from a tertiary neurology clinic and inherently missing those with severe disease 
requiring institutional or nursing care, is unavoidable.  
 
Neuropathological issues include the diversity of tau species and 
ultrastructure, quantity and affinity in AD versus non-AD tauopathy. The tau 
pathology of PSP is chemically and morphologically different from AD, and it is 
perhaps not surprising that [18F]AV1451, which was developed to bind AD tau-
pathology, is not optimal to study PSP (see Chapter 4, section 4.5.2). New ligands 
might address this issue with higher affinity for PSP tau forms, but evidence is 
awaited for the performance of these new ligands in non-AD pathologies.  
 
Finally, although brain donation contributed to the validation of the NIMROD 
study, there is a long interval between PET and donation. Additional post mortem 
validation studies from brain tissue that has undergone PET in vivo would be a 
major step forward, but there are few studies that have attempted this (Marquié 
et al., 2015; Passamonti et al., 2017), in part because of the time lag between 
being well enough for PET and brain donation, and partly from the limited number 
of centres with both brain banking and PET programs.  
 
 
6.4. Conclusion  
In conclusion, [18F]AV1451 and [11C](R)-PK11195 are useful PET ligands for 
in vivo and in post mortem studies in clinical populations with Alzheimer’s disease 
and non-AD tauopathy, including PSP-Richardson’s syndrome, despite the 
potential contribution of non-specific or “off-target” binding. The brain regions that 
showed increased [18F]AV1451 and [11C](R)-PK11195 binding were those 
predicted from the well-established pattern of regional cortical and subcortical 
neurodegeneration in each disease. Together, the current findings support the 
further use of [18F]AV1451 and [11C](R)-PK11195 PET to evaluate tau pathology 
and microglial activation in neurodegenerative disorders and with further 
validation they could play a role in clinical trials that aim to modulate tau  
accumulation and neuroinflammation in neurodegenerative disease. 
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Appendix 
 
Appendix 1: Provisional analysis of the small longitudinal study of [18F]AV-1451 
PET imaging in Progressive Supranuclear Palsy.  
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